Adeno-associated virus virions with variant capsids and methods of use thereof

By inserting heterologous peptides into the capsid protein of the AAV virions, the infectivity and localization ability of retinal cells is enhanced, and the problem of existing AAV difficulty in infecting retinal cells is solved, achieving more efficient gene delivery and eye disease treatment.

CN114672516BActive Publication Date: 2024-11-26RGT UNIV OF CALIFORNIA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210504372.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-07-29
Filing Date
2017-07-27
Publication Date
2024-11-26
Estimated Expiration
2037-07-27

AI Technical Summary

Technical Problem

Existing adeno-associated viruses (AAVs) are difficult to effectively infect retinal cells, especially cells in the retinal recirculation pathway, such as retinal pigment epithelial cells and photoreceptor cells, resulting in poor treatment of hereditary retinal diseases.

Method used

By designing the variant AAV virions, the infectivity of the virus to retinal cells is enhanced by inserting a heterologous peptide of about 5-20 amino acids into its capsid protein, especially in the GH ring or ring IV region of the AAV capsid protein, and significantly The localization ability of virions in the inner core layer, outer nuclear layer, photoreceptor layer, ganglion cell layer and retinal pigment epithelial cells is improved.

Benefits of technology

The infectivity and localization ability of the AAV virions to retinal cells was significantly improved, with at least 5 times increase, and the infectivity of retinal pigment epithelial cells and photoreceptor cells was significantly improved, providing more effective gene delivery and eye disease treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114672516B_ABST
    Figure CN114672516B_ABST
Patent Text Reader

Abstract

The present disclosure provides adeno-associated virus (AAV) virions with altered capsid proteins, wherein the AAV virions exhibit greater infectivity to retinal cells compared to wild-type AAV. The present disclosure also provides methods of delivering gene products to retinal cells in individuals, and methods of treating eye diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application, and its corresponding parent application is the Chinese invention patent application with application number 201780050806.3, the application date of which is July 27, 2017, and the name of the invention is “Adeno-associated virus virions with variant capsids and methods of use thereof”.

[0002] Cross-references

[0003] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 368,929, filed July 29, 2016, which is incorporated herein by reference in its entirety.

[0004] Statement Regarding Federally Funded Research

[0005] This invention was made with government support under Contract / Grant Nos. EY022975, EY018241, and EY06855 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art

[0006] Photoreceptors are the first neurons in the retina to receive and process visual information, converting visible electromagnetic radiation into a hyperpolarizing response through photoconversion. The vast majority of inherited retinal diseases result from the loss of these cells, either directly, as in dominant mutations affecting rhodopsin folding, or indirectly, as in recessive mutations affecting the retinal recycling pathway in the retinal pigment epithelium (RPE).

[0007] Adeno-associated virus (AAV) belongs to the Parvoviridae and Dependovirus families, members of which require co-infection with a helper virus, such as adenovirus, to promote replication, and AAV establishes a latent infection in the absence of an adjuvant. The virion consists of a 25 nm icosahedral capsid surrounding a 4.9 kb single-stranded DNA genome and two open reading frames, rep and cap. The nonstructural rep gene encodes four regulatory proteins that are essential for viral replication, while cap encodes three structural proteins (VP1-3) that assemble into a 60-mer capsid. This viral capsid mediates the ability of AAV vectors to overcome many biological barriers to viral transduction, including cell surface receptor binding, endocytosis, intracellular trafficking, and nuclear unpacking. Summary of the Invention

[0008] The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid proteins, wherein the recombinant AAV (rAAV) virions exhibit greater infectivity to retinal cells compared to wild-type AAV, and wherein the rAAV virions comprise heterologous nucleic acids. The present disclosure also provides methods for delivering gene products to retinal cells in an individual, and methods for treating eye diseases. The present disclosure provides a rAAV virion, wherein the rAAV virion exhibits at least a 5-fold increase in localization to one or more of the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, and retinal pigment epithelial cells compared to the extent to which an AAV virion comprising the corresponding parent AAV capsid protein is localized to the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, and retinal pigment epithelial cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 Schematic diagram of a directed evolution approach for developing AAV variants that exhibit increased infectivity to ocular cells (eg, retinal cells) compared to the parental AAV.

[0010] Figure 2 Schematic diagram of deep sequencing of AAV variants containing green fluorescent protein (GFP)-barcode constructs.

[0011] Figure 3 Infection of cells in the ganglion cell layer, inner nuclear layer, photoreceptor layer, and retinal pigment epithelium (RPE) layer by an 18-member AAV variant library is depicted.

[0012] Figure 4 The amino acid sequence of the AAV2 capsid protein VP1 is provided. Amino acids 587 and 588 (NP) are in bold and underlined.

[0013] Figure 5 Provided are amino acid sequences corresponding to amino acids 570-610 of the AAV capsid protein VP1 of various AAV serotypes.

[0014] Figures 6A-6CAn alignment of the amino acid sequences of the loop IV (GH loop) region of the AAV capsid protein is provided. Insertion sites are shown in bold and underlined. AAV1: SEQ ID NO:35; AAV6: SEQ ID NO:36; AAV3: SEQ ID NO:37; AAV2: SEQ ID NO:38; AAV8: SEQ ID NO:39; AAV8.1: SEQ ID NO:40; AAV8 rh8: SEQ ID NO:41; AAV10: SEQ ID NO:42; AAV7: SEQ ID NO:43; AAV9: SEQ ID NO:44; AAV9.1: SEQ ID NO:45; AAV5: SEQ ID NO:46.

[0015] Figures 7A-7V Amino acid sequences of exemplary heterologous gene products are provided.

[0016] Figures 8A-8C Amino acid sequences of exemplary guide-RNA-guided endonucleases are provided.

[0017] definition

[0018] The term "retinal cell" as used herein may refer to any of the cell types that comprise the retina, such as retinal ganglion cells; amacrine cells; horizontal cells; bipolar cells; photoreceptor cells including rods and cones; Müller glial cells; astrocytes (e.g., retinal astrocytes); and retinal pigment epithelial cells.

[0019] "AAV" is an abbreviation for adeno-associated virus and can be used to refer to the virus itself or its derivatives. Unless otherwise required, the term encompasses all subtypes and both naturally occurring and recombinant forms. The abbreviation "rAAV" refers to recombinant adeno-associated virus, also known as recombinant AAV vector (or "rAAV vector"). The term "AAV" includes AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), AAV type 9 (AAV-9), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. "Primate AAV" refers to AAV isolated from primates, "non-primate AAV" refers to AAV isolated from non-primate mammals, "bovine AAV" refers to AAV isolated from bovine mammals (eg, cows), and so on.

[0020] As used herein, "rAAV vector" refers to an AAV vector comprising a polynucleotide sequence of non-AAV origin (i.e., a polynucleotide heterologous to AAV), typically a sequence of interest for genetic transformation of a cell. Generally speaking, the heterologous polynucleotide is flanked by at least one and typically two AAV inverted terminal repeats (ITRs). The term rAAV vector encompasses both rAAV vector particles and rAAV vector plasmids.

[0021] "AAV virus" or "AAV virus particle" or "rAAV vector particle" refers to a virus particle composed of at least one AAV capsid protein (typically all capsid proteins of wild-type AAV) and the encapsidated polynucleotide rAAV vector. If the particle contains a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene to be delivered to mammalian cells), it is typically referred to as a "rAAV vector particle" or simply "rAAV vector". Therefore, the production of rAAV particles naturally includes the production of rAAV vectors, as such vectors are contained within the rAAV particles.

[0022] "Packaging" refers to the series of intracellular events that result in the assembly and encapsidation of AAV particles.

[0023] The AAV "rep" and "cap" genes refer to polynucleotide sequences encoding the replication and capsid proteins of adeno-associated virus. AAV rep and cap are referred to herein as AAV "packaging genes."

[0024] AAV "helper virus" refers to a virus that allows mammalian cells to replicate and package AAV (e.g., wild-type AAV). A variety of such AAV helper viruses are known in the art, including adenoviruses, herpes viruses, and pox viruses, such as vaccinia. Adenoviruses encompass many different subclasses, but adenovirus type 5 of subclass C is the most commonly used. Many adenoviruses of human, non-human mammalian, and avian origin are known and can be obtained from collections such as ATCC. Herpes viruses include, for example, herpes simplex viruses (HSV) and Epstein-Barr virus (EBV) as well as cytomegalovirus (CMV) and pseudorabies virus (PRV); they can also be obtained from collections such as ATCC.

[0025] "Helper virus functions" refers to functions encoded in the helper virus genome that allow AAV replication and packaging (in conjunction with other requirements for replication and packaging as described herein). As described herein, "helper virus functions" can be provided in many ways, including by providing a helper virus or providing, for example, a polynucleotide sequence encoding the necessary functions to the producer cell in transit.

[0026] "Infectious" viruses or virions are viruses or virions that contain a polynucleotide component that can be delivered to cells tropistic for the viral species. This term does not necessarily imply any ability of the virus to replicate. As used herein, "infectious" viruses or virions are viruses or virions that can approach target cells, infect target cells, and express heterologous nucleic acids in target cells. Thus, "infectivity" refers to the ability of a virion to approach a target cell, infect a target cell, and express heterologous nucleic acids in the target cell. Infectivity can refer to in vitro infectivity or in vivo infectivity. Assays for counting infectious virions are described elsewhere in this disclosure and in the art. Viral infectivity can be expressed as the ratio of infectious virions to total virions. Total virions can be expressed as the number of viral genome (vg) copies. The ability of a virion to express a heterologous nucleic acid in a cell can be referred to as "transduction." The ability of a virion to express a heterologous nucleic acid in a cell can be determined using a number of techniques, including assessment of a marker gene, such as a green fluorescent protein (GFP) assay (e.g., wherein the virus comprises a nucleotide sequence encoding GFP), wherein GFP is produced in cells infected with the virion and detected and / or measured; or measurement of the protein produced, such as by an enzyme-linked immunosorbent assay (ELISA). Viral infectivity can be expressed as a ratio of infectious virions to total virions. Methods for determining the ratio of infectious virions to total virions are known in the art. See, for example, Grainger et al. (2005) Mol. Ther. 11: S337 (describing the TCID50 infectious titer assay); and Zolotukhin et al. (1999) Gene Ther. 6: 973.

[0027] A "replication-competent" virus (e.g., replication-competent AAV) refers to a phenotypically wild-type virus that is infectious and is also able to replicate in infected cells (i.e., in the presence of a helper virus or helper virus function). In the case of AAV, replication competence generally requires the presence of functional AAV packaging genes. Generally speaking, rAAV vectors as described herein are unable to replicate in mammalian cells (particularly human cells) due to the lack of one or more AAV packaging genes. Typically, such rAAV vectors lack any AAV gene sequences, thereby minimizing the possibility of generating replication-competent AAV by recombination between the AAV packaging genes and the introduced rAAV vector. In many embodiments, the rAAV vector preparations as described herein are those containing very few, if any, replication-competent AAV (rcAAV, also known as RCA) (e.g., 10 2 rAAV particles are less than about 1rcAAV per 10 4 rAAV particles are less than about 1rcAAV per 10 8 rAAV particles are less than about 1rcAAV per 10 12 Preparations containing less than about 1 rcAAV particles or no rcAAV).

[0028] The term "polynucleotide" refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides or their analogs. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be interspersed with non-nucleotide components. If present, nucleotide structural modifications may be given before or after polymer assembly. As used herein, the term polynucleotide refers interchangeably to double-stranded and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein as a polynucleotide encompasses each of the double-stranded form and the two complementary single-stranded forms known or predicted to constitute the double-stranded form.

[0029] A polynucleotide or polypeptide has a certain percentage of "sequence identity" with another polynucleotide or polypeptide, meaning that when compared, the percentage of bases or amino acids is the same when the two sequences are compared. Sequence similarity can be measured in many different ways. To determine sequence identity, methods and computer programs including BLAST, which can be obtained on the World Wide Web at ncbi.nlm.nih.gov / BLAST / BLAST, can be used to align sequences. Another alignment algorithm is FASTA, which can be obtained from the Genetics Computing Group (GCG) program package (a wholly owned subsidiary of Oxford Molecular Group, Inc.) in Madison, Wisconsin, USA. Other alignment techniques are described in Methods in Enzymology, Volume 266: Computer Methods for Macromolecular Sequence Analysis (1996), edited by Doolittle, Academic Press, a subsidiary of Harcourt Brace & Co., San Diego, California, USA. Particular attention is paid to alignment programs that allow gaps in sequences. Smith-Waterman is a class of algorithms that allows gaps in sequence alignment. See Meth. Mol. Biol. 70:173-187 (1997). In addition, the GAP program, which uses the Needleman and Wunsch alignment method, can be used to align sequences. See J. Mol. Biol. 48:443-453 (1970).

[0030] Of interest is the BestFit program, which uses the local homology algorithm of Smith Waterman (Advances in Applied Mathematics 2:482-489 (1981) to determine sequence identity. Gap creation penalties typically range from 1 to 5, usually 2 to 4, and in many embodiments will be 3. Gap extension penalties typically range from about 0.01 to 0.20, and in many cases will be 0.10. The program has default parameters determined by the input sequences to be compared. Preferably, sequence identity is determined using the default parameters determined by the program. This program is also available from the Genetics Computing Group (GCG) program package from Madison, Wisconsin, USA.

[0031] Another program of interest is the FastDB algorithm. FastDB is described in Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1988, Alan R. Liss, Inc. The percent sequence identity is calculated by FastDB based on the following parameters:

[0032] Mismatch penalty: 1.00;

[0033] Gap penalty: 1.00;

[0034] Gap size penalty: 0.33; and

[0035] Engagement penalty: 30.0.

[0036] "Gene" refers to a polynucleotide containing at least one open reading frame capable of encoding a specific protein after transcription and translation.

[0037] As used herein, the term "guide RNA" refers to an RNA comprising: i) an "activating" nucleotide sequence that binds to a guide RNA-guided endonuclease (e.g., a Class 2 CRISPR / Cas endonuclease, such as a Type II, Type V, or Type VI CRISPR / Cas endonuclease) and activates the RNA-guided endonuclease; and ii) a "target" nucleotide sequence that comprises a nucleotide sequence that hybridizes with a target nucleic acid. The "activating" nucleotide sequence and the "target" nucleotide sequence can be on separate RNA molecules (e.g., a "dual-guide RNA") or can be on the same RNA molecule (a "single-guide RNA").

[0038] "Small interfering" or "short interfering RNA" or siRNA is an RNA duplex of nucleotides that targets a gene of interest ("target gene"). "RNA duplex" refers to the structure formed by the complementary pairing between two regions of an RNA molecule. siRNA "targets" a gene because the nucleotide sequence of the duplex portion of the siRNA is complementary to the nucleotide sequence of the targeted gene. In some embodiments, the duplex of the siRNA is less than 30 nucleotides in length. In some embodiments, the duplex can be 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 nucleotides in length. In some embodiments, the duplex is 19-25 nucleotides long. The RNA duplex portion of the siRNA can be part of a hairpin structure. In addition to the duplex portion, the hairpin structure may contain a loop portion that is located between the two sequences that form the duplex. The length of the loop can vary. In some embodiments, the loop length is 5, 6, 7, 8, 9, 10, 11, 12, or 13 nucleotides. The hairpin structure may also contain a 3' or 5' overhang.

[0039] In some embodiments, the overhang is a 3' or 5' overhang of 0, 1, 2, 3, 4, or 5 nucleotides in length.

[0040] As used herein, the term "microRNA" refers to any type of interfering RNA, including but not limited to endogenous microRNA and artificial microRNA (e.g., synthetic miRNA). Endogenous microRNA is a small RNA naturally encoded in the genome that can regulate the productive utilization of mRNA. Artificial microRNA can be any type of RNA sequence that can regulate the activity of mRNA other than endogenous microRNA. A microRNA sequence can be an RNA molecule composed of any one or more of these sequences. MicroRNA (or "miRNA") sequences have been described in publications such as Lim et al., 2003, Genes & Development, 17, 991-1008; Lim et al., 2003, Science, 299, 1540; Lee and Ambrose, 2001, Science, 294, 862; Lau et al., 2001, Science 294, 858-861; Lagos-Quintana et al., 2002, Current Biology, 12, 735-739; Lagos-Quintana et al., 2001, Science, 294, 853-857; and Lagos-Quintana et al., 2003, RNA, 9, 175-179. The example of microRNA includes any RNA that is a fragment of a larger RNA, or is miRNA, siRNA, stRNA, sncRNA, tncRNA, snoRNA, smRNA, shRNA, snRNA or other small non-coding RNA. See, for example, U.S. Patent Applications 20050272923, 20050266552, 20050142581 and 20050075492. "MicroRNA precursor" (or "pre-miRNA") refers to a nucleic acid with a stem-loop structure into which a microRNA sequence is incorporated. "Mature microRNA" (or "mature miRNA") includes a microRNA that has been cleaved from a microRNA precursor ("pre-miRNA") or synthesized (e.g., synthesized in a laboratory by cell-free synthesis), and has a length of about 19 nucleotides to about 27 nucleotides, for example, a mature microRNA can have a length of 19nt, 20nt, 21nt, 22nt, 23nt, 24nt, 25nt, 26nt or 27nt. Mature microRNAs can bind to target mRNAs and inhibit translation of the target mRNAs.

[0041] "Recombinant" as applied to a polynucleotide means that the polynucleotide is the product of various combinations of cloning, restriction or ligation steps and other procedures that result in a construct that is different from the polynucleotide found in nature. A recombinant virus is a viral particle that contains a recombinant polynucleotide. The terms include replicas of the original polynucleotide construct and progeny of the original viral construct, respectively.

[0042] "Control elements" or "control sequences" are nucleotide sequences that participate in the interaction of molecules that promote the regulation of the function of a polynucleotide, including the replication, repetition, transcription, splicing, translation, or degradation of the polynucleotide. Regulation can affect the frequency, speed, or specificity of the process and can be enhancing or inhibitory. Control elements known in the art include, for example, transcriptional regulatory sequences, such as promoters and enhancers. A promoter is a region of DNA that is capable of binding ribonucleic acid polymerase under certain conditions and initiates transcription of a coding region that is typically located downstream (in the 3' direction) of the promoter.

[0043] "Operatively linked" or "operably linked" refers to the juxtaposition of genetic elements wherein the elements are in a relationship permitting them to operate in their intended manner. For example, a promoter is operably linked to a coding region if it helps initiate transcription of the coding sequence. Intervening residues may exist between the promoter and the coding region as long as this functional relationship is maintained.

[0044] An "expression vector" is a vector that contains a region encoding a polypeptide of interest and is used to achieve expression of the protein in the intended target cell. The expression vector also contains control elements operably linked to the coding region to promote expression of the protein in the target. The combination of a control element and a gene to which it is operably linked for expression is sometimes referred to as an "expression cassette." Many expression cassettes are known and available in the art, or can be readily constructed from components available in the art.

[0045] "Heterologous" means derived from an entity that is genotypically distinct from the rest of the entity being compared. For example, a polynucleotide introduced into a plasmid or vector derived from a different species by genetic engineering techniques is a heterologous polynucleotide. A promoter that is removed from a native coding sequence and operably linked to a coding sequence that is not found linked in nature is a heterologous promoter. Thus, for example, an rAAV comprising a heterologous nucleic acid encoding a heterologous gene product is an rAAV comprising a nucleic acid that is not normally included in naturally occurring wild-type AAV, and the encoded heterologous gene product is a gene product that is not normally encoded by naturally occurring wild-type AAV. As another example, a variant AAV capsid protein comprising a heterologous peptide inserted into the GH loop of the capsid protein is a variant AAV capsid protein comprising a peptide insertion that is not normally included in naturally occurring wild-type AAV.

[0046] The terms "genetic alteration" and "genetic modification" (and grammatical variations thereof) are used interchangeably herein to refer to a process in which a genetic element (e.g., a polynucleotide) is introduced into a cell other than through mitosis or meiosis. The element may be heterologous to the cell, or it may be an additional copy or modified version of an element already present in the cell. Genetic alteration can be achieved, for example, by transfecting the cell with a recombinant plasmid or other polynucleotide by any method known in the art, such as electroporation, calcium phosphate precipitation, or contact with a polynucleotide-lipid complex. Genetic alteration can also be achieved, for example, by transduction or infection with a DNA or RNA virus or viral vector. Typically, the genetic element is introduced into a chromosome or minichromosome in the cell; however, any alteration that changes the phenotype and / or genotype of the cell and its progeny is included in this term.

[0047] A cell is said to be "stably" altered, transduced, genetically modified, or transformed with a genetic sequence if the sequence can be used to perform its function during long-term in vitro culture of the cell. Generally, such cells are "genetically" altered (genetically modified) because a genetic change has been introduced that is also inheritable by progeny of the altered cell.

[0048] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The terms also encompass amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation to a labeling component. When discussed in the context of gene product delivery to a mammalian subject, polypeptides such as anti-angiogenic polypeptides, neuroprotective polypeptides, and compositions thereof refer to the corresponding intact polypeptides or any fragments or genetically engineered derivatives thereof that retain the desired biochemical function of the intact protein. Similarly, references to nucleic acids encoding anti-angiogenic polypeptides, nucleic acids encoding neuroprotective polypeptides, and other such nucleic acids for gene product delivery to mammalian subjects (which may be referred to as "transgenes" delivered to recipient cells) include polynucleotides encoding intact polypeptides or any fragments or genetically engineered derivatives having the desired biochemical function.

[0049] An "isolated" plasmid, nucleic acid, vector, virus, virion, host cell or other substance refers to a preparation of the substance that lacks at least some of the other components with which the substance or similar substance is naturally present or that may also be present when it is initially prepared. Thus, for example, an isolated substance can be prepared by enriching it from a source mixture using purification techniques. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured relative to a second substance present in the source mixture that may interfere. The more enriched the embodiments of the present invention, the more isolated. In some embodiments, the isolated plasmid, nucleic acid, vector, virus, host cell or other substance is purified, such as, for example, from about 80% to about 90% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, or at least about 99% pure or purer.

[0050] As used herein, the terms "treatment," "treating," and the like refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic, in terms of partially or completely curing a disease and / or adverse effects attributable to the disease. As used herein, "treatment" encompasses any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject susceptible to the disease or at risk of developing the disease but not yet diagnosed as having the disease; (b) inhibiting the disease, i.e., suppressing its development; and (c) alleviating the disease, i.e., causing regression of the disease.

[0051] The terms "subject," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans and non-human primates, including apes and humans; mammalian sports animals (e.g., horses, camels, etc.); mammalian farm animals (e.g., sheep, goats, cows, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.). In some cases, the subject is a human.

[0052] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, and thus can certainly vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments, and is not intended to be limiting, as the scope of the present invention is limited only by the appended claims.

[0053] Where a range of values ​​is provided, it is understood that unless the context clearly dictates otherwise, every intervening value between the upper and lower limits of that range, to the tenth of the unit of the lower limit, and any other stated or intervening value in the stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also encompassed within the invention.

[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials to which the publications are referred.

[0055] It must be noted that as used herein and in the appended claims, the singular forms "a / an," "or," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an AAV capsid" includes a plurality of such capsids, and reference to "the AAV virion" includes reference to one or more AAV virions and their equivalents known to those skilled in the art, and so forth. It is further noted that the claims can be drafted to exclude any optional elements. Thus, this statement is intended to serve as a prior basis for using exclusive terms such as "solely," "only," and the like in conjunction with the recitation of claim elements, or for adopting a "negative" limitation.

[0056] It should be understood that certain features of the present invention that are described in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the present invention that are described in the context of a single embodiment for simplicity may also be provided separately or in any suitable subcombination. All combinations of embodiments of the present invention are specifically contemplated and disclosed herein as if each combination were individually and specifically disclosed. In addition, all subcombinations of the various embodiments and elements thereof are also specifically contemplated and disclosed herein as if each such subcombination were individually and specifically disclosed herein.

[0057] The publications discussed herein are provided solely for their disclosures prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention. Furthermore, the publication dates provided may differ from the actual publication dates, which can be independently verified. DETAILED DESCRIPTION

[0058] The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid proteins, wherein the recombinant AAV (rAAV) virions exhibit greater infectivity to retinal cells compared to wild-type AAV; and wherein the rAAV virions comprise heterologous nucleic acids. Compared to the infectivity of corresponding wild-type AAV to retinal cells, rAAV virions exhibit greater infectivity to retinal cells. Retinal cells can be photoreceptors (e.g., rods; cones), retinal ganglion cells (RGCs), Müller cells (Müller glial cells), astrocytes (e.g., retinal astrocytes), bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelial cells (RPE). The present disclosure also provides methods for delivering gene products to retinal cells in an individual, and methods for treating eye diseases. The present disclosure provides a rAAV virion with an altered capsid protein, wherein the rAAV virion exhibits at least a 5-fold increase in localization to one or more of the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, and retinal pigment epithelial cells compared to the extent to which an AAV virion comprising the corresponding parental AAV capsid protein localizes to the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, or retinal pigment epithelial cells; and wherein the rAAV virion comprises a heterologous nucleic acid.

[0059] Variant AAV capsid polypeptide

[0060] The present disclosure provides a variant AAV capsid protein. The variant AAV capsid protein of the present disclosure comprises an insertion of a heterologous peptide of 5 to 20 amino acids in the surface accessible (e.g., solvent accessible) portion of the parent AAV capsid protein, such that the variant capsid protein imparts increased infectivity to retinal cells when present in an AAV virion compared to the infectivity of the AAV virion comprising the corresponding parent AAV capsid protein to retinal cells. In other cases, the retinal cells are Müller cells. Other retinal cells include amacrine cells, bipolar cells, and horizontal cells. "Insertion of about 5 to about 20 amino acids" is also referred to herein as "peptide insertion" (e.g., heterologous peptide insertion). "Corresponding parent AAV capsid protein" refers to an AAV capsid protein of the same AAV serotype without peptide insertion. In many cases, the variant AAV capsid comprises a single heterologous peptide insertion of 5 to 20 amino acids (e.g., 5 to 7, 7 to 10, 10 to 12, 12 to 15, or 15 to 20 amino acids).

[0061] The insertion site is in the GH loop or loop IV of the AAV capsid protein, for example, in a solvent accessible portion of the GH loop or loop IV of the AAV capsid protein. For the GH loop / loop IV of the AAV capsid, see, for example, van Vliet et al. (2006) Mol. Ther. 14:809; Padron et al. (2005) J. Virol. 79:5047; and Shen et al. (2007) Mol. Ther. 15:1955. For example, the insertion site can be within amino acids 411-650 of the AAV capsid protein, such as Figures 6A-6C For example, the insertion site can be within amino acids 570-611 of AAV2, within amino acids 571-612 of AAV1, within amino acids 560-601 of AAV5, within amino acids 571 to 612 of AAV6, within amino acids 572 to 613 of AAV7, within amino acids 573 to 614 of AAV8, within amino acids 571 to 612 of AAV9, or within amino acids 573 to 614 of AAV10, as depicted in FIG. Figure 5 In some cases, the insertion site is between amino acids 588 and 589 of the AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the insertion site is between amino acids 587 and 588 of the AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype.

[0062] In some cases, a heterologous peptide of about 5 to about 20 amino acids (e.g., 5 to 7, 7 to 10, 10 to 12, 12 to 15, or 15 to 20 amino acids) in length is inserted into an insertion site in the GH loop or loop IV of the capsid protein relative to the corresponding parent AAV capsid protein. For example, the insertion site can be between amino acids 587 and 588 of AAV2, or a corresponding position of a capsid subunit of another AAV serotype. It should be noted that insertion sites 587 / 588 are based on the AAV2 capsid protein. Heterologous peptides of 5 to about 20 amino acids (e.g., 5 to 7, 7 to 10, 10 to 12, 12 to 15, or 15 to 20 amino acids) in length can be inserted into corresponding sites in AAV serotypes other than AAV2 (e.g., AAV8, AAV9, etc.). Based on a comparison of the amino acid sequences of capsid proteins of various AAV serotypes, one skilled in the art will know the location of the insertion site "corresponding to amino acids 587-588 of AAV2" in the capsid protein of any given AAV serotype. Figure 4 ) The corresponding sequence is shown in Figure 5See, e.g., GenBank Accession No. NP_049542, AAV1; GenBank Accession No. AAD13756, AAV5; GenBank Accession No. AAB95459, AAV6; GenBank Accession No. YP_077178, AAV7; GenBank Accession No. YP_077180, AAV8; GenBank Accession No. AAS99264, AAV9; and GenBank Accession No. AAT46337, AAV10.

[0063] For example, the insertion site can be between amino acids 587 and 588 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, or between amino acids 588 and 589 of AAV10. Figure 5 Insertion sites are underlined; amino acid numbering is based on Figure 5 The number depicted in .

[0064] In some embodiments, the subject capsid protein comprises an amino acid sequence similar to Figures 6A-6C The amino acid sequence set forth in has at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity and is inserted into the GH loop of a heterologous peptide of 5 to 20 amino acids (e.g., 5 to 7, 7 to 10, 10 to 12, 12 to 15, or 15 to 20 amino acids) in length.

[0065] Insertion peptide

[0066] As described above, a heterologous peptide of about 5 amino acids to about 20 amino acids in length is inserted into the GH loop of the AAV capsid. In some cases, the insertion peptide has a length of 5 to 20 amino acids. In some cases, the insertion peptide has a length of 7 to 15 amino acids. In some cases, the insertion peptide has a length of 9 to 15 amino acids. In some cases, the insertion peptide has a length of 9 to 12 amino acids. The insertion peptide has a length of 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids. In some cases, the insertion peptide has a length of 7 amino acids. In some cases, the insertion peptide has a length of 8 amino acids. In some cases, the insertion peptide has a length of 9 amino acids. In some cases, the insertion peptide has a length of 10 amino acids. In some cases, the insertion peptide has a length of 11 amino acids. In some cases, the insertion peptide has a length of 12 amino acids. In some cases, the insertion peptide has a length of 13 amino acids. In some cases, the insertion peptide has a length of 14 amino acids. In some cases, the insertion peptide has a length of 15 amino acids.

[0067] In some cases, the peptide insert is a peptide of Formula I:

[0068] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0069] X1 is Leu, Ile, Pro or Gln;

[0070] X2 is Ala, Pro, Ser, Asp, Gly, Thr or Val;

[0071] X3 is Lys, His, Thr, Ile, Pro, Val, Arg, Ala, Asp, Glu, Asn, Gln or Tyr;

[0072] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile, Asn, Glu, Lys or Arg;

[0073] X5 is Asp, Ser, Gln, Val, Thr, Gly, Ala, Asn, Lys or Tyr;

[0074] X6 is Thr, Ala, Gln, Ser, Glu, Pro or Ile;

[0075] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys, Ala or Cys;

[0076] X8 is Lys, Ser, Arg, Thr, Ala, Glu, Ile or Asn;

[0077] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0078] X 10 is Ala, Phe, Asp, Thr, Val or Met.

[0079] The peptide inserts of Formula I include (but are not limited to) (1) LAKDATKNA (SEQ ID NO:47); (2) PAHQDTTKNA (SEQ ID NO:48); (3) LAHQDTTKNA (SEQ ID NO:49); (4) LATTSQNKPA (SEQ ID NO:50); (5) LAISDQTKHA (SEQ ID NO:51); (6) IARGVAPSSA (SEQ ID NO:52); (7) LAPDSTTRSA (SEQ ID NO:53); (8) LAKGTELKPA (SEQ ID NO:54); (9) LAIIDATKNA (SEQ ID NO:55); (10) LAVDGAQRSA (SEQ ID NO:56); (11) PAPQDTTKKA (SEQ ID NO:57); (12) LPHQDTTKNA (SEQ ID NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (15) LAKSDQSKPA (SEQ ID NO:61); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); (18) LAVSDSTKAA (SEQ ID NO:64); (19) LAAQGTAKKPA (SEQ ID NO:65); (20) LAPDQTTRNA (SEQ ID NO:66); (21) LAASDSTKAA (SEQ ID NO:67); (22) LAPQDTTKNA (SEQ ID NO:68); (23) LAKADETRPA (SEQ ID NO:69); (24) LAHQDTAKNA (SEQ ID NO:70); (25) LAHQDTKKNA (SEQ ID NO:71); (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (28) LAHQDTTRNA (SEQ ID NO:74); (29) LAHQDTTNA (SEQ ID NO:75); (30) LAHQGTTKNA (SEQ ID NO:76); (31) LAHQVTTKNA (SEQ ID NO:77); (32) LAISDQSKPA (SEQ ID NO:78); (33) LADATKTA (SEQ ID NO:79); (34) LAKDTTKNA (SEQ ID NO:80);(35)LAKSDQSRPA(SEQ ID NO:81);(36)LAPQDTKKNA(SEQ ID NO:82);(37)LATSDSTKAA(SEQ ID NO:83);(38)LAVDGSQRSA(SEQ IDNO:84);(39)LPISDQTKHA(SEQ ID NO:85);(40)LPKDATKTIA(SEQ ID NO:86);(41)LPPQDTTKNA(SEQ ID NO:87);(42)PAPQDTTKNA(SEQ ID NO:88);(43)QAHQDTTKNA(SEQ IDNO:89);(44)LAHETSPRPA(SEQ ID NO:90);(45)LAKSTSTAPA(SEQ ID NO:91);(46)LADQDTTKNA(SEQ ID NO:92);(47)LAESDQSKPA(SEQ ID NO:93);(48)LAHKDTTKNA(SEQ ID NO:94);(49)LAHKTQQKM(SEQ ID NO:95);(50)LAHQDTTENA(SEQ ID NO:96);(51)LAHQDTTINA(SEQ ID NO:97);(52)LAHQDTTKKT(SEQ ID NO:98);(53)LAHQDTTKND(SEQ ID NO:99);(54)LAHQDTTKNT(SEQ ID NO:100);(55)LAHQDTTKNV(SEQ ID NO:101);(56)LAHQDTTKTM(SEQ ID NO:102);(57)LAHQNTTKNA(SEQ ID NO:103);(58)LAHRDTTKNA(SEQ ID NO:104);(59)LAISDQTNHA(SEQ ID NO:105);(60)LAKQKSASTA(SEQ ID NO:106);(61)LAKSDQCKPA(SEQ ID NO:107);(62)LAKSDQSKPD(SEQ ID NO:108);(63)LAKSDQSNPA(SEQ ID NO:109);(64)LAKSYQSKPA(SEQ ID NO:110);(65)LANQDTTKNA(SEQ ID NO:110) NO:111);(66)LAPQNTTKNA(SEQ ID NO:112);(67)LAPSSIQKPA(SEQ ID NO:113);(68)LAQQDTTKNA(SEQ IDNO:114);(69) LAYQDTTKNA (SEQ ID NO: 115); (70) LDHQDTTKNA (SEQ ID NO: 116); (71) LDHQDTTKSA (SEQ ID NO: 117); (72) LGHQDTTKNA (SEQ ID NO: 118); (73) LPHQDTTKND (SEQ ID NO: 119); (74) LPHQDTTKNT (SEQ ID NO: 120); (75) LPHQDTTNNA (SEQ ID NO: 121); (76) LTHQDTTKNA (SEQ ID NO: 122); (77) LTKDATKTIA (SEQ ID NO: 123); (78) LTPQDTTKNA (SEQ ID NO:124); and (79) LVHQDTTKNA (SEQ ID NO:125). ;

[0080] In some cases, the peptide insert is a peptide of Formula II:

[0081] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0082] X1 is Leu, Ile or Pro;

[0083] X2 is Ala, Pro or Ser;

[0084] X3 is Lys, His, Thr, Ile, Pro, Val, Arg or Ala;

[0085] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile or Asn;

[0086] X5 is Asp, Ser, Gln, Val, Thr, Gly or Ala;

[0087] X6 is Thr, Ala, Gln, Ser, Glu or Pro;

[0088] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys or Ala;

[0089] X8 is Lys, Ser, Arg or Thr;

[0090] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0091] X 10 For Ala.

[0092] The peptide inserts of formula II include (but are not limited to) (1) LAKDATKNA (SEQ ID NO:47); (2) PAHQDTTKNA (SEQ ID NO:48); (3) LAHQDTTKNA (SEQ ID NO:49); (4) LATTSQNKPA (SEQ ID NO:50); (5) LAISDQTKHA (SEQ ID NO:51); (6) IARGVAPSSA (SEQ ID NO:52); (7) LAPDSTTRSA (SEQ ID NO:53); (8) LAKGTELKPA (SEQ ID NO:54); (9) LAIIDATKNA (SEQ ID NO:55); (10) LAVDGAQRSA (SEQ ID NO:56); (11) PAPQDTTKKA (SEQ ID NO:57); (12) LPHQDTTKNA (SEQ ID NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (15) LAKSDQSKPA (SEQ ID NO:61); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); (18) LAVSDSTKAA (SEQ ID NO:64); (19) LAAQGTAKKPA (SEQ ID NO:65); (20) LAPDQTTRNA (SEQ ID NO:66); (21) LAASDSTKAA (SEQ ID NO:67); (22) LAPQDTTKNA (SEQ ID NO:68); (23) LAKADETRPA (SEQ ID NO:69); (24) LAHQDTAKNA (SEQ ID NO:70); (25) LAHQDTKKNA (SEQ ID NO:71); (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (28) LAHQDTTRNA (SEQ ID NO:74); (29) LAHQDTTNA (SEQ ID NO:75); (30) LAHQGTTKNA (SEQ ID NO:76); (31) LAHQVTTKNA (SEQ ID NO:77); (32) LAISDQSKPA (SEQ ID NO:78); (33) LADATKTA (SEQ ID NO:79); (34) LAKDTTKNA (SEQ ID NO:80);(35) LAKSDQSRPA (SEQ ID NO:81); (36) LAPQDTKKNA (SEQ ID NO:82); (37) LATSDSTKAA (SEQ ID NO:83); (38) LAVDGSQRSA (SEQ ID NO:84); (39) LPISDQTKHA (SEQ ID NO:85); (40) LPKDATKTIA (SEQ ID NO:86); (41) LPPQDTTKNA (SEQ ID NO:87); and (42) PAPQDTTKNA (SEQ ID NO:88).;

[0093] Peptides of Formula II include, but are not limited to: (1) LAKDATKNA (SEQ ID NO: 47); (2) PAHQDTTKNA (SEQ ID NO: 48); (3) LAHQDTTKNA (SEQ ID NO: 49); (4) LATTSQNKPA (SEQ ID NO: 50); (5) LAISDQTKHA (SEQ ID NO: 51); (6) IARGVAPSSA (SEQ ID NO: 52); (7) LAPDSTTRSA (SEQ ID NO: 53); (8) LAKGTELKPA (SEQ ID NO: 54); (9) LAIIDATKNA (SEQ ID NO: 55); (10) LAVDGAQRSA (SEQ ID NO: 56); (11) PAPQDTTKKA (SEQ ID NO: 57); (12) LPHQDTTKNA (SEQ ID NO: 58). NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (15) LAKSDQSKPA (SEQ ID NO:61); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); and (18) LAVSDSTKAA (SEQ ID NO:64). In some cases, the peptide insert is (1) LAKDATKNA (SEQ ID NO:47). In some cases, the peptide insert is (2) PAHQDTTKNA (SEQ ID NO:48). In some cases, the peptide insert is (3) LAHQDTTKNA (SEQ ID NO:49). In some cases, the peptide insert is (4) LATTSQNKPA (SEQ ID NO:50). In some cases, the peptide insert is (5) LAISDQTKHA (SEQ ID NO: 51). In some cases, the peptide insert is (6) IARGVAPSSA (SEQ ID NO: 52). In some cases, the peptide insert is (7) LAPDSTTRSA (SEQ ID NO: 53). In some cases, the peptide insert is (8) LAKGTELKPA (SEQ ID NO: 54). In some cases, the peptide insert is (9) LAIIDATKNA (SEQ ID NO: 55). In some cases, the peptide insert is (10) LAVDGAQRSA (SEQ ID NO: 56). In some cases, the peptide insert is (11) PAPQDTTKKA (SEQ ID NO: 57).In some cases, the peptide insert is (12) LPHQDTTKNA (SEQ ID NO: 58). In some cases, the peptide insert is (13) LAKDATKTIA (SEQ ID NO: 59). In some cases, the peptide insert is (14) LAKQQSASTA (SEQ ID NO: 60). In some cases, the peptide insert is (15) LAKSDQSKPA (SEQ ID NO: 61). In some cases, the peptide insert is (16) LSHQDTTKNA (SEQ ID NO: 62). In some cases, the peptide insert is (17) LAANQPSKPA (SEQ ID NO: 63). In some cases, the peptide insert is (18) LAVSDSTKAA (SEQ ID NO: 64).

[0094] In some cases, the peptide insert is a peptide of Formula III:

[0095] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0096] X1 is Leu, Ile or Pro;

[0097] X2 is Ala, Pro or Ser;

[0098] X3 is Lys, His, Thr, Ile, Pro, Val, Arg or Ala;

[0099] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile or Asn;

[0100] X5 is Asp, Ser, Gln, Val, Thr, Gly or Ala;

[0101] X6 is Thr, Ala, Gln, Ser, Glu or Pro;

[0102] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys or Ala;

[0103] X8 is Lys, Ser, Arg or Thr;

[0104] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0105] X10 is Ala, Thr, Asp Val or Met.

[0106] The peptide inserts of formula III include, but are not limited to, (1) LAKDATKNA (SEQ ID NO:47); (2) PAHQDTTKNA (SEQ ID NO:48); (3) LAHQDTTKNA (SEQ ID NO:49); (6) IARGVAPSSA (SEQ ID NO:52); (7) LAPDSTTRSA (SEQ ID NO:53); (8) LAKGTELKPA (SEQ ID NO:54); (9) LAIIDATKNA (SEQ ID NO:55); (10) LAVDGAQRSA (SEQ ID NO:56); (11) PAPQDTTKKA (SEQ ID NO:57); (12) LPHQDTTKNA (SEQ ID NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); (18) LAVSDSTKAA (SEQ ID NO:64); (19) LAAQGTAKPA (SEQ ID NO:65); (20) LAPDQTTRNA (SEQ ID NO:66); (24) LAHQDTAKNA (SEQ ID NO:70); (25) LAHQDTKKNA (SEQ ID NO:71); (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (28) LAHQDTTRNA (SEQ ID NO:74); (29) LAHQDTTTNA (SEQ ID NO:75); (30) LAHQGTTKNA (SEQ ID NO:76); (21) LAASDSTKAA (SEQ ID NO:67); (22) LAPQDTTKNA (SEQ ID NO:68); (31) LAHQVTTKNA (SEQ ID NO:77); (33) LAKDATKTA (SEQ ID NO:79); (34) LAKDTTKNA (SEQ ID NO:80); (36) LAPQDTKKNA (SEQ ID NO:82); (37) LATSDSTKAA (SEQ ID NO:83); (38) LAVDGSQRSA (SEQ ID NO:84); (41) LPPQDTTKNA (SEQ ID NO:87); (42) PAPQDTTKNA (SEQ ID NO:88);(52) LAHQDTTKT (SEQ ID NO: 98); (53) LAHQDTTKND (SEQ ID NO: 99); (54) LAHQDTTKNT (SEQ ID NO: 100); (55) LAHQDTTKNV (SEQ ID NO: 101); (56) LAHQDTTKTM (SEQ ID NO: 102); (73) LPHQDTTKND (SEQ ID NO:119); and (74) LPHQDTTKNT (SEQ ID NO:120). ;

[0107] In some cases, the peptide insert is a peptide of Formula IV:

[0108] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0109] X1 is Leu;

[0110] X2 is Ala;

[0111] X3 is Lys, His, Thr, Ile, Pro or Val;

[0112] X4 (if present) is Gln, Asp, Ser or Gly;

[0113] X5 is Asp, Ser or Gln;

[0114] X6 is Thr, Ala, Gln or Ser;

[0115] X7 is Thr or Ser;

[0116] X8 is Lys, Ser or Arg;

[0117] X9 is Asn, Pro or Ser; and

[0118] X 10 For Ala.

[0119] Peptide inserts of Formula IV include, but are not limited to, (1) LAKDATKNA (SEQ ID NO:47); (3) LAHQDTTKNA (SEQ ID NO:49); (7) LAPDSTTRSA (SEQ ID NO:53); (15) LAKSDQSKPA (SEQ ID NO:61); (20) LAPDQTTRNA (SEQ ID NO:66); (22) LAPQDTTKNA (SEQ ID NO:68); (28) LAHQDTTRNA (SEQ ID NO:74); (32) LAISDQSKPA (SEQ ID NO:78); (34) LAKDTTKNA (SEQ ID NO:80); and (35) LAKSDQSRPA (SEQ ID NO:81).

[0120] In some cases, the peptide insert is a peptide of Formula V:

[0121] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0122] X1 is Leu;

[0123] X2 is Ala;

[0124] X3 is Lys or His;

[0125] X4 (if present) is Gln, Asp, Ser or Gly;

[0126] X5 is Asp, Ser or Gln;

[0127] X6 is Thr, Ala, Gln or Ser;

[0128] X7 is Thr or Ser;

[0129] X8 is Lys, Ser or Arg;

[0130] X9 is Asn, Pro or Ser; and

[0131] X 10 For Ala.

[0132] Peptide inserts of Formula V include, but are not limited to, (1) LAKDATKNA (SEQ ID NO:47); (15) LAKSDQSKPA (SEQ ID NO:51); (34) LAKDTTKNA (SEQ ID NO:80); and (35) LAKSDQSRPA (SEQ ID NO:81).

[0133] In some cases, the peptide insert is a peptide of Formula VI:

[0134] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0135] X1 is Leu;

[0136] X2 is Ala;

[0137] X3 is Asn, Lys, Thr, Gln, Ser, Ile or Leu;

[0138] X4 is Ser, Ala, Thr, Glu, Gln, Gly, Lys, or Pro;

[0139] X5 is Asp, Pro, Glu, Thr, Asn, or Arg;

[0140] X6 is Ile, His, Thr, Gln, Asn, Tyr, Asp or Glu;

[0141] X7 is Gln, Thr, Asn, Ala or Lys;

[0142] X8 is Lys, Thr, Arg or Asp;

[0143] X9 is Pro, Asn, Thr, Arg, Lys or Ser; and

[0144] X 10 For Ala.

[0145] Peptides of Formula VI include, but are not limited to: (80) LAKANQNTPA (SEQ ID NO: 126); (81) LATTPITKPA (SEQ ID NO: 127); (82) LATTPIAKPA (SEQ ID NO: 128); (83) LAIEDHTKSA (SEQ ID NO: 129); (84) LAQSEHQRPA (SEQ ID NO: 130); (85) LAKSPNKDNA (SEQ ID NO: 131); (86) LANQDYTKTA (SEQ ID NO: 132); (87) LANSTDQTRA (SEQ ID NO: 133); (88) LALGETTRPA (SEQ ID NO: 134); (89) LANSTEQTRA (SEQ ID NO: 135); (90) LAQADTTKNA (SEQ ID NO: 136); (91) LASKDITKTA (SEQ ID NO: 137). NO: 137); and (92) LASPRHNKKC (SEQ ID NO: 138).

[0146] In some cases, the peptide insert is a peptide of Formula VII: LAHQDTTKX1X2X3 (SEQ ID NO: 148), wherein X1 is Lys, Thr, Asn, or His; X2 is Ala, Thr, Val, Ile, Met, or Asp; and X3, if present, is Ala. Peptides of Formula VII include, but are not limited to: (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (52) LAHQDTTKKT (SEQ ID NO:98); (53) LAHQDTTKND (SEQ ID NO:99); (54) LAHQDTTKNT (SEQ ID NO:100); (55) LAHQDTTKNV (SEQ ID NO:101); (56) LAHQDTTKTM (SEQ ID NO:102); and (93) LAHQDTTKTIA (SEQ ID NO:139).

[0147] In some cases, the peptide insert is a peptide of Formula VIII: LAX1QX2TX3X4X5X6 (SEQ ID NO: 149), wherein X1 is Ala, Pro, Asp, or His; X2 is Gly or Asp; X3 is Ala, Thr, or Lys; X4 is Asn, Glu, Lys, Arg, or Thr; X5 is Leu, Asn, Lys, or Thr; and X6, if present, is Ala, Thr, Asp, Val, or Met. Peptides of Formula VIII include (but are not limited to) (94) LAAQGTANL (SEQ ID NO:140); (22) LAPQDTTKNA (SEQ ID NO:68); (46) LADQDTTKNA (SEQ ID NO:92); (24) LAHQDTAKNA (SEQ ID NO:70); (25) LAHQDTKKNA (SEQ ID NO:71); (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (28) LAHQDTTRNA (SEQ ID NO:74); (29) LAHQDTTTNA (SEQ ID NO:75); (50) LAHQDTTENA (SEQ ID NO:96); (51) LAHQDTTINA (SEQ ID NO:74) NO:97); (52)LAHQDTTKKT(SEQ ID NO:98); (53) LAHQDTTKND (SEQ ID NO:99); (54) LAHQDTTKNT (SEQ ID NO:100); (55) LAHQDTTKNV (SEQ ID NO:101); and (56) LAHQDTTKTM (SEQ ID NO:102).

[0148] In some cases, the peptide insert is a peptide of Formula IX: X1AX2X3DX4TKX5A (SEQ ID NO: 150), wherein X1 is Val or Leu; X2 is Ile, Val, His, or Asp; X3 is Glu, Ser, Lys, or Gln; X4 is His, Ser, or Thr; and X5 is Ser, Ala, Asn, His, or Lys. Peptides of Formula IX include, but are not limited to, (95) VAIEDHTKSA (SEQ ID NO: 141); (18) LAVSDSTKAA (SEQ ID NO: 64); (46) LADQDTTKNA (SEQ ID NO: 92); (48) LAHKDTTKNA (SEQ ID NO: 94); (26) LAHQDTTKHA (SEQ ID NO: 72); and (27) LAHQDTTKKA (SEQ ID NO: 73).

[0149] In some cases, the peptide insert is a peptide of formula X: XXAXQXTXKNA (SEQ ID NO: 151), wherein X1, if present, is Leu; X2, if present, is Ala; X3 is Lys, Leu, or Pro; X4 is Asn, His, Pro, or Tyr; X5 is Asn, Gly, Val, or Asp; and X6 is Pro or Thr. Peptides of Formula X include, but are not limited to, (96) LAKANQNTPKNA (SEQ ID NO: 142); (57) LAHQNTTKNA (SEQ ID NO: 103); (66) LAPQNTTKNA (SEQ ID NO: 112); (69) LAYQDTTKNA (SEQ ID NO: 115); (30) LAHQGTTKNA (SEQ ID NO: 76); (31) LAHQVTTKNA (SEQ ID NO: 77); and (42) PAPQDTTKNA (SEQ ID NO: 88).

[0150] In some cases, the peptide insert is LAHQDTTKKX (SEQ ID NO: 143), wherein X is any amino acid. In some cases, the peptide insert is LAHQDTTKKX (SEQ ID NO: 143), wherein X is Ala, Thr, Asp, Val, or Met. In some cases, the peptide insert is (27) LAHQDTTKKA (SEQ ID NO: 73). In some cases, the peptide insert is (52) LAHQDTTKKT (SEQ ID NO: 98). In some cases, the peptide insert is LAHQDTTKKD (SEQ ID NO: 144). In some cases, the peptide insert is LAHQDTTKKV (SEQ ID NO: 145). In some cases, the peptide insert is LAHQDTTKKM (SEQ ID NO: 146).

[0151] In some cases, the peptide insert is not (88) LALGETTRPA (SEQ ID NO: 134). In some cases, the peptide insert is not LGETTRP (SEQ ID NO: 147).

[0152] Suitable peptide inserts include (but are not limited to) (1) LAKDATKNA (SEQ ID NO:47); (2) PAHQDTTKNA (SEQ ID NO:48); (3) LAHQDTTKNA (SEQ ID NO:49); (4) LATTSQNKPA (SEQ ID NO:50); (5) LAISDQTKHA (SEQ ID NO:51); (6) IARGVAPSSA (SEQ ID NO:52); (7) LAPDSTTRSA (SEQ ID NO:53); (8) LAKGTELKPA (SEQ ID NO:54); (9) LAIIDATKNA (SEQ ID NO:55); (10) LAVDGAQRSA (SEQ ID NO:56); (11) PAPQDTTKKA (SEQ ID NO:57); (12) LPHQDTTKNA (SEQ ID NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (15) LAKSDQSKPA (SEQ ID NO:61); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); (18) LAVSDSTKAA (SEQ ID NO:64); (19) LAAQGTAKKPA (SEQ ID NO:65); (20) LAPDQTTRNA (SEQ ID NO:66); (21) LAASDSTKAA (SEQ ID NO:67); (22) LAPQDTTKNA (SEQ ID NO:68); (23) LAKADETRPA (SEQ ID NO:69); (24) LAHQDTAKNA (SEQ ID NO:70); (25) LAHQDTKKNA (SEQ ID NO:71); (26) LAHQDTTKHA (SEQ ID NO:72); (27) LAHQDTTKKA (SEQ ID NO:73); (28) LAHQDTTRNA (SEQ ID NO:74); (29) LAHQDTTNA (SEQ ID NO:75); (30) LAHQGTTKNA (SEQ ID NO:76); (31) LAHQVTTKNA (SEQ ID NO:77); (32) LAISDQSKPA (SEQ ID NO:78); (33) LADATKTA (SEQ ID NO:79); (34) LAKDTTKNA (SEQ ID NO:80);(35)LAKSDQSRPA(SEQ ID NO:81);(36)LAPQDTKKNA(SEQ ID NO:82);(37)LATSDSTKAA(SEQ ID NO:83);(38)LAVDGSQRSA(SEQ IDNO:84);(39)LPISDQTKHA(SEQ ID NO:85);(40)LPKDATKTIA(SEQ ID NO:86);(41)LPPQDTTKNA(SEQ ID NO:87);(42)PAPQDTTKNA(SEQ ID NO:88);(43)QAHQDTTKNA(SEQ IDNO:89);(44)LAHETSPRPA(SEQ ID NO:90);(45)LAKSTSTAPA(SEQ ID NO:91);(46)LADQDTTKNA(SEQ ID NO:92);(47)LAESDQSKPA(SEQ ID NO:93);(48)LAHKDTTKNA(SEQ ID NO:94);(49)LAHKTQQKM(SEQ ID NO:95);(50)LAHQDTTENA(SEQ ID NO:96);(51)LAHQDTTINA(SEQ ID NO:97);(52)LAHQDTTKKT(SEQ ID NO:98);(53)LAHQDTTKND(SEQ ID NO:99);(54)LAHQDTTKNT(SEQ ID NO:100);(55)LAHQDTTKNV(SEQ ID NO:101);(56)LAHQDTTKTM(SEQ ID NO:102);(57)LAHQNTTKNA(SEQ ID NO:103);(58)LAHRDTTKNA(SEQ ID NO:104);(59)LAISDQTNHA(SEQ ID NO:105);(60)LAKQKSASTA(SEQ ID NO:106);(61)LAKSDQCKPA(SEQ ID NO:107);(62)LAKSDQSKPD(SEQ ID NO:108);(63)LAKSDQSNPA(SEQ ID NO:109);(64)LAKSYQSKPA(SEQ ID NO:110);(65)LANQDTTKNA(SEQ ID NO:110) NO:111);(66)LAPQNTTKNA(SEQ ID NO:112);(67)LAPSSIQKPA(SEQ ID NO:113);(68)LAQQDTTKNA(SEQ IDNO:114);(69) LAYQDTTKNA (SEQ ID NO: 115); (70) LDHQDTTKNA (SEQ ID NO: 116); (71) LDHQDTTKSA (SEQ ID NO: 117); (72) LGHQDTTKNA (SEQ ID NO: 118); (73) LPHQDTTKND (SEQ ID NO: 119); (74) LPHQDTTKNT (SEQ ID NO: 120); (75) LPHQDTTNNA (SEQ ID NO: 121); (76) LTHQDTTKNA (SEQ ID NO: 122); (77) LTKDATKTIA (SEQ ID NO: 123); (78) LTPQDTTKNA (SEQ IDNO:124); (79)LVHQDTTKNA(SEQ ID NO:125); (80)LAKANQNTPA(SEQ ID NO:126); (81) LATTPITKPA (SEQ ID NO:127); (82) LATTPIAKPA (SEQ ID NO:128); (83) LAIEDHTKSA (SEQ ID NO:129); (84) LAQSEHQRPA (SEQ ID NO:130); (85) LAKSPNKDNA (SEQ ID NO:131); (86) LANQDYTKTA (SEQ ID NO:132); (87) LANSTDQTRA (SEQ ID NO:133); (88) LALGETTRPA (SEQ ID NO:134); (89) LANSTEQTRA (SEQ ID NO:135); (90) LAQADTTKNA (SEQ ID NO: 136); (91) LASKDITKTA (SEQ ID NO: 137); (92) LASPRHNKKC (SEQ ID NO:138); (93) LAHQDTTKTIA (SEQ ID NO:139); (94) LAAQGTANL (SEQ ID NO:140); (95) VAIEDHTKSA (SEQ ID NO:141); and (96) LAKANQNTPKNA (SEQ ID NO:142). ;

[0153] In some cases, the peptide insert is (11) PAPQDTTKKA (SEQ ID NO: 57). In some cases, the peptide insert is (7) LAPDSTTRSA (SEQ ID NO: 53).

[0154] In some embodiments, other than an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to the corresponding parent AAV capsid protein, the subject rAAV virion capsid does not comprise any other amino acid substitutions, insertions, or deletions. In other embodiments, a subject rAAV virion capsid comprises 1 to about 25 amino acid insertions, deletions, or substitutions compared to the parental AAV capsid protein, in addition to an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to the corresponding parental AAV capsid protein. For example, in some embodiments, a subject rAAV virion capsid comprises 1 to about 5, about 5 to about 10, about 10 to about 15, about 15 to about 20, or about 20 to about 25 amino acid insertions, deletions, or substitutions compared to the parental AAV capsid protein, in addition to an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to the corresponding parental AAV capsid protein.

[0155] In some cases, a subject rAAV virion capsid does not include one, two, three, or four of the following amino acid substitutions: Y273F, Y444F, Y500F, and Y730F.

[0156] In some cases, in addition to the inserted peptide as described above, a subject variant capsid polypeptide comprises one, two, three, or four of the following amino acid substitutions: Y273F, Y444F, Y500F, and Y730F.

[0157] In some cases, a subject rAAV virion capsid is a chimeric capsid, e.g., a capsid comprising a portion of an AAV capsid of a first AAV serotype and a portion of an AAV capsid of a second serotype; and comprises from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to the corresponding parental AAV capsid protein.

[0158] In some embodiments, a subject rAAV virion comprises a capsid protein having an amino acid sequence similar to Figure 4 and an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to the corresponding parent AAV capsid protein. In some embodiments, the subject rAAV virion comprises a capsid protein having an amino acid sequence having a sequence similar to that of the parent AAV capsid protein. Figure 4 at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence provided in Figure 4 The amino acid sequence depicted in , comprises an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; for example, 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between amino acids 587 and 588, or at corresponding positions relative to the corresponding parent AAV capsid protein.

[0159] In some embodiments, a subject rAAV virion comprises a capsid protein comprising a GH loop comprising Figure 5The amino acid sequences set forth in are amino acid sequences having at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity and comprising an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between the bold and underlined amino acids.

[0160] In some embodiments, a subject rAAV virion comprises a capsid protein having an amino acid sequence similar to Figures 6A-6C and comprises an insertion of about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between amino acids 587 and 588 of AAV2, or at a corresponding site relative to another AAV genotype. In some cases, the corresponding insertion site is as Figure 6B The sites are indicated by bold text and underline.

[0161] The subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of retinal cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein.

[0162] In some cases, a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of retinal cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0163] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of photoreceptor (rod or cone) cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein.

[0164] In some embodiments, the subject rAAV virions, when administered via intravitreal injection, exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of photoreceptor (rod or cone) cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0165] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity to RGCs compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein to RGCs.

[0166] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity to RGCs when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection to RGCs.

[0167] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity on RPE cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein on RPE cells.

[0168] In some embodiments, the subject rAAV virions exhibit an increase of at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold in infectivity to RPE cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parent AAV capsid protein when administered via intravitreal injection to RPE cells.

[0169] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity towards Müller cells compared to the infectivity towards Müller cells of AAV virions comprising the corresponding parental AAV capsid protein.

[0170] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity to Müller cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0171] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity on bipolar cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein on bipolar cells.

[0172] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of bipolar cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0173] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity on amacrine cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein on amacrine cells.

[0174] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of amacrine cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0175] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity on horizontal cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein on horizontal cells.

[0176] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of horizontal cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0177] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of retinal astrocytes compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein.

[0178] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of retinal astrocytes when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0179] In some cases, a subject rAAV virion exhibits at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more than a 50-fold increase in the ability to cross the inner limiting membrane (ILM) compared to the ability of an AAV virion comprising the corresponding parental AAV capsid protein to cross the ILM.

[0180] In some cases, the subject rAAV virions, when administered via intravitreal injection, exhibit at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more increased ability to cross the ILM compared to the ability of AAV virions comprising the corresponding parental AAV capsid protein to cross the ILM when administered via intravitreal injection.

[0181] The subject rAAV virions can cross the ILM and can also cross cell layers, including Mueller cells, amacrine cells, etc., to reach photoreceptor cells and or RPE cells. For example, the subject rAAV virions can cross the ILM when administered via intravitreal injection and can also cross cell layers, including Mueller cells, amacrine cells, etc., to reach photoreceptor cells and or RPE cells.

[0182] In some cases, the subject rAAV virions, when injected intravitreally, exhibit an increase of at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold in localization through the ILM compared to the control AAV virions comprising the corresponding parental AAV capsid proteins injected intravitreally. For example, in some cases, the subject rAAV virions, when injected intravitreally, exhibit an increase of at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold in localization to the retinal pigment epithelium (RPE) layer compared to the control AAV virions comprising the corresponding parental AAV capsid proteins injected intravitreally. As another example, in some cases, the subject rAAV virions, when injected intravitreally, exhibit at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more than 50-fold increase in localization to the photoreceptor (PR) layer compared to the extent to which control AAV virions comprising the corresponding parental AAV capsid protein, injected intravitreally, localize to the PR layer. As another example, in some cases, the subject rAAV virions, when injected intravitreally, exhibit at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more than 50-fold increase in localization to the inner nuclear layer compared to the extent to which control AAV virions comprising the corresponding parental AAV capsid protein, injected intravitreally, localize to the inner nuclear layer. As another example, in some cases, the subject rAAV virions, when injected intravitreally, exhibit at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more increase in localization to the outer nuclear layer compared to the extent to which a control AAV virion comprising the corresponding parental AAV capsid protein, injected intravitreally, localizes to the outer nuclear layer. As another example, in some cases, the subject rAAV virions, when injected intravitreally, exhibit at least a 5-fold, at least a 10-fold, at least a 15-fold, at least a 20-fold, at least a 25-fold, at least a 50-fold, or more increase in localization to the ganglion cell layer compared to the extent to which a control AAV virion comprising the corresponding parental AAV capsid protein, injected intravitreally, localizes to the ganglion cell layer.

[0183] In some embodiments, the subject rAAV virions selectively infect retinal cells, e.g., the subject rAAV virions infect retinal cells with a specificity that is 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold greater than non-retinal cells (e.g., cells outside the eye). For example, in some embodiments, the subject rAAV virions selectively infect retinal cells, e.g., the subject rAAV virions infect photoreceptor cells with a specificity that is 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold greater than non-retinal cells (e.g., cells outside the eye).

[0184] In some embodiments, a subject rAAV virion selectively infects photoreceptor cells, e.g., a subject rAAV virion infects photoreceptor cells with a specificity that is 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold greater than non-photoreceptor cells present in the eye (e.g., retinal ganglion cells, Müller cells, etc.).

[0185] In some embodiments, the subject rAAV virions exhibit at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold increased infectivity of photoreceptor cells when administered via intravitreal injection compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein when administered via intravitreal injection.

[0186] gene products

[0187] The subject rAAV virions comprise a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product (heterologous gene product). In some cases, the gene product is a polypeptide.

[0188] In some cases, the gene product is RNA. In the case where the gene product is RNA, in some cases, the RNA gene product encodes a polypeptide. In some cases, the rAAV virion of the present disclosure comprises a single heterologous nucleic acid comprising a nucleotide sequence encoding a single heterologous gene product. In some cases, the rAAV virion of the present disclosure comprises a single heterologous nucleic acid comprising a nucleotide sequence encoding two heterologous gene products. In some cases, the rAAV virion of the present disclosure comprises two heterologous nucleic acids, each heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous gene product.

[0189] In some embodiments, the gene product is an interfering RNA. In some embodiments, the gene product is an aptamer. In some embodiments, the gene product is a polypeptide. In some embodiments, the gene product is a site-specific nuclease that provides site-specific knockdown of gene function. In some embodiments, the gene product is an RNA-guided endonuclease that provides modification of the target nucleic acid.

[0190] interfering RNA

[0191] In the case where the gene product is an interfering RNA (RNAi), suitable RNAi includes RNAi that reduces the level of apoptosis or angiogenic factors in cells. For example, RNAi can be shRNA or siRNA that reduces the level of a gene product that induces or promotes apoptosis in cells. Genes whose gene products induce or promote apoptosis are referred to herein as "pro-apoptotic genes", and the products (mRNA; protein) of those genes are referred to as "pro-apoptotic gene products". Pro-apoptotic gene products include, for example, Bax, Bid, Bak, and Bad gene products. See, for example, U.S. Patent No. 7,846,730.

[0192] Interfering RNA can also be directed against angiogenic products, such as vascular endothelial growth factor (VEGF) (e.g., Cand5; see, e.g., U.S. Patent Publication No. 2011 / 0143400; U.S. Patent Publication No. 2008 / 0188437; and Reich et al. (2003) Mol. Vis. 9:210); VEGF receptor-1 (VEGFR1) (e.g., Sirna-027; see, e.g., Kaiser et al. (2010) Am. J. Ophthalmol. 150:33; and Shen et al. (2006) Gene Ther. 13:225); or VEGF receptor-2 (VEGFR2) (Kou et al. (2005) Biochem. 44:15064). See also U.S. Patent Nos. 6,649,596, 6,399,586, 5,661,135, 5,639,872, and 5,639,736; and U.S. Patent Nos. 7,947,659 and 7,919,473.

[0193] Aptamer

[0194] Where the gene product is an aptamer, exemplary aptamers of interest include those directed against VEGF. See, e.g., Ng et al. (2006) Nat. Rev. Drug Discovery 5:123; and Lee et al. (2005) Proc. Natl. Acad. Sci. USA 102:18902. For example, a VEGF aptamer may comprise the nucleotide sequence 5'-cgcaaucagugaaugcuuauacau ccg-3' (SEQ ID NO: / / ). Platelet-derived growth factor (PDGF)-specific aptamers, such as E10030, are also suitable; see, e.g., Ni and Hui (2009) Ophthalmologica 223:401; and Akiyama et al. (2006) J. Cell Physiol. 207:407).

[0195] peptides

[0196] Where the gene product is a polypeptide, the polypeptide is generally a polypeptide that enhances the function of retinal cells, such as rod or cone photoreceptor cells, retinal ganglion cells, Müller cells, bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelial cells. Exemplary polypeptides include neuroprotective polypeptides (e.g., glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), neurotrophin-4 (NT4), nerve growth factor (NGF), and neurturin (NTN)); anti-angiogenic polypeptides (e.g., soluble VEGF receptor; VEGF-binding antibody; VEGF-binding antibody fragment (e.g., single-chain anti-VEGF antibody); endostatin; tumstatin; angiostatin; soluble Flt polypeptide (Lai et al. (2005) Mol. Ther. 12:659); Fc fusion proteins comprising a soluble Flt polypeptide (see, e.g., Pechan et al. (2009) Gene Ther.16:10); pigment epithelium-derived factor (PEDF); soluble Tie-2 receptor, etc.); tissue inhibitor of metalloproteinase-3 (TIMP-3); light-responsive opsins, such as rhodopsin; anti-apoptotic polypeptides (such as Bcl-2, Bcl-Xl; XIAP), etc. Suitable polypeptides include (but are not limited to) glial-derived neurotrophic factor (GDNF); fibroblast growth factor; fibroblast growth factor 2; neural rank protein (NTN); ciliary neurotrophic factor (CNTF); nerve growth factor (NGF); neurotrophin-4 (NT4); brain-derived neurotrophic factor (BDNF; for example, an amino acid sequence having a similar Figure 7B11) (SEQ ID NO: 11); epidermal growth factor; rhodopsin; X-linked inhibitor of apoptosis; and sonic hedgehog.

[0197] Suitable light-responsive opsins include, for example, those described in U.S. Patent Publication No. 2007 / 0261127 (e.g., channelrhodopsin-2; ChR2; Chop2); U.S. Patent Publication No. 2001 / 0086421; U.S. Patent Publication No. 2010 / 0015095; U.S. Patent Publication No. 2016 / 0002302; U.S. Patent Publication No. 2013 / 0347137; U.S. Patent Publication No. 2013 / 0019325; and Diester et al. (2011) Nat. Neurosci. 14:387. See Thyagarajan et al. (2010) J Neurosci. 30(26):8745-8758; Lagali et al. (2008) Nat Neurosci. 11(6):667-675; Doroudchi et al. (2011) Mol Ther. 19(7):1220-1229; Henriksen et al. (2014) J. Ophthalmic Vis. Res. 9:374; Tomita et al. (2014) Mol. Ther. 22:1434.

[0198] Suitable polypeptides include light-gated ion channel polypeptides. See, for example, Gaub et al. (2014) Proc. Natl. Acad. Sci. USA 111: E5574. For example, a suitable polypeptide is a light-gated ionotropic glutamate receptor (LiGluR). Expression of LiGluR in retinal ganglion cells and ON-bipolar cells in the presence of a photoisomerizable compound causes the cells to respond to light. LiGluR comprises an L439C substitution; see Caporale et al. (2011) Mol Ther. 19: 1212-1219; Volgraf et al. (2006) Nat Chem Biol. 2: 47-52; and Gorostiza et al. (2007) Proc Natl Acad Sci USA. 104: 10865-10870. Photoisomerizable compounds include, for example, maleimide-azobenzene-glutamate 0 (MAG0) having a peak efficiency at 460 nm. 460 ). MAG0 460 Has the following structure:

[0199]

[0200] Suitable polypeptides also include retinoschisis proteins (e.g., Figure 7A 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to a contiguous stretch of about 200 amino acids to about 224 amino acids of the amino acid sequence depicted in (SEQ ID NO: 10). Suitable polypeptides include, for example, retinitis pigmentosa GTPase regulator (RPGR) interacting protein-1 (see, e.g., GenBank Accession Nos. Q96KN7, Q9EPQ2, and Q9GLM3) (e.g., amino acid sequences having a sequence identity to Figure 7F 1150 to 1200 amino acids, or a contiguous stretch of about 1200 to 1286 amino acids having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence depicted in (SEQ ID NO: 15); peripherin-2 (Prph2) (see, e.g., GenBank Accession No. NP_000313 (e.g., an amino acid sequence having a sequence identity to Figure 7D A polypeptide having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to a contiguous stretch of about 300 amino acids to about 346 amino acids of the amino acid sequence depicted in (SEQ ID NO: 13); and Travis et al. (1991) Genomics 10:733); a peripherin (e.g., an amino acid sequence having a sequence identity to Figure 7E A polypeptide having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to a contiguous stretch of about 400 amino acids to about 470 amino acids of the amino acid sequence depicted in (SEQ ID NO: 14); a ... Figure 7C 12) (see, e.g., GenBank AAC39660; and Morimura et al. (1998) Proc. Natl. Acad. Sci. USA 95:3088); rod-derived cone cell viability factor (RdCVF) (e.g., an amino acid sequence having a contiguous stretch of at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to a contiguous stretch of about 200 amino acids to 247 amino acids of the amino acid sequence depicted in SEQ ID NO: 12); Figure 7H 、 7Iand 7J; polypeptides having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence depicted in any of 7J; choroideremia (e.g., an amino acid sequence having a Figure 7G a polypeptide having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence depicted in ); a retinitis pigmentosa GTPase regulator (RPGR) (e.g., an amino acid sequence having a sequence identity to Figures 7S-7V ), etc. For example, in some cases, suitable RPGR polypeptides include polypeptides having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to an amino acid sequence depicted in one of Figure 7S

[0013] As another example, in some cases, suitable RPGR polypeptides comprise amino acid sequences that have at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequences depicted in

[0013] . Figure 7T

[0014] For example, in some cases, suitable RPGR polypeptides comprise amino acid sequences that have at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequences depicted in

[0014] . Figure 7U

[0014] For example, in some cases, suitable RPGR polypeptides comprise amino acid sequences that have at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequences depicted in

[0014] . Figure 7V An amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence depicted in .

[0201] Suitable polypeptides also include: CHM (choroideremia (Rab escort protein 1 (REP1))), a polypeptide that, when defective or absent, causes choroideremia (see, e.g., Donnelly et al. (1994) Hum. Mol. Genet. 3:1017; and van Bokhoven et al. (1994) Hum. Mol. Genet. 3:1041); and Crumbs homolog 1 (CRB1), a polypeptide that, when defective or absent, causes Leber congenital amaurosis and retinitis pigmentosa (see, e.g., den Hollander et al. (1999) Nat. Genet. 23:217; and GenBank Accession No. CAM23328). For example, a suitable REP1 polypeptide may comprise a polypeptide having a nucleotide sequence similar to that of Figure 7G An amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the group of amino acid sequences depicted in .

[0202] Suitable polypeptides include rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha (PDE6α), rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta isoform 1 (PDE6β isoform 1), rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta isoform 2 (PDE6β isoform 2), rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta isoform 3 (PDE6β isoform 3). For example, a suitable PDE6α polypeptide may comprise a polypeptide having a nucleotide sequence similar to that of rod cGMP. Figure 7K As another example, a suitable PDE6β6 isoform 1 polypeptide may comprise an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99% or 100% amino acid sequence identity to the group of amino acid sequences depicted in Figure 7L As another example, a suitable PDE6β6 isoform 2 polypeptide may comprise an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99% or 100% amino acid sequence identity to the group of amino acid sequences depicted in Figure 7M As another example, a suitable PDE6β6 isoform 3 polypeptide may comprise an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99% or 100% amino acid sequence identity to the group of amino acid sequences depicted in Figure 7N An amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the group of amino acid sequences depicted in .

[0203] Suitable polypeptides also include polypeptides that, when defective or absent, cause achromatopsia, including, for example, cone photoreceptor cGMP-gated channel subunit alpha (CNGA3) (see, for example, GenBank Accession No. NP_001289; and Booij et al. (2011) Ophthalmology 118: 160-167); cone photoreceptor cGMP-gated cation channel beta-subunit (CNGB3) (see, for example, Kohl et al. (2005) Eur J Hum Genet. 13(3): 302); guanine nucleotide binding protein (G protein), alpha transducing active polypeptide 2 (GNAT2) (ACHM4); and ACHM5; and various forms of polypeptides that, when defective or absent, cause color blindness (e.g., L-opsin, M-opsin, and S-opsin). See Mancuso et al. (2009) Nature 461(7265): 784-787.

[0204] For example, a suitable CNGA3 (also known as ACHM2) isoform 1 polypeptide may comprise a polypeptide having Figure 7O As another example, a suitable CNGA3 (also known as ACHM2) isoform 2 polypeptide may comprise an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence set forth in . Figure 7P An amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the group of amino acid sequences depicted in .

[0205] As another example, a suitable CNGB3 (also known as ACHM3) polypeptide may comprise a polypeptide having Figure 7Q As another example, GNAT2 (also known as ACHM4) may comprise an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence set forth in . Figure 7R An amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the group of amino acid sequences depicted in .

[0206] site-specific endonucleases

[0207] In some cases, the gene product of interest is the site-specific endonuclease that knocks down the site-specificity of providing gene function, for example, wherein endonuclease knocks out the allele relevant to retinal disease.For example, in the case of the defective copy of the gene that is retinal structural protein and / or normal retinal function is provided when dominant allele encoding when wild type, site-specific endonuclease can target defective allele and knock out defective allele.In some cases, site-specific endonuclease is the endonuclease guided by RNA.

[0208] In addition to knocking out defect alleles, site-specific nucleases can also be used to stimulate the homologous recombination of the donor DNA of the functional copy of the protein encoded by the defect allele. Therefore, for example, theme rAAV virions can be used to deliver the site-specific endonuclease for knocking out defect alleles, and can be used to deliver the functional copy of defect alleles, causing the repair of defect alleles, thereby producing functional retinal proteins (such as functional retinoschisis protein, functional RPE65, functional peripherin etc.). See, for example, Li et al. (2011) Nature 475:217. In some embodiments, theme rAAV virions include the heterologous nucleotide sequence encoding site-specific endonuclease; With the heterologous nucleotide sequence encoding the functional copy of defect alleles, wherein the functional copy encodes functional retinal proteins. Functional retinal proteins include, for example, retinoschisis protein, RPE65, retinitis pigmentosa GTPase regulatory factor (RGPR) interacting protein-1, peripherin, peripherin-2, RdCVF etc.

[0209] Applicable site-specific endonucleases include, for example, zinc finger nucleases (ZFNs); meganucleases; and transcription activator-like effector nucleases (TALENs), wherein such site-specific endonucleases are not naturally occurring and are modified to target specific genes. Such site-specific nucleases can be engineered to cut a specific position in the genome, and then non-homologous end joining can repair the break when several nucleotides are inserted or deleted. Such site-specific endonucleases (also known as "INDELs") then throw the protein out of the frame and effectively knock out the gene. See, for example, U.S. Patent Publication No. 2011 / 0301073. Suitable site-specific endonucleases include engineered meganucleases, re-engineered homing endonucleases. Suitable endonucleases include I-Tevl nuclease. Suitable meganucleases include I-Sce1 (see, eg, Bellaiche et al. (1999) Genetics 152: 1037); and I-Cre1 (see, eg, Heath et al. (1997) Nature Sructural Biology 4: 468).

[0210] RNA-guided endonucleases

[0211] In some cases, the gene product is an RNA-guided endonuclease. In some cases, the gene product is an RNA comprising a nucleotide sequence encoding an RNA-guided endonuclease. In some cases, the gene product is a guide RNA, such as a single guide RNA. In some cases, the gene product is: 1) a guide RNA; and 2) an RNA-guided endonuclease. The guide RNA may comprise: a) a protein binding region that binds to the RNA-guided endonuclease; and b) a region that binds to the target nucleic acid. RNA-guided endonucleases are also referred to herein as "genome-editing nucleases."

[0212] Examples of suitable genome editing nucleases are CRISPR / Cas endonucleases (e.g., Class 2 CRISPR / Cas endonucleases, such as Type II, Type V, or Type VI CRISPR / Cas endonucleases). Thus, the genome targeting composition can include a CRISPR / Cas endonuclease (e.g., Class 2 CRISPR / Cas endonucleases, such as Type II, Type V, or Type VI CRISPR / Cas endonucleases). In some cases, the genome targeting composition includes Class 2 CRISPR / Cas endonucleases. In some cases, the genome targeting composition includes Class 2 Type II CRISPR / Cas endonucleases (e.g., Cas9 proteins). In some cases, the genome targeting composition includes Class 2 Type V CRISPR / Cas endonucleases (e.g., Cpf1 proteins, C2c1 proteins, or C2c3 proteins). In some cases, the genome targeting composition includes Class 2 Type VI CRISPR / Cas endonucleases (e.g., C2c2 proteins).

[0213] In some cases, the genome-editing nuclease is a fusion protein fused to a heterologous polypeptide (also referred to as a "fusion partner"). In some cases, the genome-editing nuclease is fused to an amino acid sequence that provides subcellular localization (fusion partner), i.e., the fusion partner is a subcellular localization sequence (e.g., one or more nuclear localization signals (NLS) for nuclear targeting, two or more NLSs, three or more NLSs, etc.).

[0214] In some cases, the genome editing nuclease is a type II CRISPR / Case nuclease. In some cases, the genome editing nuclease is a Cas9 polypeptide. The Cas9 protein is guided to a target site (e.g., stabilized at a target site) within a target nucleic acid sequence (e.g., a chromosomal sequence or an extrachromosomal sequence, such as an episomal sequence, a minicircle sequence, a mitochondrial sequence, a chloroplast sequence, etc.) due to association with the protein binding segment of the Cas9 guide RNA. In some cases, the Cas9 polypeptide comprises a Figure 8AIn some cases, the Cas9 polypeptide used in the compositions or methods of the present disclosure is a Staphylococcus aureus Cas9 (saCas9) polypeptide. In some cases, the saCas9 polypeptide comprises an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more than 99% amino acid sequence identity to the Streptococcus pyogenes Cas9 depicted in . Figure 8B An amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% amino acid sequence identity to the saCas9 amino acid sequence depicted in .

[0215] In some cases, a suitable Cas9 polypeptide is a high-fidelity (HF) Cas9 polypeptide. Kleinstiver et al. (2016) Nature 529:490. For example, Figure 8A The amino acids N497, R661, Q695 and Q926 of the amino acid sequence depicted in the embodiment are substituted with, for example, alanine. For example, the HF Cas9 polypeptide may comprise a polypeptide having Figure 8A An amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99% or 100% amino acid sequence identity to the amino acid sequence depicted in , wherein amino acids N497, R661, Q695 and Q926 are substituted, for example, with alanine.

[0216] In some cases, suitable Cas9 polypeptides exhibit altered PAM specificity. See, e.g., Kleinstiver et al. (2015) Nature 523:481.

[0217] In some cases, the genome editing nuclease is a type V CRISPR / Cas nuclease. In some cases, the type V CRISPR / Cas nuclease is a Cpf1 protein. In some cases, the Cpf1 protein comprises a Cpf1 protein having ... Figure 8C An amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100% amino acid sequence identity to the Cpf1 amino acid sequence depicted in .

[0218] Nucleic acids that bind to two types of CRISPR / Cas endonucleases (e.g., Cas9 protein; type V or type VI CRISPR / Cas proteins; Cpf1 protein, etc.) and target the complex to a specific location within the target nucleic acid are referred to herein as "guide RNAs," "CRISPR / Cas guide nucleic acids," or "CRISPR / Cas guide RNAs." The guide RNA provides specificity for the complex (RNP complex) by including a targeting segment that includes a guide sequence (also referred to herein as a targeting sequence), which is a nucleotide sequence complementary to the sequence of the target nucleic acid.

[0219] In some cases, the guide RNA comprises two separate nucleic acid molecules: an "activator" and a "targeter," and is referred to herein as a "dual-guide RNA," "double-molecule guide RNA," "two-molecule guide RNA," or "dgRNA." In some cases, the guide RNA is one molecule (e.g., for some Class 2 CRISPR / Cas proteins, the corresponding guide RNA is a single molecule; and in some cases, the activator and targeter are covalently linked to each other, for example, via intervening nucleotides), and the guide RNA is referred to as a "single-guide RNA," "single-molecule guide RNA," "one-molecule guide RNA," or simply "sgRNA."

[0220] In cases where the gene product is an RNA-guided endonuclease or an RNA-guided endonuclease with a guide RNA, the gene product can modify the target nucleic acid. In some cases, such as where the target nucleic acid comprises a deleterious mutation in a defective allele (e.g., a deleterious mutation in a retinal cell target nucleic acid), the RNA-guided endonuclease / guide RNA complex together with a donor nucleic acid comprising a nucleotide sequence that corrects the deleterious mutation (e.g., a donor nucleic acid comprising a nucleotide sequence encoding a functional copy of a protein encoded by the defective allele) can be used to correct the deleterious mutation, for example, via homology-directed repair (HDR).

[0221] In some cases, the gene product is an RNA-guided endonuclease and two separate sgRNAs, wherein the two separate sgRNAs provide for deletion of the target nucleic acid via non-homologous end joining (NHEJ).

[0222] The present disclosure provides a method for modifying a target nucleic acid in a retinal cell in an individual, wherein the target nucleic acid comprises a deleterious mutation, the method comprising administering to the individual (e.g., intraocularly, intravitreally, etc.) a rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising: i) a nucleotide sequence encoding an RNA-guided endonuclease (e.g., a Cas9 endonuclease); ii) a nucleotide sequence encoding an sgRNA comprising a nucleotide sequence complementary to the target nucleic acid; and iii) a nucleotide sequence encoding a donor DNA template comprising a nucleotide sequence that corrects the deleterious mutation. Administration of the rAAV virion corrects the deleterious mutation in the target nucleic acid by HDR.

[0223] The present disclosure provides a method for modifying a target nucleic acid in a retinal cell in an individual, wherein the target nucleic acid comprises a deleterious mutation, the method comprising administering to the individual (e.g., intraocularly, intravitreally, etc.) a rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising: i) a nucleotide sequence encoding an RNA-guided endonuclease (e.g., a Cas9 endonuclease); ii) a nucleotide sequence encoding a first sgRNA comprising a nucleotide sequence complementary to a first sequence in the target nucleic acid; and iii) a nucleotide sequence encoding a second sgRNA comprising a nucleotide sequence complementary to a second sequence in the target nucleic acid. Administration of the rAAV virion excises the deleterious mutation in the target nucleic acid by NHEJ.

[0224] Regulatory sequences

[0225] In some cases, the nucleotide sequence of the gene product of interest may be operably connected to a transcriptional control element. For example, in some cases, the nucleotide sequence of the gene product of interest may be operably connected to a constitutive promoter. In other cases, the nucleotide sequence of the gene product of interest may be operably connected to an inducible promoter. In some cases, the nucleotide sequence of the gene product of interest may be operably connected to a tissue-specific or cell type-specific regulatory element. For example, in some cases, the nucleotide sequence of the gene product of interest may be operably connected to a retinal cell-specific promoter. For example, in some cases, the nucleotide sequence of the gene product of interest may be operably connected to a photoreceptor-specific regulatory element (such as a photoreceptor-specific promoter), such as a regulatory element that imparts selective expression of an operably connected gene in photoreceptor cells. Suitable photoreceptor-specific regulatory elements include, for example, the rhodopsin promoter; the rhodopsin kinase promoter (Young et al. (2003) Ophthalmol. Vis. Sci. 44:4076); the beta phosphodiesterase gene promoter (Nicoud et al. (2007) J. Gene Med. 9:1015); the retinitis pigmentosa gene promoter (Nicoud et al. (2007) supra); the interphotoreceptor retinoid binding protein (IRBP) gene enhancer (Nicoud et al. (2007) supra); the IRBP gene promoter (Yokoyama et al. (1992) Exp Eye Res. 55:225).

[0226] Pharmaceutical composition

[0227] The present disclosure provides a pharmaceutical composition comprising: a) the subject rAAV virion as described above; and b) a pharmaceutically acceptable carrier, diluent, excipient, or buffer. In some embodiments, the pharmaceutically acceptable carrier, diluent, excipient, or buffer is suitable for use in humans.

[0228] Such excipients, carriers, diluents and buffers include any pharmaceutical agent that can be administered without excessive toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol and ethanol. Pharmaceutically acceptable salts may be included, such as inorganic acid salts, such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and organic acid salts, such as acetates, propionates, malonates, benzoates, and the like. In addition, auxiliary substances such as wetting agents or emulsifiers, pH buffering substances, and the like may be present in such vehicles. A variety of pharmaceutically acceptable excipients are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients are described fully in a number of publications, including, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) HC Ansel et al., eds., 7th edition, Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) AK Hibbe et al., eds., 3rd edition Amer. Pharmaceutical Assoc.

[0229] Methods and treatments for delivering gene products to retinal cells

[0230] The present disclosure provides a method for delivering a gene product to retinal cells in an individual, the method comprising administering to the individual the subject rAAV virion as described above. As described above, the gene product can be a polypeptide or interfering RNA (such as shRNA, siRNA, etc.), an aptamer or a site-specific endonuclease (such as an RNA-guided endonuclease). The gene product is delivered to retinal cells and can treat retinal diseases. Retinal cells can be photoreceptors, retinal ganglion cells, Mueller cells, bipolar cells, amacrine cells, horizontal cells or retinal pigment epithelial cells. In some cases, retinal cells are photoreceptors, such as rods or cones.

[0231] The present disclosure provides a method for modifying a target nucleic acid in a retinal cell, the method comprising contacting the retinal cell with: 1) an rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising a nucleotide sequence encoding an RNA-guided endonuclease that binds to a guide RNA; and 2) a guide RNA. The present disclosure provides a method for modifying a target nucleic acid in a retinal cell, the method comprising contacting the retinal cell with an rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising a nucleotide sequence encoding: i) an RNA-guided endonuclease that binds to a guide RNA; and ii) a guide RNA. In some cases, the method comprises contacting the retinal cell with a donor DNA template. In some cases, the RNA-guided endonuclease is a Cas9 polypeptide. In some cases, the guide RNA is a single guide RNA.

[0232] The present disclosure provides a method for treating an eye disease (e.g., a retinal disease), comprising administering to an individual in need thereof an effective amount of the subject rAAV virion as described above. The subject rAAV virion can be administered via intraocular injection, intravitreal injection, or any other suitable mode of administration or route. Other suitable modes of administration or routes include, for example, intravenous, intranasal, and the like.

[0233] A "therapeutically effective amount" will be within a relatively wide range that can be determined experimentally and / or clinically. For example, for in vivo injection, i.e., injection directly into the eye, a therapeutically effective dose will be approximately about 10 6 to about 10 15 rAAV virions, such as about 10 8 to 10 12 For in vitro transduction, the effective amount of rAAV virions to be delivered to cells will be approximately 10 8 to about 10 13 Other effective dosages can be easily determined by one of ordinary skill in the art through routine experiments and determination of dose-response curves.

[0234] In some embodiments, more than one administration (e.g., twice, three times, four times or more administrations) can be used to achieve desired gene expression levels. In some cases, more than one administration is administered at multiple time intervals, such as daily, weekly, half-monthly, monthly, every 3 months, every 6 months, annually, etc. In some cases, multiple administrations are administered over a period of 1 month to 2 months, 2 months to 4 months, 4 months to 8 months, 8 months to 12 months, 1 year to 2 years, 2 years to 5 years, or more than 5 years.

[0235] Ocular diseases that may be treated using the subject methods include, but are not limited to, acute macular neuroretinopathy; Behcet's disease; choroidal neovascularization; diabetic uveitis; histoplasmosis; macular degeneration, such as acute macular degeneration, non-exudative age-related macular degeneration, and exudative age-related macular degeneration; edema, such as macular edema, cystoid macular edema, and diabetic macular edema; multifocal choroiditis; ocular trauma affecting the posterior ocular site or location; ocular tumors; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal artery occlusive disease, retinal detachment, uveitic retinopathy; sympathetic ophthalmia; Vogt-Koyanagi-Harada Koyanagi-Harada (VKH) syndrome; uveal tract ectasia; posterior ocular conditions caused by or affected by ocular laser treatment; posterior ocular conditions caused by or affected by photodynamic therapy; photocoagulation, radiation retinopathy; epiretinal membrane disorders; branch retinal vein occlusion; anterior ischemic optic neuropathy; non-retinopathy diabetic retinopathy; retinoschisis; retinitis pigmentosa; glaucoma; Usher syndrome, cone-rod dystrophy; Stargardt disease (yellow spots); hereditary macular degeneration; chorioretinal degeneration; Leber's congenital amaurosis; congenital stationary night blindness; choroideremia; Bardet-Biedl syndrome; macular telangiectasia; Leber's hereditary optic neuropathy; retinopathy of prematurity; color vision disorders, including achromatopsia, protanopia, deuteranopia, and tritanopia; and Bietti's crystalline retinal dystrophy. dystrophy).

[0236] Nucleic acids and host cells

[0237] The present disclosure provides an isolated nucleic acid comprising a nucleotide sequence encoding a subject variant adeno-associated virus (AAV) capsid protein as described above, wherein the variant AAV capsid protein comprises an insertion of about 5 amino acids to about 20 amino acids in the GH loop or loop IV relative to the corresponding parent AAV capsid protein, and wherein the variant capsid protein has increased infectivity to retinal cells when present in AAV virions compared to the infectivity of AAV virions comprising the corresponding parent AAV capsid protein to retinal cells. The subject isolated nucleic acid can be an AAV vector, such as a recombinant AAV vector.

[0238] Insertion peptide

[0239] The variant AAV capsid protein encoded by the subject nucleic acid has an insertion peptide of about 5 amino acids to about 20 amino acids in length, which is inserted into the GH loop of the AAV capsid. The insertion peptide has a length of 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids. Suitable insertion peptides are described above. Suitable insertion peptides include peptides of any one of Formula IX described above.

[0240] The subject recombinant AAV vectors can be used to produce the subject recombinant AAV virions as described above. Accordingly, the present disclosure provides a recombinant AAV vector that, when introduced into suitable cells, can produce the subject recombinant AAV virions.

[0241] The present invention also provides host cells, such as isolated (genetically modified) host cells, which contain the subject nucleic acid. The subject host cell can be an isolated cell, such as a cell cultured in vitro. The subject host cell can be used to produce the subject rAAV virion as described below. In the case where the subject host cell is used to produce the subject rAAV virion, it is referred to as a "packaging cell". In some embodiments, the subject host cell is stably genetically modified through the subject nucleic acid. In other embodiments, the subject host cell is transiently genetically modified through the subject nucleic acid.

[0242] The subject nucleic acid is stably or transiently introduced into the host cell using established techniques, including but not limited to electroporation, calcium phosphate precipitation, liposome-mediated transfection, etc. For stable transformation, the subject nucleic acid generally also includes a selectable marker, such as any of several well-known selectable markers, e.g., neomycin resistance, etc.

[0243] The subject host cells are produced by introducing the subject nucleic acid into any of a variety of cells, such as mammalian cells, including, for example, murine cells and primate cells (e.g., human cells). Suitable mammalian cells include, but are not limited to, primary cells and cell lines, wherein suitable cell lines include, but are not limited to, 293 cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1 / 2 fibroblasts, CHO cells, and the like. Non-limiting examples of suitable host cells include, for example, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2), CHO cells (e.g., ATCC No. CRL9618, CCL61, CRL9096), 293 cells (e.g., ATCC No. CRL-1573), Vero cells, NIH 3T3 cells (e.g., ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS-7 cells (ATCC No. CRL1651), RAT1 cells, mouse L cells (ATCC No. CCL1.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, and the like. The subject host cells can also be made using baculovirus to infect insect cells, such as Sf9 cells, to produce AAV (see, eg, US Patent No. 7,271,002; US Patent Application 12 / 297,958).

[0244] In some embodiments, in addition to a nucleic acid comprising a nucleotide sequence encoding a variant AAV capsid protein as described above, the subject genetically modified host cell further comprises a nucleic acid comprising a nucleotide sequence encoding one or more AAV rep proteins. In other embodiments, the subject host cell further comprises a rAAV vector. rAAV virions can be produced using the subject host cells. Methods for producing rAAV virions are described, for example, in U.S. Patent Publication No. 2005 / 0053922 and U.S. Patent Publication No. 2009 / 0202490.

[0245] Examples of non-limiting aspects of the present disclosure

[0246] The aspects of the subject matter of the present invention described above, including the embodiments, may be beneficial alone or in combination with one or more other aspects or embodiments. Without limiting the above description, certain non-limiting aspects of the disclosure numbered 1-34 are provided below. As will be apparent to those skilled in the art after reading this disclosure, each individually numbered aspect may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to the combinations of aspects explicitly provided below:

[0247] Aspect 1. A recombinant adeno-associated virus (rAAV) virion comprising: a) a variant AAV capsid protein, wherein relative to the corresponding parental AAV capsid protein, the variant AAV capsid protein comprises an insertion of a heterologous peptide having a length of 5 amino acids to about 20 amino acids in the capsid protein GH loop, and wherein the variant capsid protein has increased infectivity to retinal cells compared to the infectivity of a control AAV virion comprising the corresponding parental AAV capsid protein to retinal cells; and b) a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous gene product.

[0248] Aspect 2. The rAAV virion of aspect 1, wherein the rAAV virion exhibits a 5-fold increase in infectivity to retinal cells compared to the infectivity of a control AAV virion comprising the corresponding parental AAV capsid protein to retinal cells.

[0249] Aspect 3. The rAAV virion of aspect 1, wherein the rAAV virion exhibits at least a 10-fold increase in infectivity to retinal cells compared to the infectivity of AAV virions comprising the corresponding parental AAV capsid protein to retinal cells.

[0250] Aspect 4. The rAAV virion of any one of Aspects 1 to 3, wherein the rAAV virion exhibits at least a 5-fold increase in localization to one or more of the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, and retinal pigment epithelial cells compared to the extent to which AAV virions comprising the corresponding parental AAV capsid protein localize to the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, or retinal pigment epithelial cells.

[0251] Aspect 5. The rAAV virion of any one of aspects 1 to 4, wherein the insertion site is between amino acids corresponding to amino acids 570 and 611 of VP1 of AAV2, or a corresponding position in the capsid protein of another AAV serotype.

[0252] Aspect 6. The rAAV virion of any one of aspects 1 to 5, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VP1 of AAV2, or a corresponding position in the capsid protein of another AAV serotype.

[0253] Aspect 7. The rAAV virion of any one of Aspects 1 to 6, wherein the gene product is an interfering RNA or an aptamer.

[0254] Aspect 8. The rAAV virion of any one of Aspects 1 to 6, wherein the gene product is a polypeptide.

[0255] Aspect 9. The rAAV virion of aspect 8, wherein the polypeptide is a neuroprotective polypeptide, an anti-angiogenic polypeptide, or a polypeptide that enhances the function of retinal cells.

[0256] Aspect 10. The rAAV virion of Aspect 8, wherein the polypeptide is an RNA-guided endonuclease.

[0257] Aspect 11. The rAAV virion of Aspect 10, wherein the RNA-guided endonuclease is a Cas9 polypeptide.

[0258] Aspect 12. The rAAV virion of aspect 10, wherein the gene products are RNA-guided endonuclease and guide RNA.

[0259] Aspect 13. The rAAV virion of any one of Aspects 1 to 12, wherein the heterologous peptide inserted into the GH loop has any one of Formula IX.

[0260] Aspect 14. The rAAV virion of any one of aspects 1 to 12, wherein the heterologous peptide is a peptide of formula I: X1X2X3X4X5X6X7X8X9X 10 ,

[0261] in:

[0262] X1 is Leu, Ile, Pro or Gln;

[0263] X2 is Ala, Pro, Ser, Asp, Gly, Thr or Val;

[0264] X3 is Lys, His, Thr, Ile, Pro, Val, Arg, Ala, Asp, Glu, Asn, Gln or Tyr;

[0265] X4, if present, is Gln, Asp, Ser, Gly, Thr, Ile, Asn, Glu, Lys, or Arg;

[0266] X5 is Asp, Ser, Gln, Val, Thr, Gly, Ala, Asn, Lys or Tyr;

[0267] X6 is Thr, Ala, Gln, Ser, Glu, Pro or Ile;

[0268] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys, Ala or Cys;

[0269] X8 is Lys, Ser, Arg, Thr, Ala, Glu, Ile or Asn;

[0270] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0271] X 10 is Ala, Phe, Asp, Thr, Val or Met.

[0272] (1)LAKDATKNA(SEQ ID) NO:47);(2)PAHQDTTKNA(SEQ ID NO:48);(3)LAHQDTTKNA(SEQ IDNO:49);(4)LATTSQNKPA(SEQ ID NO:50);(5)LAISDQTKHA(SEQ ID NO:51);(6)IARGVAPSSA(SEQ ID NO:52);(7)LAPDSTTRSA(SEQ ID NO:53);(8)LAKGTELKPA(SEQ ID NO:54);(9)LAIIDATKNA(SEQ ID NO:55);(10)LAVDGAQRSA(SEQ ID NO:56);(11)PAPQDTTKKA(SEQ IDNO:57);(12)LPHQDTTKNA(SEQ ID NO:58);(13)LAKDATKTIA(SEQ ID NO:59);(14)LAKQQSASTA(SEQ ID NO:60);(15)LAKSDQSKPA(SEQ ID NO:61);(16)LSHQDTTKNA(SEQ IDNO:62);(17)LAANQPSKPA(SEQ ID NO:63);(18)LAVSDSTKAA(SEQ ID NO:64);(19)LAAQGTAKKPA(SEQ ID NO:65);(20)LAPDQTTRNA(SEQ ID NO:66);(21)LAASDSTKAA(SEQ ID NO:67);(22)LAPQDTTKNA(SEQ ID NO:68);(23)LAKADETRPA(SEQ ID NO:69);(24)LAHQDTAKNA(SEQ ID NO:70);(25)LAHQDTKKNA(SEQ ID NO:71);(26)LAHQDTTKHA(SEQ ID NO:72);(27)LAHQDTTKKA(SEQ ID NO:73);(28)LAHQDTTRNA(SEQ ID NO:74);(29)LAHQDTTNA(SEQ ID NO:75) NO:75);(30)LAHQGTTKNA(SEQ ID NO:76);(31)LAHQVTTKNA(SEQ IDNO:77);(32)LAISDQSKPA(SEQ ID NO:78);(33)LADATKTA(SEQ ID NO:79);(34)LAKDTTKNA(SEQ ID NO:80);(35)LAKSDQSRPA(SEQ ID NO:81);(36)LAPQDTKKNA(SEQ ID NO:82);(37)LATSDSTKAA(SEQ ID NO:83);(38)LAVDGSQRSA(SEQ ID NO:84);(39)LPISDQTKHA(SEQ IDNO:85);(40)LPKDATKTIA(SEQ ID NO:86);(41)LPPQDTTKNA(SEQ ID NO:87);(42)PAPQDTTKNA(SEQ ID NO:88);(43)QAHQDTTKNA(SEQ ID NO:89);(44)LAHETSPRPA(SEQ IDNO:90);(45)LAKSTSTAPA(SEQ ID NO:91);(46)LADQDTTKNA(SEQ ID NO:92);(47)LAESDQSKPA(SEQ ID NO:93);(48)LAHKDTTKNA(SEQ ID NO:94);(49)LAHKTQQKM(SEQ IDNO:95);(50)LAHQDTTENA(SEQ ID NO:96);(51)LAHQDTTINA(SEQ ID NO:97);(52)LAHQDTTKKT(SEQ ID NO:98);(53)LAHQDTTKND(SEQ ID NO:99);(54)LAHQDTTKNT(SEQ IDNO:100);(55)LAHQDTTKNV(SEQ ID NO:101);(56)LAHQDTTKTM(SEQ ID NO:102);(57)LAHQNTTKNA(SEQ ID NO:103);(58)LAHRDTTKNA(SEQ ID NO:104);(59)LAISDQTNHA(SEQ IDNO:105);(60)LAKQKSASTA(SEQ ID NO:106);(61)LAKSDQCKPA(SEQ ID NO:107);(62)LAKSDQSKPD(SEQ ID NO:108);(63)LAKSDQSNPA(SEQ ID NO:109);(64)LAKSYQSKPA(SEQ IDNO:110);(65)LANQDTTKNA(SEQ ID NO:111);(66)LAPQNTTKNA(SEQ ID NO:112);(67)LAPSSIQKPA(SEQ ID NO:113);(68) LAQQDTTKNA (SEQ ID NO: 114); (69) LAYQDTTKNA (SEQ ID NO: 115); (70) LDHQDTTKNA (SEQ ID NO: 116); (71) LDHQDTTKSA (SEQ ID NO: 117); (72) LGHQDTTKNA (SEQ ID NO:118); (73) LPHQDTTKND (SEQ ID NO:119); (74) LPHQDTTKNT (SEQ ID NO:120); (75) LPHQDTTNNA (SEQ ID NO:121); (76) LTHQDTTKNA (SEQ ID NO:122); (77) LTKDATKTIA (SEQ ID NO:123); (78) LTPQDTTKNA (SEQ ID NO:124); and (79) LVHQDTTKNA (SEQ ID NO:125). ;

[0273] Aspect 16. The rAAV virion of any one of Aspects 1 to 12, wherein the heterologous peptide is a peptide of Formula II:

[0274] X1X2X3X4X5X6X7X8X9X 10 ,in:

[0275] X1 is Leu, Ile or Pro;

[0276] X2 is Ala, Pro or Ser;

[0277] X3 is Lys, His, Thr, Ile, Pro, Val, Arg or Ala;

[0278] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile or Asn;

[0279] X5 is Asp, Ser, Gln, Val, Thr, Gly or Ala;

[0280] X6 is Thr, Ala, Gln, Ser, Glu or Pro;

[0281] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys or Ala;

[0282] X8 is Lys, Ser, Arg or Thr;

[0283] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0284] X10 For Ala.

[0285] (1)LAKDATKNA(SEQ ID) NO:47);(2)PAHQDTTKNA(SEQ ID NO:48);(3)LAHQDTTKNA(SEQ ID NO:49);(4)LATTSQNKPA(SEQ ID NO:50);(5)LAISDQTKHA(SEQ ID NO:51);(6)IARGVAPSSA(SEQID) NO:52);(7)LAPDSTTRSA(SEQ ID NO:53);(8)LAKGTELKPA(SEQ ID NO:54);(9)LAIIDATKNA(SEQ ID NO:55);(10)LAVDGAQRSA(SEQ ID NO:56);(11)PAPQDTTKKA(SEQ IDNO:57);(12)LPHQDTTKNA(SEQ ID NO:58);(13)LAKDATKTIA(SEQ ID NO:59);(14)LAKQQSASTA(SEQ ID NO:60);(15)LAKSDQSKPA(SEQ ID NO:61);(16)LSHQDTTKNA(SEQ IDNO:62);(17)LAANQPSKPA(SEQ ID NO:63);(18)LAVSDSTKAA(SEQ ID NO:64);(19)LAAQGTAKKPA(SEQ ID NO:65);(20)LAPDQTTRNA(SEQ ID NO:66);(21)LAASDSTKAA(SEQ ID NO:67);(22)LAPQDTTKNA(SEQ ID NO:68);(23)LAKADETRPA(SEQ ID NO:69);(24)LAHQDTAKNA(SEQ ID NO:70);(25)LAHQDTKKNA(SEQ ID NO:71);(26)LAHQDTTKHA(SEQ ID NO:72);(27)LAHQDTTKKA(SEQ ID NO:73);(28)LAHQDTTRNA(SEQ ID NO:74);(29)LAHQDTTNA(SEQ ID NO:75) NO:75);(30)LAHQGTTKNA(SEQ ID NO:76);(31)LAHQVTTKNA(SEQ IDNO:77);(32)LAISDQSKPA(SEQ ID NO:78);(33)LADATKTA(SEQ ID NO:79);(34) LAKDTTKNA (SEQ ID NO:80); (35) LAKSDQSRPA (SEQ ID NO:81); (36) LAPQDTKKNA (SEQ ID NO:82); (37) LATSDSTKAA (SEQ ID NO:83); (38) LAVDGSQRSA (SEQ ID NO:84); (39) LPISDQTKHA (SEQ ID NO:85); (40) LPKDATKTIA (SEQ ID NO:86); (41) LPPQDTTKNA (SEQ ID NO:87); and (42) PAPQDTTKNA (SEQ ID NO:88). ;

[0286] Aspect 18. The rAAV virion of aspect 16, wherein the peptide comprises one of the following amino acid sequences: (1) LAKDATKNA (SEQ ID NO: 47); (2) PAHQDTTKNA (SEQ ID NO: 48); (3) LAHQDTTKNA (SEQ ID NO: 49); (4) LATTSQNKPA (SEQ ID NO: 50); (5) LAISDQTKHA (SEQ ID NO: 51); (6) IARGVAPSSA (SEQ ID NO: 52); (7) LAPDSTTRSA (SEQ ID NO: 53); (8) LAKGTELKPA (SEQ ID NO: 54); (9) LAIIDATKNA (SEQ ID NO: 55); (10) LAVDGAQRSA (SEQ ID NO: 56); (11) PAPQDTTKKA (SEQ ID NO: 57); (12) LPHQDTTKNA (SEQ ID NO: 58). NO:58); (13) LAKDATKTIA (SEQ ID NO:59); (14) LAKQQSASTA (SEQ ID NO:60); (15) LAKSDQSKPA (SEQ ID NO:61); (16) LSHQDTTKNA (SEQ ID NO:62); (17) LAANQPSKPA (SEQ ID NO:63); and (18) LAVSDSTKAA (SEQ ID NO:64).

[0287] Aspect 19. A pharmaceutical composition comprising: a) the recombinant adeno-associated virus virion of any one of Aspects 1 to 18; and b) a pharmaceutically acceptable excipient.

[0288] Aspect 20. A method of delivering a gene product to retinal cells in an individual, the method comprising administering to the individual the recombinant adeno-associated virus (rAAV) virion of any one of aspects 1 to 18.

[0289] Aspect 21. The method of aspect 20, wherein the gene product is a polypeptide.

[0290] Aspect 22. The method of aspect 20, wherein the gene product is a short interfering RNA or an aptamer.

[0291] Aspect 23. The method of aspect 21, wherein the polypeptide is a neuroprotective factor, an anti-angiogenic polypeptide, an anti-apoptotic factor, or a polypeptide that enhances the function of retinal cells.

[0292] Aspect 24. The method of Aspect 21, wherein the polypeptide is glial-derived neurotrophic factor, fibroblast growth factor 2, neurotrophin, ciliary neurotrophic factor, nerve growth factor, brain-derived neurotrophic factor, epidermal growth factor, rhodopsin, X-linked inhibitor of apoptosis, retinoschisis protein, RPE65, retinitis pigmentosa GTPase-interacting protein-1, peripherin, peripherin-2, rhodopsin, RdCVF, retinitis pigmentosa GTPase regulator (RPGR) or sonic hedgehog.

[0293] Aspect 25. The method of aspect 21, wherein the polypeptide is an RNA-guided endonuclease.

[0294] Aspect 26. A method of treating an eye disease, comprising administering to an individual in need thereof an effective amount of the recombinant adeno-associated virus (rAAV) virion of any one of aspects 1 to 18.

[0295] Aspect 27. The method of Aspect 26, wherein the administration is by intraocular injection.

[0296] Aspect 28. The method of aspect 26, wherein the administration is by intravitreal injection.

[0297] Aspect 29. The method of aspect 26, wherein the eye disease is glaucoma, retinitis pigmentosa, macular degeneration, retinoschisis, Leber's Congenital Amaurosis, diabetic retinopathy, achromatopsia, or color blindness.

[0298] Aspect 30. An isolated nucleic acid comprising a nucleotide sequence encoding a variant adeno-associated virus (AAV) capsid protein, wherein the variant AAV capsid protein comprises an insertion of about 5 amino acids to about 20 amino acids in the capsid protein GH loop relative to the corresponding parent AAV capsid protein, and wherein the variant capsid protein, when present in an AAV virion, increases the infectivity of the AAV virion to retinal cells, and wherein the amino acid insertion is in the GH loop of a native AAV capsid, wherein the insertion is a peptide having any one of Formula IX.

[0299] Aspect 31. The isolated nucleic acid of Aspect 30, wherein the insertion site is between amino acids 587 and 588 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, or between amino acids 588 and 589 of AAV10.

[0300] Aspect 32. An isolated genetically modified host cell comprising the nucleic acid of aspect 30 or aspect 31.

[0301] Aspect 33. A variant adeno-associated virus (AAV) capsid protein, wherein the variant AAV capsid protein comprises an insertion of about 5 amino acids to about 20 amino acids, wherein the amino acid insertion is in the GH loop of the native AAV capsid, wherein the insertion is a peptide having any one of Formula IX.

[0302] Aspect 34. In any one of aspects 1 to 33, the heterologous peptide inserted into the GH loop may have one of Formulas IX, wherein:

[0303] Formula I is X1X2X3X4X5X6X7X8X9X 10 ,in:

[0304] X1 is Leu, Ile, Pro or Gln;

[0305] X2 is Ala, Pro, Ser, Asp, Gly, Thr or Val;

[0306] X3 is Lys, His, Thr, Ile, Pro, Val, Arg, Ala, Asp, Glu, Asn, Gln or Tyr;

[0307] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile, Asn, Glu, Lys or Arg;

[0308] X5 is Asp, Ser, Gln, Val, Thr, Gly, Ala, Asn, Lys or Tyr;

[0309] X6 is Thr, Ala, Gln, Ser, Glu, Pro or Ile;

[0310] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys, Ala or Cys;

[0311] X8 is Lys, Ser, Arg, Thr, Ala, Glu, Ile or Asn;

[0312] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0313] X 10 is Ala, Phe, Asp, Thr, Val or Met;

[0314] Formula II is X1X2X3X4X5X6X7X8X9X 10 ,in:

[0315] X1 is Leu, Ile or Pro;

[0316] X2 is Ala, Pro or Ser;

[0317] X3 is Lys, His, Thr, Ile, Pro, Val, Arg or Ala;

[0318] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile or Asn;

[0319] X5 is Asp, Ser, Gln, Val, Thr, Gly or Ala;

[0320] X6 is Thr, Ala, Gln, Ser, Glu or Pro;

[0321] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys or Ala;

[0322] X8 is Lys, Ser, Arg or Thr;

[0323] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0324] X 10 for Ala;

[0325] Formula III is X1X2X3X4X5X6X7X8X9X10 ,in:

[0326] X1 is Leu, Ile or Pro;

[0327] X2 is Ala, Pro or Ser;

[0328] X3 is Lys, His, Thr, Ile, Pro, Val, Arg or Ala;

[0329] X4 (if present) is Gln, Asp, Ser, Gly, Thr, Ile or Asn;

[0330] X5 is Asp, Ser, Gln, Val, Thr, Gly or Ala;

[0331] X6 is Thr, Ala, Gln, Ser, Glu or Pro;

[0332] X7 is Thr, Ser, Asn, Pro, Leu, Gln, Lys or Ala;

[0333] X8 is Lys, Ser, Arg or Thr;

[0334] X9 is Asn, Pro, Ser, Lys, His, Ile, Thr or Ala; and

[0335] X10 is Ala, Thr, Asp Val or Met;

[0336] Formula IV is X1X2X3X4X5X6X7X8X9X 10 ,in:

[0337] X1 is Leu;

[0338] X2 is Ala;

[0339] X3 is Lys, His, Thr, Ile, Pro or Val;

[0340] X4 (if present) is Gln, Asp, Ser or Gly;

[0341] X5 is Asp, Ser or Gln;

[0342] X6 is Thr, Ala, Gln or Ser;

[0343] X7 is Thr or Ser;

[0344] X8 is Lys, Ser or Arg;

[0345] X9 is Asn, Pro or Ser; and

[0346] X 10 for Ala;

[0347] Formula V is X1X2X3X4X5X6X7X8X9X 10 ,in:

[0348] X1 is Leu;

[0349] X2 is Ala;

[0350] X3 is Lys or His;

[0351] X4 (if present) is Gln, Asp, Ser or Gly;

[0352] X5 is Asp, Ser or Gln;

[0353] X6 is Thr, Ala, Gln or Ser;

[0354] X7 is Thr or Ser;

[0355] X8 is Lys, Ser or Arg;

[0356] X9 is Asn, Pro or Ser; and

[0357] X 10 for Ala;

[0358] Formula VI is X1X2X3X4X5X6X7X8X9X 10 ,in:

[0359] X1 is Leu;

[0360] X2 is Ala;

[0361] X3 is Asn, Lys, Thr, Gln, Ser, Ile or Leu;

[0362] X4 is Ser, Ala, Thr, Glu, Gln, Gly, Lys, or Pro;

[0363] X5 is Asp, Pro, Glu, Thr, Asn, or Arg;

[0364] X6 is Ile, His, Thr, Gln, Asn, Tyr, Asp or Glu;

[0365] X7 is Gln, Thr, Asn, Ala or Lys;

[0366] X8 is Lys, Thr, Arg or Asp;

[0367] X9 is Pro, Asn, Thr, Arg, Lys or Ser; and

[0368] X 10 for Ala;

[0369] Formula VII is LAHQDTTKX1X2X3 (SEQ ID NO: 148), wherein X1 is Lys, Thr, Asn, or His; X2 is Ala, Thr, Val, Ile, Met, or Asp; and X3, if present, is Ala;

[0370] Formula VIII is LAX1QX2TX3X4X5X6 (SEQ ID NO: 149), wherein X1 is Ala, Pro, Asp, or His; X2 is Gly or Asp; X3 is Ala, Thr, or Lys; X4 is Asn, Glu, Lys, Arg, or Thr; X5 is Leu, Asn, Lys, or Thr; and X6, if present, is Ala, Thr, Asp, Val, or Met;

[0371] Formula IX is X1AX2X3DX4TKX5A (SEQ ID NO: 150), wherein X1 is Val or Leu; X2 is Ile, Val, His, or Asp; X3 is Glu, Ser, Lys, or Gln; X4 is His, Ser, or Thr; and X5 is Ser, Ala, Asn, His, or Lys; and

[0372] Formula X is X1X2X3AX4QX5TX6KNA (SEQ ID NO: 151), wherein X1, if present, is Leu; X2, if present, is Ala; X3 is Lys, Leu, or Pro; X4 is Asn, His, Pro, or Tyr; X5 is Asn, Gly, Val, or Asp; and X6 is Pro or Thr.

[0373] Example

[0374] The following examples are presented so as to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the experiments below are all or the only experiments performed. While efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as bp, base pairs; kb, kilobase; pl, picoliter; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acid; kb, kilobase; bp, base pairs; nt, nucleotides; im, intramuscular; ip, intraperitoneal; sc, subcutaneous, etc.

[0375] Example 1: Generation and characterization of AAV virions with AAV capsid variants

[0376] An iterative in vivo screening approach was used to generate AAVs with capsid variants that can overcome significant and complex obstacles to preventing panretinal AAV infection in large animal eyes. Dogs are an important preclinical model for retinal degenerative diseases, as their eye size and structure are similar to humans, and many forms of retinal disease occur naturally in a variety of canine breeds. The screening method was used to identify 96 AAV variants capable of panretinal infection in the canine retina. Deep sequencing was used to quantify the performance of 18 of these variants from the screened AAV variant pool in the canine retina. Infectivity was quantified based on the levels of viral DNA and mRNA in retinal cells after intravitreal injection. These variants can be used in a variety of gene delivery strategies in large animals and human eyes.

[0377] A peptide presentation library containing random 21 nucleotide insertions (surrounded by 5' 6-nucleotide linkers and 3' 3-nucleotide linkers) at surface-exposed positions on the AAV capsid was generated. Viruses were packaged such that each viral genome was encapsidated within a capsid protein shell encoded by that genome. Thus, functional improvements identified by selection could be linked to the genomic sequence contained within the viral capsid. From this library, an iterative in vivo screening selection process was used to identify variants capable of infecting the canine retina from the vitreous. Figure 1 ). Each round of injection of approximately 250 μL of 10E+13-10E+14 viral genomes / mL (vg / mL) titer virus was injected into the canine eye. Three weeks after the injection, the eye was enucleated and retinal punches were removed from the central and peripheral regions of the retina. RPE cells were isolated from the retinal tissue and the tissue was frozen. DNA was then collected from the retinal cells, and the cap gene was amplified from the isolated sample by polymerase chain reaction (PCR). The cap gene was used for subsequent AAV packaging.

[0378] Figure 1 Illustration of a directed evolution approach for the development of canine retinal AAV variants. A peptide display library was generated, packaged into AAV vectors, and injected into the canine eye via intravitreal injection. Iterative rounds of selection were used to positively select AAV variants from the vector pool. Three rounds of selection were followed by one round of error-prone PCR, followed by several additional rounds of selection.

[0379] After five rounds of selection, Illumina deep sequencing was used to identify variants in the AAV variant library whose relative expression increased over the rounds. Increased expression in the viral library indicates positive selection and the ability to infect the canine retina from the vitreous. From a library of approximately 10E+7 variants, the top 96 variants selected in the in vivo screen are provided in Table 1.

[0380] Table 1

[0381]

[0382]

[0383]

[0384] High throughput sequencing was used to further quantify the ability of the top 18 variants of the 96 variants depicted in Table 1 to infect the canine retina. Table 2 depicts the top 18 variants selected for further quantification.

[0385] Table 2

[0386]

[0387] Eighteen variants were packaged using a universal CAG promoter that drives GFP expression. GFP cDNA was fused to a unique 25-base pair barcode identifier. Each of the 18 variants was packaged with a unique GFP barcode. The packaged variants were mixed in equal ratios and injected into the retina together with a control AAV2-based vector (a negative control representing a naturally occurring parental serotype). After injection, DNA and mRNA were collected from photoreceptors and RPE cells. DNA and mRNA levels were quantified to determine the ability of canine-derived vectors to deliver DNA to the retina and cause transgene expression ( Figure 2 ).

[0388] Figure 2 Deep sequencing of variants containing GFP-barcode constructs. Infection of the canine retina by canine-derived variants was quantified by deep sequencing of GFP-tagged cDNA and mRNA.

[0389] The expression of the 18-member library was imaged using confocal microscopy of frozen retinal sections. GFP expression indicated that the 18-member library targeted retinal cells in the inner retina and photoreceptors in the outer retina ( Figure 3 ).

[0390] Figure 3 The 18-member canine-derived AAV variant library infects cells in the ganglion cell layer, inner nuclear layer, photoreceptor layer, and RPE layer.

[0391] Of the top 18 variants tested, two variants resulted in the highest levels of DNA and mRNA recovery. The variant that resulted in the highest level of DNA recovery had an insertion sequence of ˜588-PAPQDTTKKA (SEQ ID NO: 57). The variant that resulted in the highest level of mRNA expression had an insertion sequence of ˜588-LAPDSTTRSA (SEQ ID NO: 53).

[0392] Although the present invention has been described with reference to specific embodiments thereof, it should be understood that various modifications may be made by those skilled in the art and that equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many changes may be made to adapt specific circumstances, materials, compositions of matter, methods, and method steps to the objectives, spirit, and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. Sequence Listing <110> Regents of the University of California Board of Governors of the University of Pennsylvania <120> Adeno-associated virus virions with variant capsids and methods of use thereof <130> BERK-335WO <150> 62 / 368,929 <151> 2016-07-29 <160> 152 <170> PatentIn version 3.5 <210> 1 <211> 733 <212> PRT <213> Adeno-associated virus-2 <400> 1 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser 1 5 10 15 Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro 20 25 30 Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Pro Val Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu His Ser Pro Val Glu Pro Asp Ser Ser Ser Gly Thr Gly 145 150 155 160 Lys Ala Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Ala Asp Ser Val Pro Asp Pro Gln Pro Leu Gly Gln Pro Pro 180 185 190 Ala Ala Pro Ser Gly Leu Gly Thr Asn Thr Met Ala Thr Gly Ser Gly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr 260 265 270 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His 275 280 285 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp 290 295 300 Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val 305 310 315 320 Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu 325 330 335 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr 340 345 350 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp 355 360 365 Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser 370 375 380 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser 385 390 395 400 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu 405 410 415 Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg 420 425 430 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr 435 440 445 Asn Thr Pro Ser Gly Thr Thr Thr Gln Ser Arg Leu Gln Phe Ser Gln 450 455 460 Ala Gly Ala Ser Asp Ile Arg Asp Gln Ser Arg Asn Trp Leu Pro Gly 465 470 475 480 Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ser Ala Asp Asn Asn 485 490 495 Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly 500 505 510 Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp 515 520 525 Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly Val Leu Ile Phe Gly Lys 530 535 540 Gln Gly Ser Glu Lys Thr Asn Val Asp Ile Glu Lys Val Met Ile Thr 545 550 555 560 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr 565 570 575 Gly Ser Val Ser Thr Asn Leu Gln Arg Gly Asn Arg Gln Ala Ala Thr 580 585 590 Ala Asp Val Asn Thr Gln Gly Val Leu Pro Gly Met Val Trp Gln Asp 595 600 605 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr 610 615 620 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys 625 630 635 640 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn 645 650 655 Pro Ser Thr Thr Phe Ser Ala Ala Lys Phe Ala Ser Phe Ile Thr Gln 660 665 670 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys 675 680 685 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr 690 695 700 Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr 705 710 715 720 Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 <210> 2 <211> 42 <212> PRT <213> Adeno-associated virus-2 <400> 2 Pro Val Ala Thr Glu Gln Tyr Gly Ser Val Ser Thr Asn Leu Gln Arg 1 5 10 15 Gly Asn Arg Gln Ala Ala Thr Ala Asp Val Asn Thr Gln Gly Val Leu 20 25 30 Pro Gly Met Val Trp Gln Asp Arg Asp Val 35 40 <210> 3 <211> 42 <212> PRT <213> Adeno-associated virus-1 <400> 3 Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser 1 5 10 15 Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu 20 25 30 Pro Gly Met Val Trp Gln Asp Arg Asp Val 35 40 <210> 4 <211> 42 <212> PRT <213> Adeno-associated virus-5 <400> 4 Arg Val Ala Tyr Asn Val Gly Gly Gln Met Ala Thr Asn Asn Gln Ser 1 5 10 15 Ser Thr Thr Ala Pro Ala Thr Gly Thr Tyr Asn Leu Gln Glu Ile Val 20 25 30 Pro Gly Ser Val Trp Met Glu Arg Asp Val 35 40 <210> 5 <211> 42 <212> PRT <213> Adeno-associated virus-6 <400> 5 Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Leu Gln Ser 1 5 10 15 Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Val Met Gly Ala Leu 20 25 30 Pro Gly Met Val Trp Gln Asp Arg Asp Val 35 40 <210> 6 <211> 42 <212> PRT <213> Adeno-associated virus-7 <400> 6 Pro Val Ala Thr Glu Glu Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala 1 5 10 15 Ala Asn Thr Ala Ala Gln Thr Gln Val Val Asn Asn Gln Gly Ala Leu 20 25 30 Pro Gly Met Val Trp Gln Asn Arg Asp Val 35 40 <210> 7 <211> 42 <212> PRT <213> Adeno-associated virus-8 <400> 7 Pro Val Ala Thr Glu Glu Tyr Gly Ile Val Ala Asp Asn Leu Gln Gln 1 5 10 15 Gln Asn Thr Ala Pro Gln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu 20 25 30 Pro Gly Met Val Trp Gln Asn Arg Asp Val 35 40 <210> 8 <211> 42 <212> PRT <213> Adeno-associated virus-9 <400> 8 Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser 1 5 10 15 Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu 20 25 30 Pro Gly Met Val Trp Gln Asp Arg Asp Val 35 40 <210> 9 <211> 42 <212> PRT <213> Adeno-associated virus-10 <400> 9 Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln 1 5 10 15 Ala Asn Thr Gly Pro Ile Val Gly Asn Val Asn Ser Gln Gly Ala Leu 20 25 30 Pro Gly Met Val Trp Gln Asn Arg Asp Val 35 40 <210> 10 <211> 224 <212> PRT <213> Homo sapiens <400> 10 Met Ser Arg Lys Ile Glu Gly Phe Leu Leu Leu Leu Leu Phe Gly Tyr 1 5 10 15 Glu Ala Thr Leu Gly Leu Ser Ser Thr Glu Asp Glu Gly Glu Asp Pro 20 25 30 Trp Tyr Gln Lys Ala Cys Lys Cys Asp Cys Gln Gly Gly Pro Asn Ala 35 40 45 Leu Trp Ser Ala Gly Ala Thr Ser Leu Asp Cys Ile Pro Glu Cys Pro 50 55 60 Tyr His Lys Pro Leu Gly Phe Glu Ser Gly Glu Val Thr Pro Asp Gln 65 70 75 80 Ile Thr Cys Ser Asn Pro Glu Gln Tyr Val Gly Trp Tyr Ser Ser Trp 85 90 95 Thr Ala Asn Lys Ala Arg Leu Asn Ser Gln Gly Phe Gly Cys Ala Trp 100 105 110 Leu Ser Lys Phe Gln Asp Ser Ser Gln Trp Leu Gln Ile Asp Leu Lys 115 120 125 Glu Ile Lys Val Ile Ser Gly Ile Leu Thr Gln Gly Arg Cys Asp Ile 130 135 140 Asp Glu Trp Met Thr Lys Tyr Ser Val Gln Tyr Arg Thr Asp Glu Arg 145 150 155 160 Leu Asn Trp Ile Tyr Tyr Lys Asp Gln Thr Gly Asn Asn Arg Val Phe 165 170 175 Tyr Gly Asn Ser Asp Arg Thr Ser Thr Val Gln Asn Leu Leu Arg Pro 180 185 190 Pro Ile Ile Ser Arg Phe Ile Arg Leu Ile Pro Leu Gly Trp His Val 195 200 205 Arg Ile Ala Ile Arg Met Glu Leu Leu Glu Cys Val Ser Lys Cys Ala 210 215 220 <210> 11 <211> 247 <212> PRT <213> Homo sapiens <400> 11 Met Thr Ile Leu Phe Leu Thr Met Val Ile Ser Tyr Phe Gly Cys Met 1 5 10 15 Lys Ala Ala Pro Met Lys Glu Ala Asn Ile Arg Gly Gln Gly Gly Leu 20 25 30 Ala Tyr Pro Gly Val Arg Thr His Gly Thr Leu Glu Ser Val Asn Gly 35 40 45 Pro Lys Ala Gly Ser Arg Gly Leu Thr Ser Leu Ala Asp Thr Phe Glu 50 55 60 His Val Ile Glu Glu Leu Leu Asp Glu Asp His Lys Val Arg Pro Asn 65 70 75 80 Glu Glu Asn Asn Lys Asp Ala Asp Leu Tyr Thr Ser Arg Val Met Leu 85 90 95 Ser Ser Gln Val Pro Leu Glu Pro Pro Leu Leu Phe Leu Leu Glu Glu 100 105 110 Tyr Lys Asn Tyr Leu Asp Ala Ala Asn Met Ser Met Met Val Leu Arg 115 1,20 125 His Ser Asp Pro Ala Arg Arg Gly Glu Leu Ser Val Cys Asp Ser Ile 130 135 140 Ser Glu Trp Val Thr Ala Ala Asp Lys Lys Thr Ala Val Asp Met Ser 145 150 155 160 Gly Gly Thr Val Thr Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln 165 170 175 Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr 180 185 190 Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys 195 200 205 Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys 210 215 220 Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr 225 230 235 240 Leu Thr Ile Lys Arg Gly Arg 245 <210> 12 <211> 533 <212> PRT <213> Homo sapiens <400> 12 Met Ser Ile Gln Val Glu His Pro Ala Gly Gly Tyr Lys Lys Leu Phe 1 5 10 15 Glu Thr Val Glu Glu Leu Ser Ser Pro Leu Thr Ala His Val Thr Gly 20 25 30 Arg Ile Pro Leu Trp Leu Thr Gly Ser Leu Leu Arg Cys Gly Pro Gly 35 40 45 Leu Phe Glu Val Gly Ser Glu Pro Phe Tyr His Leu Phe Asp Gly Gln 50 55 60 Ala Leu Leu His Lys Phe Asp Phe Lys Glu Gly His Val Thr Tyr His 65 70 75 80 Arg Arg Phe Ile Arg Thr Asp Ala Tyr Val Arg Ala Met Thr Glu Lys 85 90 95 Arg Ile Val Ile Thr Glu Phe Gly Thr Cys Ala Phe Pro Asp Pro Cys 100 105 110 Lys Asn Ile Phe Ser Arg Phe Phe Ser Tyr Phe Arg Gly Val Glu Val 115 120 125 Thr Asp Asn Ala Leu Val Asn Val Tyr Pro Val Gly Glu Asp Tyr Tyr 130 135 140 Ala Cys Thr Glu Thr Asn Phe Ile Thr Lys Ile Asn Pro Glu Thr Leu 145 150 155 160 Glu Thr Ile Lys Gln Val Asp Leu Cys Asn Tyr Val Ser Val Asn Gly 165 170 175 Ala Thr Ala His Pro His Ile Glu Asn Asp Gly Thr Val Tyr Asn Ile 180 185 190 Gly Asn Cys Phe Gly Lys Asn Phe Ser Ile Ala Tyr Asn Ile Val Lys 195 200 205 Ile Pro Pro Leu Gln Ala Asp Lys Glu Asp Pro Ile Ser Lys Ser Glu 210 215 220 Ile Val Val Gln Phe Pro Cys Ser Asp Arg Phe Lys Pro Ser Tyr Val 225 230 235 240 His Ser Phe Gly Leu Thr Pro Asn Tyr Ile Val Phe Val Glu Thr Pro 245 250 255 Val Lys Ile Asn Leu Phe Lys Phe Leu Ser Ser Trp Ser Leu Trp Gly 260 265 270 Ala Asn Tyr Met Asp Cys Phe Glu Ser Asn Glu Thr Met Gly Val Trp 275 280 285 Leu His Ile Ala Asp Lys Lys Arg Lys Lys Tyr Leu Asn Asn Lys Tyr 290 295 300 Arg Thr Ser Pro Phe Asn Leu Phe His His Ile Asn Thr Tyr Glu Asp 305 310 315 320 Asn Gly Phe Leu Ile Val Asp Leu Cys Cys Trp Lys Gly Phe Glu Phe 325 330 335 Val Tyr Asn Tyr Leu Tyr Leu Ala Asn Leu Arg Glu Asn Trp Glu Glu 340 345 350 Val Lys Lys Asn Ala Arg Lys Ala Pro Gln Pro Glu Val Arg Arg Tyr 355 360 365 Val Leu Pro Leu Asn Ile Asp Lys Ala Asp Thr Gly Lys Asn Leu Val 370 375 380 Thr Leu Pro Asn Thr Thr Ala Thr Ala Ile Leu Cys Ser Asp Glu Thr 385 390 395 400 Ile Trp Leu Glu Pro Glu Val Leu Phe Ser Gly Pro Arg Gln Ala Phe 405 410 415 Glu Phe Pro Gln Ile Asn Tyr Gln Lys Tyr Cys Gly Lys Pro Tyr Thr 420 425 430 Tyr Ala Tyr Gly Leu Gly Leu Asn His Phe Val Pro Asp Arg Leu Cys 435 440 445 Lys Leu Asn Val Lys Thr Lys Glu Thr Trp Val Trp Gln Glu Pro Asp 450 455 460 Ser Tyr Pro Ser Glu Pro Ile Phe Val Ser His Pro Asp Ala Leu Glu 465 470 475 480 Glu Asp Asp Gly Val Val Leu Ser Val Val Val Ser Pro Gly Ala Gly 485 490 495 Gln Lys Pro Ala Tyr Leu Leu Ile Leu Asn Ala Lys Asp Leu Ser Glu 500 505 510 Val Ala Arg Ala Glu Val Glu Ile Asn Ile Pro Val Thr Phe His Gly 515 520 525 Leu Phe Lys Lys Ser 530 <210> 13 <211> 346 <212> PRT <213> Homo sapiens <400> 13 Met Ala Leu Leu Lys Val Lys Phe Asp Gln Lys Lys Arg Val Lys Leu 1 5 10 15 Ala Gln Gly Leu Trp Leu Met Asn Trp Phe Ser Val Leu Ala Gly Ile 20 25 30 Ile Ile Phe Ser Leu Gly Leu Phe Leu Lys Ile Glu Leu Arg Lys Arg 35 40 45 Ser Asp Val Met Asn Asn Ser Glu Ser His Phe Val Pro Asn Ser Leu 50 55 60 Ile Gly Met Gly Val Leu Ser Cys Val Phe Asn Ser Leu Ala Gly Lys 65 70 75 80 Ile Cys Tyr Asp Ala Leu Asp Pro Ala Lys Tyr Ala Arg Trp Lys Pro 85 90 95 Trp Leu Lys Pro Tyr Leu Ala Ile Cys Val Leu Phe Asn Ile Ile Leu 100 105 110 Phe Leu Val Ala Leu Cys Cys Phe Leu Leu Arg Gly Ser Leu Glu Asn 115 120 125 Thr Leu Gly Gln Gly Leu Lys Asn Gly Met Lys Tyr Tyr Arg Asp Thr 130 135 140 Asp Thr Pro Gly Arg Cys Phe Met Lys Lys Thr Ile Asp Met Leu Gln 145 150 155 160 Ile Glu Phe Lys Cys Cys Gly Asn Asn Gly Phe Arg Asp Trp Phe Glu 165 170 175 Ile Gln Trp Ile Ser Asn Arg Tyr Leu Asp Phe Ser Ser Lys Glu Val 180 185 190 Lys Asp Arg Ile Lys Ser Asn Val Asp Gly Arg Tyr Leu Val Asp Gly 195 200 205 Val Pro Phe Ser Cys Cys Asn Pro Ser Ser Pro Arg Pro Cys Ile Gln 210 215 220 Tyr Gln Ile Thr Asn Asn Ser Ala His Tyr Ser Tyr Asp His Gln Thr 225 230 235 240 Glu Glu Leu Asn Leu Trp Val Arg Gly Cys Arg Ala Ala Leu Leu Ser 245 250 255 Tyr Tyr Ser Ser Leu Met Asn Ser Met Gly Val Val Thr Leu Leu Ile 260 265 270 Trp Leu Phe Glu Val Thr Ile Thr Ile Gly Leu Arg Tyr Leu Gln Thr 275 280 285 Ser Leu Asp Gly Val Ser Asn Pro Glu Glu Ser Glu Ser Glu Ser Gln 290 295 300 Gly Trp Leu Leu Glu Arg Ser Val Pro Glu Thr Trp Lys Ala Phe Leu 305 310 315 320 Glu Ser Val Lys Lys Leu Gly Lys Gly Asn Gln Val Glu Ala Glu Gly 325 330 335 Ala Asp Ala Gly Gln Ala Pro Glu Ala Gly 340 345 <210> 14 <211> 470 <212> PRT <213> Homo sapiens <400> 14 Met Ser His His Pro Ser Gly Leu Arg Ala Gly Phe Ser Ser Thr SerAla Asp Ala Gly Gln Ala Pro Glu Ala Gly 1 ******** 15 Tyr Arg Arg Thr Phe Gly Pro Pro Pro Ser Leu Ser Pro Gly Ala Phe [[ID=;36]] 20 25 30 Ser Tyr Ser Ser Ser Ser Arg Phe Ser Ser Ser Arg Leu Leu Gly Ser 35 40 45 Ala Ser Pro Ser Ser Ser Val Arg Leu Gly Ser Phe Arg Ser Pro Arg 50 55 60 It should be noted that there seems to be an unresolved "********" in the "1 ******** 15" part in the original text. This might be an error or an incomplete notation. You may want to double-check the original content for accuracy.Ala Gly Ala Gly Ala Leu Leu Arg Leu Pro Ser Glu Arg Leu Asp Phe 65 70 75 80 Ser Met Ala Glu Ala Leu Asn Gln Glu Phe Leu Ala Thr Arg Ser Asn 85 90 95 Glu Lys Gln Glu Leu Gln Glu Leu Asn Asp Arg Phe Ala Asn Phe Ile 100 105 110 Glu Lys Val Arg Phe Leu Glu Gln Gln Asn Ala Ala Leu Arg Gly Glu 115 120 125 Leu Ser Gln Ala Arg Gly Gln Glu Pro Ala Arg Ala Asp Gln Leu Cys 130 135 140 Gln Gln Glu Leu Arg Glu Leu Arg Arg Glu Leu Glu Leu Leu Gly Arg 145 150 155 160 Glu Arg Asp Arg Val Gln Val Glu Arg Asp Gly Leu Ala Glu Asp Leu 165 170 175 Ala Ala Leu Lys Gln Arg Leu Glu Glu Glu Thr Arg Lys Arg Glu Asp 180 185 190 Ala Glu His Asn Leu Val Leu Phe Arg Lys Asp Val Asp Asp Ala Thr 195 200 205 Leu Ser Arg Leu Glu Leu Glu Arg Lys Ile Glu Ser Leu Met Asp Glu 210 215 220 Ile Glu Phe Leu Lys Lys Leu His Glu Glu Glu Leu Arg Asp Leu Gln 225 230 235 240 Val Ser Val Glu Ser Gln Gln Val Gln Gln Val Glu Val Glu Ala Thr 245 250 255 Val Lys Pro Glu Leu Thr Ala Ala Leu Arg Asp Ile Arg Ala Gln Tyr 260 265 270 Glu Ser Ile Ala Ala Lys Asn Leu Gln Glu Ala Glu Glu Trp Tyr Lys 275 280 285 Ser Lys Tyr Ala Asp Leu Ser Asp Ala Ala Asn Arg Asn His Glu Ala 290 295 300 Leu Arg Gln Ala Lys Gln Glu Met Asn Glu Ser Arg Arg Gln Ile Gln 305 310 315 320 Ser Leu Thr Cys Glu Val Asp Gly Leu Arg Gly Thr Asn Glu Ala Leu 325 330 335 Leu Arg Gln Leu Arg Glu Leu Glu Glu Gln Phe Ala Leu Glu Ala Gly 340 345 350 Gly Tyr Gln Ala Gly Ala Ala Arg Leu Glu Glu Glu Leu Arg Gln Leu 355 360 365 Lys Glu Glu Met Ala Arg His Leu Arg Glu Tyr Gln Glu Leu Leu Asn 370 375 380 Val Lys Met Ala Leu Asp Ile Glu Ile Ala Thr Tyr Arg Lys Leu Leu 385 390 395 400 Glu Gly Glu Glu Ser Arg Ile Ser Val Pro Val His Ser Phe Ala Ser 405 410 415 Leu Asn Ile Lys Thr Thr Val Pro Glu Val Glu Pro Pro Gln Asp Ser 420 425 430 His Ser Arg Lys Thr Val Leu Ile Lys Thr Ile Glu Thr Arg Asn Gly 435 440 445 Glu Val Val Thr Glu Ser Gln Lys Glu Gln Arg Ser Glu Leu Asp Lys 450 455 460<0001�41>Ser Ser Ala His Ser Tyr 465 470 <210> 15 <211> 1286 <212> PRT <213> Homo sapiens <400> 15 Met Ser His Leu Val Asp Pro Thr Ser Gly Asp Leu Pro Val Arg Asp 1 5 10 15 Ile Asp Ala Ile Pro Leu Val Leu Pro Ala Ser Lys Gly Lys Asn Met 20 25 30 Lys Thr Gln Pro Pro Leu Ser Arg Met Asn Arg Glu Glu Leu Glu Asp 35 40 45 Ser Phe Phe Arg Leu Arg Glu Asp His Met Leu Val Lys Glu Leu Ser 50 55 60 Trp Lys Gln Gln Asp Glu Ile Lys Arg Leu Arg Thr Thr Leu Leu Arg 65 70 75 80 Leu Thr Ala Ala Gly Arg Asp Leu Arg Val Ala Glu Glu Ala Ala Pro 85 90 95 Leu Ser Glu Thr Ala Arg Arg Gly Gln Lys Ala Gly Trp Arg Gln Arg 100 105 110 Leu Ser Met His Gln Arg Pro Gln Met His Arg Leu Gln Gly His Phe 115 120 125 His Cys Val Gly Pro Ala Ser Pro Arg Arg Ala Gln Pro Arg Val Gln 130 135 140 Val Gly His Arg Gln Leu His Thr Ala Gly Ala Pro Val Pro Glu Lys 145 150 155 160 Pro Lys Arg Gly Pro Arg Asp Arg Leu Ser Tyr Thr Ala Pro Pro Ser 165 170 175 Phe Lys Glu His Ala Thr Asn Glu Asn Arg Gly Glu Val Ala Ser Lys 180 185 190 Pro Ser Glu Leu Val Ser Gly Ser Asn Ser Ile Ile Ser Phe Ser Ser 195 200 205 Val Ile Ser Met Ala Lys Pro Ile Gly Leu Cys Met Pro Asn Ser Ala 210 215 220 His Ile Met Ala Ser Asn Thr Met Gln Val Glu Glu Pro Pro Lys Ser 225 230 235 240 Pro Glu Lys Met Trp Pro Lys Asp Glu Asn Phe Glu Gln Arg Ser Ser 245 250 255 Leu Glu Cys Ala Gln Lys Ala Ala Glu Leu Arg Ala Ser Ile Lys Glu 260 265 270 Lys Val Glu Leu Ile Arg Leu Lys Lys Leu Leu His Glu Arg Asn Ala 275 280 285 Serum Leu Val Met Thr Lys Ala Gln Leu Thr Glu Val Gln Glu Ala Tyr 290 295 300 Glu Thr Leu Leu Gln Lys Asn Gln Gly Ile Leu Ser Ala Ala His Glu 305 310 315 320 Ala Leu Leu Lys Gln Val Asn Glu Leu Arg Ala Glu Leu Lys Glu Glu 325 330 335 Ser Lys Lys Ala Val Ser Leu Lys Ser Gln Leu Glu Asp Val Ser Ile 340 345 350 Leu Gln Met Thr Leu Lys Glu Phe Gln Glu Arg Val Glu Asp Leu Glu 355 360 365 Lys Glu Arg Lys Leu Leu Asn Asp Asn Tyr Asp Lys Leu Leu Glu Ser 370 375 380 Met Leu Asp Ser Ser Asp Ser Ser Ser Gln Pro His Trp Ser Asn Glu 385 390 395 400 Leu Ile Ala Glu Gln Leu Gln Gln Gln Val Ser Gln Leu Gln Asp Gln 405 410 415 Leu Asp Ala Glu Leu Glu Asp Lys Arg Lys Val Leu Leu Glu Leu Ser 420 425 430 Arg Glu Lys Ala Gln Asn Glu Asp Leu Lys Leu Glu Val Thr Asn Ile 435 440 445 Leu Gln Lys His Lys Gln Glu Val Glu Leu Leu Gln Asn Ala Ala Thr 450 455 460 Ile Ser Gln Pro Pro Asp Arg Gln Ser Glu Pro Ala Thr His Pro Ala 465 470 475 480 Val Leu Gln Glu Asn Thr Gln Ile Glu Pro Ser Glu Pro Lys Asn Gln 485 490 495 Glu Glu Lys Lys Leu Ser Gln Val Leu Asn Glu Leu Gln Val Ser His 500 505 510 Ala Glu Thr Thr Leu Glu Leu Glu Lys Thr Arg Asp Met Leu Ile Leu 515 520 525 Gln Arg Lys Ile Asn Val Cys Tyr Gln Glu Glu Leu Glu Ala Met Met 530 535 540 Thr Lys Ala Asp Asn Asp Asn Arg Asp His Lys Glu Lys Leu Glu Arg 545 550 555 560 Leu Thr Arg Leu Leu Asp Leu Lys Asn Asn Arg Ile Lys Gln Leu Glu 565 570 575 Gly Ile Leu Arg Ser His Asp Leu Pro Thr Ser Glu Gln Leu Lys Asp 580 585 590 Val Ala Tyr Gly Thr Arg Pro Leu Ser Leu Cys Leu Glu Thr Leu Pro 595 600 605 Ala His Gly Asp Glu Asp Lys Val Asp Ile Ser Leu Leu His Gln Gly 610 615 620 Glu Asn Leu Phe Glu Leu His Ile His Gln Ala Phe Leu Thr Ser Ala 625 630 635 640 Ala Leu Ala Gln Ala Gly Asp Thr Gln Pro Thr Thr Phe Cys Thr Tyr 645 650 655 Ser Phe Tyr Asp Phe Glu Thr His Cys Thr Pro Leu Ser Val Gly Pro 660 665 670 Gln Pro Leu Tyr Asp Phe Thr Ser Gln Tyr Val Met Glu Thr Asp Ser 675 680 685 Leu Phe Leu His Tyr Leu Gln Glu Ala Ser Ala Arg Leu Asp Ile His 690 695 700 Gln Ala Met Ala Ser Glu His Ser Thr Leu Ala Ala Gly Trp Ile Cys 705 710 715 720 Phe Asp Arg Val Leu Glu Thr Val Glu Lys Val His Gly Leu Ala Thr 725 730 735 Leu Ile Gly Ala Gly Gly Glu Glu Phe Gly Val Leu Glu Tyr Trp Met 740 745 750 Arg Leu Arg Phe Pro Ile Lys Pro Ser Leu Gln Ala Cys Asn Lys Arg 755 760 765 Lys Lys Ala Gln Val Tyr Leu Ser Thr Asp Val Leu Gly Gly Arg Lys 770 775 780 Ala Gln Glu Glu Glu Phe Arg Ser Glu Ser Trp Glu Pro Gln Asn Glu 785 790 795 800 Leu Trp Ile Glu Ile Thr Lys Cys Cys Gly Leu Arg Ser Arg Trp Leu 805 810 815 Gly Thr Gln Pro Ser Pro Tyr Ala Val Tyr Arg Phe Phe Thr Phe Ser 820 825 830 Asp His Asp Thr Ala Ile Ile Pro Ala Ser Asn Asn Pro Tyr Phe Arg 835 840 845 Asp Gln Ala Arg Phe Pro Val Leu Val Thr Ser Asp Leu Asp His Tyr 850 855 860 Leu Arg Arg Glu Ala Leu Ser Ile His Val Phe Asp Asp Glu Asp Leu 865 870 875 880 Glu Pro Gly Ser Tyr Leu Gly Arg Ala Arg Val Pro Leu Leu Pro Leu 885 890 895 Ala Lys Asn Glu Ser Ile Lys Gly Asp Phe Asn Leu Thr Asp Pro Ala 900 905 910 Glu Lys Pro Asn Gly Ser Ile Gln Val Gln Leu Asp Trp Lys Phe Pro 915 920 925 Tyr Ile Pro Pro Glu Ser Phe Leu Lys Pro Glu Ala Gln Thr Lys Gly 930 935 940 Lys Asp Thr Lys Asp Ser Ser Lys Ile Ser Ser Glu Glu Glu Lys Ala 945 950 955 960 Ser Phe Pro Ser Gln Asp Gln Met Ala Ser Pro Glu Val Pro Ile Glu 965 970 975 Ala Gly Gln Tyr Arg Ser Lys Arg Lys Pro Pro His Gly Gly Glu Arg 980 985 990 Lys Glu Lys Glu His Gln Val Val Ser Tyr Ser Arg Arg Lys His Gly 995 1000 1005 Lys Arg Ile Gly Val Gln Gly Lys Asn Arg Met Glu Tyr Leu Ser 1010 1015 1020 Leu Asn Ile Leu Asn Gly Asn Thr Pro Glu Gln Val Asn Tyr Thr 1025 1030 1035 Glu Trp Lys Phe Ser Glu Thr Asn Ser Phe Ile Gly Asp Gly Phe 1040 1045 1050 Lys Asn Gln His Glu Glu Glu Glu Met Thr Leu Ser His Ser Ala 1055 1060 1065 Leu Lys Gln Lys Glu Pro Leu His Pro Val Asn Asp Lys Glu Ser 1070 1075 1080 Ser Glu Gln Gly Ser Glu Val Ser Glu Ala Gln Thr Thr Asp Ser 1085 1090 1095 Asp Asp Val Ile Val Pro Pro Met Ser Gln Lys Tyr Pro Lys Ala 1100 1105 1110 Asp Ser Glu Lys Met Cys Ile Glu Ile Val Ser Leu Ala Phe Tyr 1115 1120 1125 Pro Glu Ala Glu Val Met Ser Asp Glu Asn Ile Lys Gln Val Tyr 1130 1135 1140 Val Glu Tyr Lys Phe Tyr Asp Leu Pro Leu Ser Glu Thr Glu Thr 1145 1150 1155 Pro Val Ser Leu Arg Lys Pro Arg Ala Gly Glu Glu Ile His Phe 1160 1165 1170 His Phe Ser Lys Val Ile Asp Leu Asp Pro Gln Glu Gln Gln Gly 1175 1180 1185 Arg Arg Arg Phe Leu Phe Asp Met Leu Asn Gly Gln Asp Pro Asp 1190 1195 1200 Gln Gly His Leu Lys Phe Thr Val Val Ser Asp Pro Leu Asp Glu 1205 1210 1215 Glu Lys Lys Glu Cys Glu Glu Val Gly Tyr Ala Tyr Leu Gln Leu 1220 1225 1230 Trp Gln Ile Leu Glu Ser Gly Arg Asp Ile Leu Glu Gln Glu Leu 1235 1240 1245 Asp Ile Val Ser Pro Glu Asp Leu Ala Thr Pro Ile Gly Arg Leu 1250 1255 1260 Lys Val Ser Leu Gln Ala Ala Ala Val Leu His Ala Ile Tyr Lys 1265 1270 1275 Glu Met Thr Glu Asp Leu Phe Ser 1280 1285 <210> 16 <211> 653 <212> PRT <213> Homo sapiens <400> 16 Met Ala Asp Thr Leu Pro Ser Glu Phe Asp Val Ile Val Ile Gly Thr 1 5 10 15 Gly Leu Pro Glu Ser Ile Ile Ala Ala Ala Cys Ser Arg Ser Gly Arg 20 25 30 Arg Val Leu His Val Asp Ser Arg Ser Tyr Tyr Gly Gly Asn Trp Ala 35 40 45 Ser Phe Ser Phe Ser Gly Leu Leu Ser Trp Leu Lys Glu Tyr Gln Glu 50 55 60 Asn Ser Asp Ile Val Ser Asp Ser Pro Val Trp Gln Asp Gln Ile Leu 65 70 75 80 Glu Asn Glu Glu Ala Ile Ala Leu Ser Arg Lys Asp Lys Thr Ile Gln 85 90 95 His Val Glu Val Phe Cys Tyr Ala Ser Gln Asp Leu His Glu Asp Val 100 105 110 Glu Glu Ala Gly Ala Leu Gln Lys Asn His Ala Leu Val Thr Ser Ala 115 120 125 Asn Ser Thr Glu Ala Ala Asp Ser Ala Phe Leu Pro Thr Glu Asp Glu 130 135 140 Ser Leu Ser Thr Met Ser Cys Glu Met Leu Thr Glu Gln Thr Pro Ser 145 150 155 160 Ser Asp Pro Glu Asn Ala Leu Glu Val Asn Gly Ala Glu Val Thr Gly 165 170 175 Glu Lys Glu Asn His Cys Asp Asp Lys Thr Cys Val Pro Ser Thr Ser 180 185 190 Ala Glu Asp Met Ser Glu Asn Val Pro Ile Ala Glu Asp Thr Thr Glu 195 200 205 Gln Pro Lys Lys Asn Arg Ile Thr Tyr Ser Gln Ile Ile Lys Glu Gly 210 215 220 Arg Arg Phe Asn Ile Asp Leu Val Ser Lys Leu Leu Tyr Ser Arg Gly 225 230 235 240 Leu Leu Ile Asp Leu Leu Ile Lys Ser Asn Val Ser Arg Tyr Ala Glu 245 250 255 Phe Lys Asn Ile Thr Arg Ile Leu Ala Phe Arg Glu Gly Arg Val Glu 260 265 270 Gln Val Pro Cys Ser Arg Ala Asp Val Phe Asn Ser Lys Gln Leu Thr 275 280 285 Met Val Glu Lys Arg Met Leu Met Lys Phe Leu Thr Phe Cys Met Glu 290 295 300 Tyr Glu Lys Tyr Pro Asp Glu Tyr Lys Gly Tyr Glu Glu Ile Thr Phe 305 310 315 320 Tyr Glu Tyr Leu Lys Thr Gln Lys Leu Thr Pro Asn Leu Gln Tyr Ile 325 330 335 Val Met His Ser Ile Ala Met Thr Ser Glu Thr Ala Ser Ser Thr Ile 340 345 350 Asp Gly Leu Lys Ala Thr Lys Asn Phe Leu His Cys Leu Gly Arg Tyr 355 360 365 Gly Asn Thr Pro Phe Leu Phe Pro Leu Tyr Gly Gln Gly Glu Leu Pro 370 375 380 Gln Cys Phe Cys Arg Met Cys Ala Val Phe Gly Gly Ile Tyr Cys Leu 385 390 395 400 Arg His Ser Val Gln Cys Leu Val Val Asp Lys Glu Ser Arg Lys Cys 405 410 415 Lys Ala Ile Ile Asp Gln Phe Gly Gln Arg Ile Ile Ser Glu His Phe 420 425 430 Leu Val Glu Asp Ser Tyr Phe Pro Glu Asn Met Cys Ser Arg Val Gln 435 440 445 Tyr Arg Gln Ile Ser Arg Ala Val Leu Ile Thr Asp Arg Ser Val Leu 450 455 460 Lys Thr Asp Ser Asp Gln Gln Ile Ser Ile Leu Thr Val Pro Ala Glu 465 470 475 480 Glu Pro Gly Thr Phe Ala Val Arg Val Ile Glu Leu Cys Ser Ser Thr 485 490 495 Met Thr Cys Met Lys Gly Thr Tyr Leu Val His Leu Thr Cys Thr Ser 500 505 510 Ser Lys Thr Ala Arg Glu Asp Leu Glu Ser Val Val Gln Lys Leu Phe 515 520 525 Val Pro Tyr Thr Glu Met Glu Ile Glu Asn Glu Gln Val Glu Lys Pro 530 535 540 Arg Ile Leu Trp Ala Leu Tyr Phe Asn Met Arg Asp Ser Ser Asp Ile 545 550 555 560 Ser Arg Ser Cys Tyr Asn Asp Leu Pro Ser Asn Val Tyr Val Cys Ser 565 570 575 Gly Pro Asp Cys Gly Leu Gly Asn Asp Asn Ala Val Lys Gln Ala Glu 580 585 590 Thr Leu Phe Gln Glu Ile Cys Pro Asn Glu Asp Phe Cys Pro Pro Pro 595 600 605 Pro Asn Pro Glu Asp Ile Ile Leu Asp Gly Asp Ser Leu Gln Pro Glu 610 615 620 Ala Ser Glu Ser Ser Ala Ile Pro Glu Ala Asn Ser Glu Thr Phe Lys 625 630 635 640 Glu Ser Thr Asn Leu Gly Asn Leu Glu Glu Ser Ser Glu 645 650 <210> 17 <211> 212 <212> PRT <213> Homo sapiens <400> 17 Met Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp 1 5 10 15 Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn<00016​​​​​​​​​​​​​​​​​​​​100 105 110 Arg Gln Phe Ser Val Glu Arg Leu Pro Ala Val Val Val Leu Lys Pro 115 120 125 Asp Gly Asp Val Leu Thr Arg Asp Gly Ala Asp Glu Ile Gln Arg Leu 130 135 140 Gly Thr Ala Cys Phe Ala Asn Trp Gln Glu Ala Ala Glu Val Leu Asp 145 150 155 160 Arg Asn Phe Gln Leu Pro Glu Asp Leu Glu Asp Gln Glu Pro Arg Ser 165 170 175 Leu Thr Glu Cys Leu Arg Arg His Lys Tyr Arg Val Glu Lys Ala Ala 180 185 190 Arg Gly Gly Arg Asp Pro Gly Gly Gly Gly Gly Glu Glu Gly Gly Ala 195 200 205 Gly Gly Leu Phe 210 <21 > 18 <211> 156 <212> PRT <213> Homo sapiens <400> 18 Met Val Asp Ile Leu Gly Glu Arg His Leu Val Thr Cys Lys Gly Ala 1 5 10 15 Thr Val Glu Ala Glu Ala Ala Leu Gln Asn Lys Val Val Ala Leu Tyr 20 25 30 Phe Ala Ala Ala Arg Cys Ala Pro Ser Arg Asp Phe Thr Pro Leu Leu 35 40 45 Cys Asp Phe Tyr Thr Ala Leu Val Ala Glu Ala Arg Arg Pro Ala Pro 50 55 60 Phe Glu Val Val Phe Val Ser Ala Asp Gly Ser Ser Gln Glu Met Leu 65 70 75 80 Asp Phe Met Arg Glu Leu His Gly Ala Trp Leu Ala Leu Pro Phe His 85 90 95 Asp Pro Tyr Arg His Glu Leu Arg Lys Arg Tyr Asn Val Thr Ala Ile 100 105 110 Pro Lys Leu Val Ile Val Lys Gln Asn Gly Glu Val Ile Thr Asn Lys 115 120 125 Gly Arg Lys Gln Ile Arg Glu Arg Gly Leu Ala Cys Phe Gln Asp Trp 130 135 140 Val Glu Ala Ala Asp Ile Phe Gln Asn Phe Ser Val 145 150 155 <210> 19 <211> 135 <212> PRT <213> Homo sapiens <400> 19 Met Val Asp Ile Leu Gly Glu Arg His Leu Val Thr Cys Lys Gly Ala 1 5 10 15 Thr Val Glu Ala Glu Ala Ala Leu Gln Asn Lys Val Val Ala Leu Tyr 20 25 30 Phe Ala Ala Ala Arg Cys Ala Pro Ser Arg Asp Phe Thr Pro Leu Leu 35 40 45 Cys Asp Phe Tyr Thr Ala Leu Val Ala Glu Ala Arg Arg Pro Ala Pro 50 55 60 Phe Glu Val Val Phe Val Ser Ala Asp Gly Ser Ser Gln Glu Met Leu 65 70 75 80 Asp Phe Met Arg Glu Leu His Gly Ala Trp Leu Ala Leu Pro Phe His 85 90 95 Asp Pro Tyr Arg Gln Arg Ser Leu Ala Leu Leu Pro Arg Leu Glu Cys 100 105 110 Ser Gly Val Ile Leu Ala His Cys Asn Leu Cys Leu Leu Gly Ser Ser 115 120 125 Asp Ser Leu Ala Leu Ala Ser 130 135 <210> 20 <211> 860 [[ID=�6]]<212> PRT [[ID=�8]]<213> Homo sapiens <400> 20 Met Gly Glu Val Thr Ala Glu Glu Val Glu Lys Phe Leu Asp Ser Asn 1 5 10 15 Ile Gly Phe Ala Lys Gln Tyr Tyr Asn Leu His Tyr Arg Ala Lys Leu 20 25 30 Ile Ser Asp Leu Leu Gly Ala Lys Glu Ala Ala Val Asp Phe Ser Asn 35 40 45 Tyr His Ser Pro Ser Ser Met Glu Glu Ser Glu Ile Ile Phe Asp Leu 50 55 60 Leu Arg Asp Phe Gln Glu Asn Leu Gln Thr Glu Lys Cys Ile Phe Asn 65 70 75 80 Val Met Lys Lys Leu Cys Phe Leu Leu Gln Ala Asp Arg Met Ser Leu 85 90 95 Phe Met Tyr Arg Thr Arg Asn Gly Ile Ala Glu Leu Ala Thr Arg Leu 100 105 110 Phe Asn Val His Lys Asp Ala Val Leu Glu Asp Cys Leu Val Met Pro 115 120 125 Asp Gln Glu Ile Val Phe Pro Leu Asp Met Gly Ile Val Gly His Val 130 135 140 Ala His Ser Lys Lys Ile Ala Asn Val Pro Asn Thr Glu Glu Asp Glu 145 150 155 160 His Phe Cys Asp Phe Val Asp Ile Leu Thr Glu Tyr Lys Thr Lys Asn 165 170 175 Ile Leu Ala Ser Pro Ile Met Asn Gly Lys Asp Val Val Ala Ile Ile 180 185 190 Met Ala Val Asn Lys Val Asp Gly Ser His Phe Thr Lys Arg Asp Glu 195 200 205 Glu Ile Leu Leu Lys Tyr Leu Asn Phe Ala Asn Leu Ile Met Lys Val 210 215 220 Tyr His Leu Ser Tyr Leu His Asn Cys Glu Thr Arg Arg Gly Gln Ile 225 230 235 240 Leu Leu Trp Ser Gly Ser Lys Val Phe Glu Glu Leu Thr Asp Ile Glu 245 250 255 Arg Gln Phe His Lys Ala Leu Tyr Thr Val Arg Ala Phe Leu Asn Cys 260 265 270 Asp Arg Tyr Ser Val Gly Leu Leu Asp Met Thr Lys Gln Lys Glu Phe 275 280 285 Phe Asp Val Trp Pro Val Leu Met Gly Glu Val Pro Pro Tyr Ser Gly 290 295 300 Pro Arg Thr Pro Asp Gly Arg Glu Ile Asn Phe Tyr Lys Val Ile Asp 305 310 315 320 Tyr Ile Leu His Gly Lys Glu Asp Ile Lys Val Ile Pro Asn Pro Pro 325 330 335 Pro Asp His Trp Ala Leu Val Ser Gly Leu Pro Ala Tyr Val Ala Gln 340 345 350 Asn Gly Leu Ile Cys Asn Ile Met Asn Ala Pro Ala Glu Asp Phe Phe 355 360 365 Ala Phe Gln Lys Glu Pro Leu Asp Glu Ser Gly Trp Met Ile Lys Asn 370 375 380 Val Leu Ser Met Pro Ile Val Asn Lys Lys Glu Glu Ile Val Gly Val 385 390 395 400 Ala Thr Phe Tyr Asn Arg Lys Asp Gly Lys Pro Phe Asp Glu Met Asp 405 410 415 Glu Thr Leu Met Glu Ser Leu Thr Gln Phe Leu Gly Trp Ser Val Leu 420 425 430 Asn Pro Asp Thr Tyr Glu Ser Met Asn Lys Leu Glu Asn Arg Lys Asp 435 440 445 Ile Phe Gln Asp Ile Val Lys Tyr His Val Lys Cys Asp Asn Glu Glu 450 455 460 Ile Gln Lys Ile Leu Lys Thr Arg Glu Val Tyr Gly Lys Glu Pro Trp 465 470 475 480 Glu Cys Glu Glu Glu Glu Leu Ala Glu Ile Leu Gln Ala Glu Leu Pro 485 490 495 Asp Ala Asp Lys Tyr Glu Ile Asn Lys Phe His Phe Ser Asp Leu Pro 500 505 510 Leu Thr Glu Leu Glu Leu Val Lys Cys Gly Ile Gln Met Tyr Tyr Glu 515 520 525 Leu Lys Val Val Asp Lys Phe His Ile Pro Gln Glu Ala Leu Val Arg 530 535 540 Phe Met Tyr Ser Leu Ser Lys Gly Tyr Arg Lys Ile Thr Tyr His Asn 545 550 555 560 Trp Arg His Gly Phe Asn Val Gly Gln Thr Met Phe Ser Leu Leu Val 565 570 575 Thr Gly Lys Leu Lys Arg Tyr Phe Thr Asp Leu Glu Ala Leu Ala Met 580 585 590 Val Thr Ala Ala Phe Cys His Asp Ile Asp His Arg Gly Thr Asn Asn 595 600 605 Leu Tyr Gln Met Lys Ser Gln Asn Pro Leu Ala Lys Leu His Gly Ser 610 615 620 Ser Ile Leu Glu Arg His His Leu Glu Phe Gly Lys Thr Leu Leu Arg 625 630 635 640 Asp Glu Ser Leu Asn Ile Phe Gln Asn Leu Asn Arg Arg Gln His Glu 645 650 655 His Ala Ile His Met Met Asp Ile Ala Ile Ile Ala Thr Asp Leu Ala 660 665 670 Leu Tyr Phe Lys Lys Arg Thr Met Phe Gln Lys Ile Val Asp Gln Ser 675 680 685 Lys Thr Tyr Glu Ser Glu Gln Glu Trp Thr Gln Tyr Met Met Leu Glu 690 695 700 Gln Thr Arg Lys Glu Ile Val Met Ala Met Met Met Thr Ala Cys Asp 705 710 715 720 Leu Ser Ala Ile Thr Lys Pro Trp Glu Val Gln Ser Gln Val Ala Leu 725 730 735 Leu Val Ala Ala Glu Phe Trp Glu Gln Gly Asp Leu Glu Arg Thr Val 740 745 750 Leu Gln Gln Asn Pro Ile Pro Met Met Asp Arg Asn Lys Ala Asp Glu 755 760 765 Leu Pro Lys Leu Gln Val Gly Phe Ile Asp Phe Val Cys Thr Phe Val 770 775 780 Tyr Lys Glu Phe Ser Arg Phe His Glu Glu Ile Thr Pro Met Leu Asp 785 790 795 800 Gly Ile Thr Asn Asn Arg Lys Glu Trp Lys Ala Leu Ala Asp Glu Tyr 805 810 815 Asp Ala Lys Met Lys Val Gln Glu Glu Lys Lys Gln Lys Gln Gln Ser 820 825 830 Ala Lys Ser Ala Ala Ala Gly Asn Gln Pro Gly Gly Asn Pro Ser Pro 835 840 845 Gly Gly Ala Thr Thr Ser Lys Ser Cys Cys Ile Gln 850 855 860 <210> 21 <211> 854 <212> PRT <213> Homo sapiens <400> 21 Met Ser Leu Ser Glu Glu Gln Ala Arg Ser Phe Leu Asp Gln Asn Pro 1 5 10 15 Asp Phe Ala Arg Gln Tyr Phe Gly Lys Lys Leu Ser Pro Glu Asn Val 20 25 30 Ala Ala Ala Cys Glu Asp Gly Cys Pro Pro Asp Cys Asp Ser Leu Arg 35 40 45 Asp Leu Cys Gln Val Glu Glu Ser Thr Ala Leu Leu Glu Leu Val Gln 50 55 60 Asp Met Gln Glu Ser Ile Asn Met Glu Arg Val Val Phe Lys Val Leu 65 70 75 80 Arg Arg Leu Cys Thr Leu Leu Gln Ala Asp Arg Cys Ser Leu Phe Met 85 90 95 Tyr Arg Gln Arg Asn Gly Val Ala Glu Leu Ala Thr Arg Leu Phe Ser 100 105 110 Val Gln Pro Asp Ser Val Leu Glu Asp Cys Leu Val Pro Pro Asp Ser 115 120 125 Glu Ile Val Phe Pro Leu Asp Ile Gly Val Val Gly His Val Ala Gln 130 135 140 Thr Lys Lys Met Val Asn Val Glu Asp Val Ala Glu Cys Pro His Phe 145 150 155 160 Ser Ser Phe Ala Asp Glu Leu Thr Asp Tyr Lys Thr Lys Asn Met Leu 165 170 175 Ala Thr Pro Ile Met Asn Gly Lys Asp Val Val Ala Val Ile Met Ala 180 185 190 Val Asn Lys Leu Asn Gly Pro Phe Phe Thr Ser Glu Asp Glu Asp Val 195 200 205 Phe Leu Lys Tyr Leu Asn Phe Ala Thr Leu Tyr Leu Lys Ile Tyr His 210 215 220 Leu Ser Tyr Leu His Asn Cys Glu Thr Arg Arg Gly Gln Val Leu Leu 225 230 235 240 Trp Ser Ala Asn Lys Val Phe Glu Glu Leu Thr Asp Ile Glu Arg Gln 245 250 255 Phe His Lys Ala Phe Tyr Thr Val Arg Ala Tyr Leu Asn Cys Glu Arg 260 265 270 Tyr Ser Val Gly Leu Leu Asp Met Thr Lys Glu Lys Glu Phe Phe Asp 275 280 285 Val Trp Ser Val Leu Met Gly Glu Ser Gln Pro Tyr Ser Gly Pro Arg 290 295 300 Thr Pro Asp Gly Arg Glu Ile Val Phe Tyr Lys Val Ile Asp Tyr Ile 305 310 315 320 Leu His Gly Lys Glu Glu Ile Lys Val Ile Pro Thr Pro Ser Ala Asp 325 330 335 His Trp Ala Leu Ala Ser Gly Leu Pro Ser Tyr Val Ala Glu Ser Gly 340 345 350 Phe Ile Cys Asn Ile Met Asn Ala Ser Ala Asp Glu Met Phe Lys Phe 355 360 365 Gln Glu Gly Ala Leu Asp Asp Ser Gly Trp Leu Ile Lys Asn Val Leu 370 375 380 Ser Met Pro Ile Val Asn Lys Lys Glu Glu Ile Val Gly Val Ala Thr 385 390 395 400 Phe Tyr Asn Arg Lys Asp Gly Lys Pro Phe Asp Glu Gln Asp Glu Val 405 410 415 Leu Met Glu Ser Leu Thr Gln Phe Leu Gly Trp Ser Val Met Asn Thr 420 425 430 Asp Thr Tyr Asp Lys Met Asn Lys Leu Glu Asn Arg Lys Asp Ile Ala 435 440 445 Gln Asp Met Val Leu Tyr His Val Lys Cys Asp Arg Asp Glu Ile Gln 450 455 460 Leu Ile Leu Pro Thr Arg Ala Arg Leu Gly Lys Glu Pro Ala Asp Cys 465 470 475 480 Asp Glu Asp Glu Leu Gly Glu Ile Leu Lys Glu Glu Leu Pro Gly Pro 485 490 495 Thr Thr Phe Asp Ile Tyr Glu Phe His Phe Ser Asp Leu Glu Cys Thr 500 505 510 Glu Leu Asp Leu Val Lys Cys Gly Ile Gln Met Tyr Tyr Glu Leu Gly 515 520 525 Val Val Arg Lys Phe Gln Ile Pro Gln Glu Val Leu Val Arg Phe Leu 530 535 540 Phe Ser Ile Ser Lys Gly Tyr Arg Arg Ile Thr Tyr His Asn Trp Arg 545 550 555 560 His Gly Phe Asn Val Ala Gln Thr Met Phe Thr Leu Leu Met Thr Gly 565 570 575 Lys Leu Lys Ser Tyr Tyr Thr Asp Leu Glu Ala Phe Ala Met Val Thr 580 585 590 Ala Gly Leu Cys His Asp Ile Asp His Arg Gly Thr Asn Asn Leu Tyr 595 600 605 Gln Met Lys Ser Gln Asn Pro Leu Ala Lys Leu His Gly Ser Ser Ile 610 615 620 Leu Glu Arg His His Leu Glu Phe Gly Lys Phe Leu Leu Ser Glu Glu 625 630 635 640 Thr Leu Asn Ile Tyr Gln Asn Leu Asn Arg Arg Gln His Glu His Val 645 650 655 Ile His Leu Met Asp Ile Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr 660 665 670 Phe Lys Lys Arg Ala Met Phe Gln Lys Ile Val Asp Glu Ser Lys Asn 675 680 685 Tyr Gln Asp Lys Lys Ser Trp Val Glu Tyr Leu Ser Leu Glu Thr Thr 690 695 700 Arg Lys Glu Ile Val Met Ala Met Met Met Thr Ala Cys Asp Leu Ser 705 710 715 720 Ala Ile Thr Lys Pro Trp Glu Val Gln Ser Lys Val Ala Leu Leu Val 725 730 735 Ala Ala Glu Phe Trp Glu Gln Gly Asp Leu Glu Arg Thr Val Leu Asp 740 745 750 Gln Gln Pro Ile Pro Met Met Asp Arg Asn Lys Ala Ala Glu Leu Pro 755 760 765 Lys Leu Gln Val Gly Phe Ile Asp Phe Val Cys Thr Phe Val Tyr Lys 770 775 780 Glu Phe Ser Arg Phe His Glu Glu Ile Leu Pro Met Phe Asp Arg Leu 785 790 795 800 Gln Asn Asn Arg Lys Glu Trp Lys Ala Leu Ala Asp Glu Tyr Glu Ala 805 810 815 Lys Val Lys Ala Leu Glu Glu Lys Glu Glu Glu Glu Arg Val Ala Ala 820 825 830 Lys Lys Val Gly Thr Glu Ile Cys Asn Gly Gly Pro Ala Pro Lys Ser 835 840 845 Ser Thr Cys Cys Ile Leu 850 <210> 22 <211> 853 <212> PRT <213> Homo sapiens <400> 22 Met Ser Leu Ser Glu Glu Gln Ala Arg Ser Phe Leu Asp Gln Asn Pro 1 5 10 15 Asp Phe Ala Arg Gln Tyr Phe Gly Lys Lys Leu Ser Pro Glu Asn Val 20 25 30 Ala Ala Ala Cys Glu Asp Gly Cys Pro Pro Asp Cys Asp Ser Leu Arg 35 40 45 Asp Leu Cys Gln Val Glu Glu Ser Thr Ala Leu Leu Glu Leu Val Gln 50 55 60 Asp Met Gln Glu Ser Ile Asn Met Glu Arg Val Val Phe Lys Val Leu 65 70 75 80 Arg Arg Leu Cys Thr Leu Leu Gln Ala Asp Arg Cys Ser Leu Phe Met 85 90 95 Tyr Arg Gln Arg Asn Gly Val Ala Glu Leu Ala Thr Arg Leu Phe Ser 100 105 110 Val Gln Pro Asp Ser Val Leu Glu Asp Cys Leu Val Pro Pro Asp Ser 115 120 125 Glu Ile Val Phe Pro Leu Asp Ile Gly Val Val Gly His Val Ala Gln 130 135 140 Thr Lys Lys Met Val Asn Val Glu Asp Val Ala Glu Cys Pro His Phe 145 150 155 160 Ser Ser Phe Ala Asp Glu Leu Thr Asp Tyr Lys Thr Lys Asn Met Leu 165 170 175 Ala Thr Pro Ile Met Asn Gly Lys Asp Val Val Ala Val Ile Met Ala 180 185 190 Val Asn Lys Leu Asn Gly Pro Phe Phe Thr Ser Glu Asp Glu Asp Val 195 200 205 Phe Leu Lys Tyr Leu Asn Phe Ala Thr Leu Tyr Leu Lys Ile Tyr His 210 215 220 Leu Ser Tyr Leu His Asn Cys Glu Thr Arg Arg Gly Gln Val Leu Leu 225 230 235 240 Trp Ser Ala Asn Lys Val Phe Glu Glu Leu Thr Asp Ile Glu Arg Gln 245 250 255 Phe His Lys Ala Phe Tyr Thr Val Arg Ala Tyr Leu Asn Cys Glu Arg 260 265 270 Tyr Ser Val Gly Leu Leu Asp Met Thr Lys Glu Lys Glu Phe Phe Asp 275 280 285 Val Trp Ser Val Leu Met Gly Glu Ser Gln Pro Tyr Ser Gly Pro Arg 290 295 300 Thr Pro Asp Gly Arg Glu Ile Val Phe Tyr Lys Val Ile Asp Tyr Ile 305 310 315 320 Leu His Gly Lys Glu Glu Ile Lys Val Ile Pro Thr Pro Ser Ala Asp 325 330 335 His Trp Ala Leu Ala Ser Gly Leu Pro Ser Tyr Val Ala Glu Ser Gly 340 345 350 Phe Ile Cys Asn Ile Met Asn Ala Ser Ala Asp Glu Met Phe Lys Phe 355 360 365 Gln Glu Gly Ala Leu Asp Asp Ser Gly Trp Leu Ile Lys Asn Val Leu 370 375 380 Ser Met Pro Ile Val Asn Lys Lys Glu Glu Ile Val Gly Val Ala Thr 385 390 395 400 Phe Tyr Asn Arg Lys Asp Gly Lys Pro Phe Asp Glu Gln Asp Glu Val 405 410 415 Leu Met Glu Ser Leu Thr Gln Phe Leu Gly Trp Ser Val Met Asn Thr 420 425 430 Asp Thr Tyr Asp Lys Met Asn Lys Leu Glu Asn Arg Lys Asp Ile Ala 435 440 445 Gln Asp Met Val Leu Tyr His Val Lys Cys Asp Arg Asp Glu Ile Gln 450 455 460 Leu Ile Leu Pro Thr Arg Ala Arg Leu Gly Lys Glu Pro Ala Asp Cys 465 470 475 480 Asp Glu Asp Glu Leu Gly Glu Ile Leu Lys Glu Glu Leu Pro Gly Pro 485 490 495 Thr Thr Phe Asp Ile Tyr Glu Phe His Phe Ser Asp Leu Glu Cys Thr 500 505 510 Glu Leu Asp Leu Val Lys Cys Gly Ile Gln Met Tyr Tyr Glu Leu Gly 515 520 525 Val Val Arg Lys Phe Gln Ile Pro Gln Glu Val Leu Val Arg Phe Leu 530 535 540 Phe Ser Ile Ser Lys Gly Tyr Arg Arg Ile Thr Tyr His Asn Trp Arg 545 550 555 560 His Gly Phe Asn Val Ala Gln Thr Met Phe Thr Leu Leu Met Thr Gly 565 570 575 Lys Leu Lys Ser Tyr Tyr Thr Asp Leu Glu Ala Phe Ala Met Val Thr 580 585 590 Ala Gly Leu Cys His Asp Ile Asp His Arg Gly Thr Asn Asn Leu Tyr 595 600 605 Gln Met Lys Ser Gln Asn Pro Leu Ala Lys Leu His Gly Ser Ser Ile 610 615 620 Leu Glu Arg His His Leu Glu Phe Gly Lys Phe Leu Leu Ser Glu Glu 625 630 635 640 Thr Leu Asn Ile Tyr Gln Asn Leu Asn Arg Arg Gln His Glu His Val 645 650 655 Ile His Leu Met Asp Ile Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr 660 665 670 Phe Lys Lys Arg Ala Met Phe Gln Lys Ile Val Asp Glu Ser Lys Asn 675 680 685 Tyr Gln Asp Lys Lys Ser Trp Val Glu Tyr Leu Ser Leu Glu Thr Thr 690 695 700 Arg Lys Glu Ile Val Met Ala Met Met Met Thr Ala Cys Asp Leu Ser 705 710 715 720 Ala Ile Thr Lys Pro Trp Glu Val Gln Ser Lys Val Ala Leu Leu Val 725 730 735 Ala Ala Glu Phe Trp Glu Gln Gly Asp Leu Glu Arg Thr Val Leu Asp 740 745 750 Gln Gln Pro Ile Pro Met Met Asp Arg Asn Lys Ala Ala Glu Leu Pro 755 760 765 Lys Leu Gln Val Gly Phe Ile Asp Phe Val Cys Thr Phe Val Tyr Lys 770 775 780 Glu Phe Ser Arg Phe His Glu Glu Ile Leu Pro Met Phe Asp Arg Leu 785 790 795 800 Gln Asn Asn Arg Lys Glu Trp Lys Ala Leu Ala Asp Glu Tyr Glu Ala 805 810 815 Lys Val Lys Ala Leu Glu Glu Lys Glu Glu Glu Glu Arg Val Ala Ala 820 825 830 Lys Lys Gly Thr Glu Ile Cys Asn Gly Gly Pro Ala Pro Lys Ser Ser 835 840 845 Thr Cys Cys Ile Leu 850 <210> 23 <211> 575 <212> PRT <213> Homo sapiens <400> 23 Met Thr Lys Glu Lys Glu Phe Phe Asp Val Trp Ser Val Leu Met Gly 1 5 10 15 Glu Ser Gln Pro Tyr Ser Gly Pro Arg Thr Pro Asp Gly Arg Glu Ile 20 25 30 Val Phe Tyr Lys Val Ile Asp Tyr Ile Leu His Gly Lys Glu Glu Ile 35 40 45 Lys Val Ile Pro Thr Pro Ser Ala Asp His Trp Ala Leu Ala Ser Gly 50 55 60 Leu Pro Ser Tyr Val Ala Glu Ser Gly Phe Ile Cys Asn Ile Met Asn 65 70 75 80 Ala Ser Ala Asp Glu Met Phe Lys Phe Gln Glu Gly Ala Leu Asp Asp 85 90 95 Ser Gly Trp Leu Ile Lys Asn Val Leu Ser Met Pro Ile Val Asn Lys 100 105 110 Lys Glu Glu Ile Val Gly Val Ala Thr Phe Tyr Asn Arg Lys Asp Gly 115 120 125 Lys Pro Phe Asp Glu Gln Asp Glu Val Leu Met Glu Ser Leu Thr Gln 130 135 140 Phe Leu Gly Trp Ser Val Met Asn Thr Asp Thr Tyr Asp Lys Met Asn 145 150 155 160 Lys Leu Glu Asn Arg Lys Asp Ile Ala Gln Asp Met Val Leu Tyr His 165 170 175 Val Lys Cys Asp Arg Asp Glu Ile Gln Leu Ile Leu Pro Thr Arg Ala 180 185 190 Arg Leu Gly Lys Glu Pro Ala Asp Cys Asp Glu Asp Glu Leu Gly Glu 195 200 205 Ile Leu Lys Glu Glu Leu Pro Gly Pro Thr Thr Phe Asp Ile Tyr Glu 210 215 220 Phe His Phe Ser Asp Leu Glu Cys Thr Glu Leu Asp Leu Val Lys Cys 225 230 235 240 Gly Ile Gln Met Tyr Tyr Glu Leu Gly Val Val Arg Lys Phe Gln Ile 245 250 255 Pro Gln Glu Val Leu Val Arg Phe Leu Phe Ser Ile Ser Lys Gly Tyr 260 265 270 Arg Arg Ile Thr Tyr His Asn Trp Arg His Gly Phe Asn Val Ala Gln 275 280 285 Thr Met Phe Thr Leu Leu Met Thr Gly Lys Leu Lys Ser Tyr Tyr Thr 290 295 300 Asp Leu Glu Ala Phe Ala Met Val Thr Ala Gly Leu Cys His Asp Ile 305 310 315 320 Asp His Arg Gly Thr Asn Asn Leu Tyr Gln Met Lys Ser Gln Asn Pro 325 330 335 Leu Ala Lys Leu His Gly Ser Ser Ile Leu Glu Arg His His Leu Glu 340 345 350 Phe Gly Lys Phe Leu Leu Ser Glu Glu Thr Leu Asn Ile Tyr Gln Asn 355 360 365 Leu Asn Arg Arg Gln His Glu His Val Ile His Leu Met Asp Ile Ala 370 375 380 Ile Ile Ala Thr Asp Leu Ala Leu Tyr Phe Lys Lys Arg Ala Met Phe 385 390 395 400 Gln Lys Ile Val Asp Glu Ser Lys Asn Tyr Gln Asp Lys Lys Ser Trp 405 410 415 Val Glu Tyr Leu Ser Leu Glu Thr Thr Arg Lys Glu Ile Val Met Ala 420 425 430 Met Met Met Thr Ala Cys Asp Leu Ser Ala Ile Thr Lys Pro Trp Glu 435 440 445 Val Gln Ser Lys Val Ala Leu Leu Val Ala Ala Glu Phe Trp Glu Gln 450 455 460 Gly Asp Leu Glu Arg Thr Val Leu Asp Gln Gln Pro Ile Pro Met Met 465 470 475 480 Asp Arg Asn Lys Ala Ala Glu Leu Pro Lys Leu Gln Val Gly Phe Ile 485 490 495 Asp Phe Val Cys Thr Phe Val Tyr Lys Glu Phe Ser Arg Phe His Glu 500 505 510 Glu Ile Leu Pro Met Phe Asp Arg Leu Gln Asn Asn Arg Lys Glu Trp 515 520 525 Lys Ala Leu Ala Asp Glu Tyr Glu Ala Lys Val Lys Ala Leu Glu Glu 530 535 540 Lys Glu Glu Glu Glu Arg Val Ala Ala Lys Lys Val Gly Thr Glu Ile 545 550 555 560 Cys Asn Gly Gly Pro Ala Pro Lys Ser Ser Thr Cys Cys Ile Leu 565 570 575 <210> 24 <211> 694 <212> PRT <213> Homo sapiens <400> 24 Met Ala Lys Ile Asn Thr Gln Tyr Ser His Pro Ser Arg Thr His Leu 1 5 1] 5 Lys Val Lys Thr Ser Asp Arg Asp Leu Asn Arg Ala Glu Asn Gly Leu 20 25 30 Ser Arg Ala His Ser Ser Ser Glu Glu Thr Ser Ser Val Leu Gln Pro 35 40 45 Gly Ile Ala Met Glu Thr Arg Gly Leu Ala Asp Ser Gly Gln Gly Ser 50 55 60 Phe Thr Gly Gln Gly Ile Ala Arg Leu Ser Arg Leu Ile Phe Leu Leu 65 70 75 80 Arg Arg Trp Ala Ala Arg His Val His His Gln Asp Gln Gly Pro Asp Note: There seems to be a formatting issue in the original text where "1 5 10 15" is written as "1 5 1] 5" in the translation. It should be corrected as "1 5 10 15" in the translation for accuracy.85 90 95 Ser Phe Pro Asp Arg Phe Arg Gly Ala Glu Leu Lys Glu Val Ser Ser 100 105 110 Gln Glu Ser Asn Ala Gln Ala Asn Val Gly Ser Gln Glu Pro Ala Asp 115 120 125 Arg Gly Arg Ser Ala Trp Pro Leu Ala Lys Cys Asn Thr Asn Thr Ser 130 135 140 Asn Asn Thr Glu Glu Glu Lys Lys Thr Lys Lys Lys Asp Ala Ile Val 145 150 155 160 Val Asp Pro Ser Ser Asn Leu Tyr Tyr Arg Trp Leu Thr Ala Ile Ala 165 170 175 Leu Pro Val Phe Tyr Asn Trp Tyr Leu Leu Ile Cys Arg Ala Cys Phe 180 185 190 Asp Glu Leu Gln Ser Glu Tyr Leu Met Leu Trp Leu Val Leu Asp Tyr 195 200 205 Ser Ala Asp Val Leu Tyr Val Leu Asp Val Leu Val Arg Ala Arg Thr 210 215 220 Gly Phe Leu Glu Gln Gly Leu Met Val Ser Asp Thr Asn Arg Leu Trp 225 230 235 240 Gln His Tyr Lys Thr Thr Thr Gln Phe Lys Leu Asp Val Leu Ser Leu 245 250 255 Val Pro Thr Asp Leu Ala Tyr Leu Lys Val Gly Thr Asn Tyr Pro Glu 260 265 270 Val Arg Phe Asn Arg Leu Leu Lys Phe Ser Arg Leu Phe Glu Phe Phe 275 280 285 Asp Arg Thr Glu Thr Arg Thr Asn Tyr Pro Asn Met Phe Arg Ile Gly 290 295 300 Asn Leu Val Leu Tyr Ile Leu Ile Ile Ile His Trp Asn Ala Cys Ile 305 310 315 320 Tyr Phe Ala Ile Ser Lys Phe Ile Gly Phe Gly Thr Asp Ser Trp Val 325 330 335 Tyr Pro Asn Ile Ser Ile Pro Glu His Gly Arg Leu Ser Arg Lys Tyr 340 345 350 Ile Tyr Ser Leu Tyr Trp Ser Thr Leu Thr Leu Thr Thr Ile Gly Glu 355 360 365 Thr Pro Pro Pro Val Lys Asp Glu Glu Tyr Leu Phe Val Val Val Asp 370 375 380 Phe Leu Val Gly Val Leu Ile Phe Ala Thr Ile Val Gly Asn Val Gly 385 390 395 400 Ser Met Ile Ser Asn Met Asn Ala Ser Arg Ala Glu Phe Gln Ala Lys 405 410 415 Ile Asp Ser Ile Lys Gln Tyr Met Gln Phe Arg Lys Val Thr Lys Asp 420 425 430 Leu Glu Thr Arg Val Ile Arg Trp Phe Asp Tyr Leu Trp Ala Asn Lys 435 440 445 Lys Thr Val Asp Glu Lys Glu Val Leu Lys Ser Leu Pro Asp Lys Leu 450 455 460 Lys Ala Glu Ile Ala Ile Asn Val His Leu Asp Thr Leu Lys Lys Val 465 470 475 480 Arg Ile Phe Gln Asp Cys Glu Ala Gly Leu Leu Val Glu Leu Val Leu 485 490 495 Lys Leu Arg Pro Thr Val Phe Ser Pro Gly Asp Tyr Ile Cys Lys Lys 500 505 510 Gly Asp Ile Gly Lys Glu Met Tyr Ile Ile Asn Glu Gly Lys Leu Ala 515 520 525 Val Val Ala Asp Asp Gly Val Thr Gln Phe Val Val Leu Ser Asp Gly 530 535 540 Ser Tyr Phe Gly Glu Ile Ser Ile Leu Asn Ile Lys Gly Ser Lys Ser 545 550 555 560 Gly Asn Arg Arg Thr Ala Asn Ile Arg Ser Ile Gly Tyr Ser Asp Leu 565 570 575 Phe Cys Leu Ser Lys Asp Asp Leu Met Glu Ala Leu Thr Glu Tyr Pro 580 585 590 Glu Ala Lys Lys Ala Leu Glu Glu Lys Gly Arg Gln Ile Leu Met Lys 595 600 605 Asp Asn Leu Ile Asp Glu Glu Leu Ala Arg Ala Gly Ala Asp Pro Lys 610 615 620 Asp Leu Glu Glu Lys Val Glu Gln Leu Gly Ser Ser Leu Asp Thr Leu 625 630 635 640 Gln Thr Arg Phe Ala Arg Leu Leu Ala Glu Tyr Asn Ala Thr Gln Met 645 650 655 Lys Met Lys Gln Arg Leu Ser Gln Leu Glu Ser Gln Val Lys Gly Gly 660 665 670 Gly Asp Lys Pro Leu Ala Asp Gly Glu Val Pro Gly Asp Ala Thr Lys 675 680 685 [[ID=3,3]]Thr Glu Asp Lys Gln Gln 690 <210> 25 <211> 676 <212> PRT <213> Homo sapiens <400> 25 Met Ala Lys Ile Asn Thr Gln Tyr Ser His Pro Ser Arg Thr His Leu 1 5 10 15 Lys Val Lys Thr Ser Asp Arg Asp Leu Asn Arg Ala Glu Asn Gly Leu 20 25 30 Ser Arg Ala His Ser Ser Ser Glu Glu Thr Ser Ser Val Leu Gln Pro 35 40 45 Gly Ile Ala Met Glu Thr Arg Gly Leu Ala Asp Ser Gly Gln Gly Ser 50 55 60 Phe Thr Gly Gln Gly Ile Ala Arg Leu Ser Arg Leu Ile Phe Leu Leu 65 70 75 80 Arg Arg Trp Ala Ala Arg His Val His His Gln Asp Gln Gly Pro Asp 85 90 95 Ser Phe Pro Asp Arg Phe Arg Gly Ala Glu Leu Lys Glu Val Ser Ser 100 105 110 Gln Glu Ser Asn Ala Gln Ala Asn Val Gly Ser Gln Glu Pro Ala Asp 115 120 125 Arg Gly Arg Arg Lys Lys Thr Lys Lys Lys Asp Ala Ile Val Val Asp 130 135 140 Pro Ser Ser Asn Leu Tyr Tyr Arg Trp Leu Thr Ala Ile Ala Leu Pro 145 150 155 160 Val Phe Tyr Asn Trp Tyr Leu Leu Ile Cys Arg Ala Cys Phe Asp Glu 165 170 175 Leu Gln Ser Glu Tyr Leu Met Leu Trp Leu Val Leu Asp Tyr Ser Ala 180 185 190 Asp Val Leu Tyr Val Leu Asp Val Leu Val Arg Ala Arg Thr Gly Phe 195 200 205 Leu Glu Gln Gly Leu Met Val Ser Asp Thr Asn Arg Leu Trp Gln His 210 215 220 Tyr Lys Thr Thr Thr Gln Phe Lys Leu Asp Val Leu Ser Leu Val Pro 225 230 235 240 Thr Asp Leu Ala Tyr Leu Lys Val Gly Thr Asn Tyr Pro Glu Val Arg 245 250 255 Phe Asn Arg Leu Leu Lys Phe Ser Arg Leu Phe Glu Phe Phe Asp Arg 260 265 270 Thr Glu Thr Arg Thr Asn Tyr Pro Asn Met Phe Arg Ile Gly Asn Leu 275 280 285 Val Leu Tyr Ile Leu Ile Ile Ile His Trp Asn Ala Cys Ile Tyr Phe 290 295 300 Ala Ile Ser Lys Phe Ile Gly Phe Gly Thr Asp Ser Trp Val Tyr Pro 305 310 315 320 Asn Ile Ser Ile Pro Glu His Gly Arg Leu Ser Arg Lys Tyr Ile Tyr 325 330 335 Ser Leu Tyr Trp Ser Thr Leu Thr Leu Thr Thr Ile Gly Glu Thr Pro 340 345 350 Pro Pro Val Lys Asp Glu Glu Tyr Leu Phe Val Val Val Asp Phe Leu 355 360 365 Val Gly Val Leu Ile Phe Ala Thr Ile Val Gly Asn Val Gly Ser Met 370 375 380 Ile Ser Asn Met Asn Ala Ser Arg Ala Glu Phe Gln Ala Lys Ile Asp 385 390 395 400 Ser Ile Lys Gln Tyr Met Gln Phe Arg Lys Val Thr Lys Asp Leu Glu 405 410 415 Thr Arg Val Ile Arg Trp Phe Asp Tyr Leu Trp Ala Asn Lys Lys Thr 420 425 430 Val Asp Glu Lys Glu Val Leu Lys Ser Leu Pro Asp Lys Leu Lys Ala 435 440 445 Glu Ile Ala Ile Asn Val His Leu Asp Thr Leu Lys Lys Val Arg Ile 450 455 460 Phe Gln Asp Cys Glu Ala Gly Leu Leu Val Glu Leu Val Leu Lys Leu 465 470 475 480 Arg Pro Thr Val Phe Ser Pro Gly Asp Tyr Ile Cys Lys Lys Gly Asp 485 490 495 Ile Gly Lys Glu Met Tyr Ile Ile Asn Glu Gly Lys Leu Ala Val Val 500 505 510 Ala Asp Asp Gly Val Thr Gln Phe Val Val Leu Ser Asp Gly Ser Tyr 515 520 525 Phe Gly Glu Ile Ser Ile Leu Asn Ile Lys Gly Ser Lys Ser Gly Asn 530 535 540 Arg Arg Thr Ala Asn Ile Arg Ser Ile Gly Tyr Ser Asp Leu Phe Cys 545 550 555 560 Leu Ser Lys Asp Asp Leu Met Glu Ala Leu Thr Glu Tyr Pro Glu Ala 565 570 575 Lys Lys Ala Leu Glu Glu Lys Gly Arg Gln Ile Leu Met Lys Asp Asn 580 585 590 Leu Ile Asp Glu Glu Leu Ala Arg Ala Gly Ala Asp Pro Lys Asp Leu 595 600 605 Glu Glu Lys Val Glu Gln Leu Gly Ser Ser Leu Asp Thr Leu Gln Thr 610 615 620 Arg Phe Ala Arg Leu Leu Ala Glu Tyr Asn Ala Thr Gln Met Lys Met 625 630 635 640 Lys Gln Arg Leu Ser Gln Leu Glu Ser Gln Val Lys Gly Gly Gly Asp 645 650 655 Lys Pro Leu Ala Asp Gly Glu Val Pro Gly Asp Ala Thr Lys Thr Glu 660 665 670 Asp Lys Gln Gln 675 <210> 26 <211> 809 <212> PRT <213> Homo sapiens <400> 26 Met Phe Lys Ser Leu Thr Lys Val Asn Lys Val Lys Pro Ile Gly Glu 1 5 10 15 Asn Asn Glu Asn Glu Gln Ser Ser Arg Arg Asn Glu Glu Gly Ser His 20 25 30 Pro Ser Asn Gln Ser Gln Gln Thr Thr Ala Gln Glu Glu Asn Lys Gly 35 40 45 Glu Glu Lys Ser Leu Lys Thr Lys Ser Thr Pro Val Thr Ser Glu Glu 50 55 60 Pro His Thr Asn Ile Gln Asp Lys Leu Ser Lys Lys Asn Ser Ser Gly 65 70 75 80 Asp Leu Thr Thr Asn Pro Asp Pro Gln Asn Ala Ala Glu Pro Thr Gly 85 90 95 Thr Val Pro Glu Gln Lys Glu Met Asp Pro Gly Lys Glu Gly Pro Asn 100 105 110 Ser Pro Gln Asn Lys Pro Pro Ala Ala Pro Val Ile Asn Glu Tyr Ala 115 120 125 Asp Ala Gln Leu His Asn Leu Val Lys Arg Met Arg Gln Arg Thr Ala 130 135 140 Leu Tyr Lys Lys Lys Leu Val Glu Gly Asp Leu Ser Ser Pro Glu Ala 145 150 155 160 Ser Pro Gln Thr Ala Lys Pro Thr Ala Val Pro Pro Val Lys Glu Ser 165 170 175 Asp Asp Lys Pro Thr Glu His Tyr Tyr Arg Leu Leu Trp Phe Lys Val 180 185 190 Lys Lys Met Pro Leu Thr Glu Tyr Leu Lys Arg Ile Lys Leu Pro Asn 195 200 205 Ser Ile Asp Ser Tyr Thr Asp Arg Leu Tyr Leu Leu Trp Leu Leu Leu 210 215 220 Val Thr Leu Ala Tyr Asn Trp Asn Cys Cys Phe Ile Pro Leu Arg Leu 225 230 235 240 Val Phe Pro Tyr Gln Thr Ala Asp Asn Ile His Tyr Trp Leu Ile Ala 245 250 255 Asp Ile Ile Cys Asp Ile Ile Tyr Leu Tyr Asp Met Leu Phe Ile Gln 260 265 270 Pro Arg Leu Gln Phe Val Arg Gly Gly Asp Ile Ile Val Asp Ser Asn 275 280 285 Glu Leu Arg Lys His Tyr Arg Thr Ser Thr Lys Phe Gln Leu Asp Val 290 295 300 Ala Ser Ile Ile Pro Phe Asp Ile Cys Tyr Leu Phe Phe Gly Phe Asn 305 310 315 320 Pro Met Phe Arg Ala Asn Arg Met Leu Lys Tyr Thr Ser Phe Phe Glu 325 330 335 Phe Asn His His Leu Glu Ser Ile Met Asp Lys Ala Tyr Ile Tyr Arg 340 345 350 Val Ile Arg Thr Thr Gly Tyr Leu Leu Phe Ile Leu His Ile Asn Ala 355 360 365 Cys Val Tyr Tyr Trp Ala Ser Asn Tyr Glu Gly Ile Gly Thr Thr Arg 370 375 380 Trp Val Tyr Asp Gly Glu Gly Asn Glu Tyr Leu Arg Cys Tyr Tyr Trp 385 390 395 400 Ala Val Arg Thr Leu Ile Thr Ile Gly Gly Leu Pro Glu Pro Gln Thr 405 410 415 Leu Phe Glu Ile Val Phe Gln Leu Leu Asn Phe Phe Ser Gly Val Phe 420 425 430 Val Phe Ser Ser Leu Ile Gly Gln Met Arg Asp Val Ile Gly Ala Ala 435 440 445 Thr Ala Asn Gln Asn Tyr Phe Arg Ala Cys Met Asp Asp Thr Ile Ala 450 455 460 Tyr Met Asn Asn Tyr Ser Ile Pro Lys Leu Val Gln Lys Arg Val Arg 465 470 475 480 Thr Trp Tyr Glu Tyr Thr Trp Asp Ser Gln Arg Met Leu Asp Glu Ser 485 490 495 Asp Leu Leu Lys Thr Leu Pro Thr Thr Val Gln Leu Ala Leu Ala Ile 500 505 510 Asp Val Asn Phe Ser Ile Ile Ser Lys Val Asp Leu Phe Lys Gly Cys 515 520 525 Asp Thr Gln Met Ile Tyr Asp Met Leu Leu Arg Leu Lys Ser Val Leu 530 535 540 Tyr Leu Pro Gly Asp Phe Val Cys Lys Lys Gly Glu Ile Gly Lys Glu 545 550 555 560 Met Tyr Ile Ile Lys His Gly Glu Val Gln Val Leu Gly Gly Pro Asp 565 570 575 Gly Thr Lys Val Leu Val Thr Leu Lys Ala Gly Ser Val Phe Gly Glu 580 585 590 Ile Ser Leu Leu Ala Ala Gly Gly Gly Asn Arg Arg Thr Ala Asn Val 595 600 605 Val Ala His Gly Phe Ala Asn Leu Leu Thr Leu Asp Lys Lys Thr Leu 610 615 620 Gln Glu Ile Leu Val His Tyr Pro Asp Ser Glu Arg Ile Leu Met Lys 625 630 635 640 Lys Ala Arg Val Leu Leu Lys Gln Lys Ala Lys Thr Ala Glu Ala Thr 645 650 655 Pro Pro Arg Lys Asp Leu Ala Leu Leu Phe Pro Pro Lys Glu Glu Thr 660 665 670 Pro Lys Leu Phe Lys Thr Leu Leu Gly Gly Thr Gly Lys Ala Ser Leu 675 680 685 Ala Arg Leu Leu Lys Leu Lys Arg Glu Gln Ala Ala Gln Lys Lys Glu 690 695 700 Asn Ser Glu Gly Gly Glu Glu Glu Gly Lys Glu Asn Glu Asp Lys Gln 705 710 715 720 Lys Glu Asn Glu Asp Lys Gln Lys Glu Asn Glu Asp Lys Gly Lys Glu 725 730 735 Asn Glu Asp Lys Asp Lys Gly Arg Glu Pro Glu Glu Lys Pro Leu Asp 740 745 750 Arg Pro Glu Cys Thr Ala Ser Pro Ile Ala Val Glu Glu Glu Pro His 755 760 765 Ser Val Arg Arg Thr Val Leu Pro Arg Gly Thr Ser Arg Gln Ser Leu 770 775 780 Ile Ile Ser Met Ala Pro Ser Ala Glu Gly Gly Glu Glu Val Leu Thr 785 �90 795 800 Ile Glu Val Lys Glu Lys Ala Lys Gln [[ID=ע]]805 <210> 27 <211> 354 <212> PRT <213> Homo sapienss <400> 27 [[ID=3ש]]Met Gly Ser Gly Ala Ser Ala Glu Asp Lys Glu Leu Ala Lys Arg Ser 1 5 10 15s Lys Glu Leu Glu Lys Lys Leu Gln Glu Asp Ala Asp Lys Glu Ala Lys 20 25 30 [[ID=ע]] Thr Val Lys Leu Leu Leu Leu Gly Ala Gly Glu Ser Gly Lys Ser Thr 35 40 45 Ile Val Lys Gln Met Lys Ile Ile His Gln Asp Gly Tyr Ser Pro Glu 50 55 60 Glu Cys Leu Glu Phe Lys Ala Ile Ile Tyr Gly Asn Val Leu Gln Ser 65 70 75 80 Ile Leu Ala Ile Ile Arg Ala Met Thr Thr Leu Gly Ile Asp Tyr Ala 85 90 95 Glu Pro Ser Cys Ala Asp Asp Gly Arg Gln Leu Asn Asn Leu Ala Asp 100 105 110 Ser Ile Glu Glu Gly Thr Met Pro Pro Glu Leu Val Glu Val Ile Arg 115 120 125 Arg Leu Trp Lys Asp Gly Gly Val Gln Ala Cys Phe Glu Arg Ala Ala 130 135 140 Glu Tyr Gln Leu Asn Asp Ser Ala Ser Tyr Tyr Leu Asn Gln Leu Glu 145 150 155 160 Arg Ile Thr Asp Pro Glu Tyr Leu Pro Ser Glu Gln Asp Val Leu Arg 165 170 175 Ser Arg Val Lys Thr Thr Gly Ile Ile Glu Thr Lys Phe Ser Val Lys 180 185 190 Asp Leu Asn Phe Arg Met Phe Asp Val Gly Gly Gln Arg Ser Glu Arg 195 200 205 Lys Lys Trp Ile His Cys Phe Glu Gly Val Thr Cys Ile Ile Phe Cys 210 215 220 Ala Ala Leu Ser Ala Tyr Asp Met Val Leu Val Glu Asp Asp Glu Val 225 230 235 240 Asn Arg Met His Glu Ser Leu His Leu Phe Asn Ser Ile Cys Asn His 245 250 255 Lys Phe Phe Ala Ala Thr Ser Ile Val Leu Phe Leu Asn Lys Lys Asp 260 265 270 Leu Phe Glu Glu Lys Ile Lys Lys Val His Leu Ser Ile Cys Phe Pro 275 280 285 Glu Tyr Asp Gly Asn Asn Ser Tyr Asp Asp Ala Gly Asn Tyr Ile Lys 290 295 300 Ser Gln Phe Leu Asp Leu Asn Met Arg Lys Asp Val Lys Glu Ile Tyr 305 310 315 320 Ser His Met Thr Cys Ala Thr Asp Thr Gln Asn Val Lys Phe Val Phe 325 330 335 Asp Ala Val Thr Asp Ile Ile Ile Lys Glu Asn Leu Lys Asp Cys Gly 340 345 350 Leu Phe <210> 28 <211> 815 <212> PRT <213> Homo sapiens <400> 28 Met Arg Glu Pro Glu Glu Leu Met Pro Asp Ser Gly Ala Val Phe Thr 1 5 10 15 Phe Gly Lys Ser Lys Phe Ala Glu Asn Asn Pro Gly Lys Phe Trp Phe 20 25 30 Lys Asn Asp Val Pro Val His Leu Ser Cys Gly Asp Glu His Ser Ala 35 40 45 Val Val Thr Gly Asn Asn Lys Leu Tyr Met Phe Gly Ser Asn Asn Trp 50 55 60 Gly Gln Leu Gly Leu Gly Ser Lys Ser Ala Ile Ser Lys Pro Thr Cys 65 70 75 80 Val Lys Ala Leu Lys Pro Glu Lys Val Lys Leu Ala Ala Cys Gly Arg 85 90 95 Asn His Thr Leu Val Ser Thr Glu Gly Gly Asn Val Tyr Ala Thr Gly 100 105 110 Gly Asn Asn Glu Gly Gln Leu Gly Leu Gly Asp Thr Glu Glu Arg Asn 115 120 125 Thr Phe His Val Ile Ser Phe Phe Thr Ser Glu His Lys Ile Lys Gln 130 135 140 Leu Ser Ala Gly Ser Asn Thr Ser Ala Ala Leu Thr Glu Asp Gly Arg 145 150 155 160 Leu Phe Met Trp Gly Asp Asn Ser Glu Gly Gln Ile Gly Leu Lys Asn 165 170 175 Val Ser Asn Val Cys Val Pro Gln Gln Val Thr Ile Gly Lys Pro Val 180 185 190 Ser Trp Ile Ser Cys Gly Tyr Tyr His Ser Ala Phe Val Thr Thr Asp 195 200 205 Gly Glu Leu Tyr Val Phe Gly Glu Pro Glu Asn Gly Lys Leu Gly Leu 210 215 220 Pro Asn Gln Leu Leu Gly Asn His Arg Thr Pro Gln Leu Val Ser Glu 225 230 235 240 Ile Pro Glu Lys Val Ile Gln Val Ala Cys Gly Gly Glu His Thr Val 245 250 255 Val Leu Thr Glu Asn Ala Val Tyr Thr Phe Gly Leu Gly Gln Phe Gly 260 265 270 Gln Leu Gly Leu Gly Thr Phe Leu Phe Glu Thr Ser Glu Pro Lys Val 275 280 285 Ile Glu Asn Ile Arg Asp Gln Thr Ile Ser Tyr Ile Ser Cys Gly Glu 290 295 300 Asn His Thr Ala Leu Ile Thr Asp Ile Gly Leu Met Tyr Thr Phe Gly 305 310 315 320 Asp Gly Arg His Gly Lys Leu Gly Leu Gly Leu Glu Asn Phe Thr Asn 325 330 335 His Phe Ile Pro Thr Leu Cys Ser Asn Phe Leu Arg Phe Ile Val Lys 340 345 350 Leo Val Ala Cys Gly Gly Cys His Met Val Val Phe Ala Ala Pro His 355 360 365 Arg Gly Val Ala Lys Glu Ile Glu Phe Asp Glu Ile Asn Asp Thr Cys 370 375 380 Leu Ser Val Ala Thr Phe Leu Pro Tyr Ser Ser Leu Thr Ser Gly Asn 385 390 395 400 Val Leu Gln Arg Thr Leu Ser Ala Arg Met Arg Arg Arg Glu Arg Glu 405 410 415 Arg Ser Pro Asp Ser Phe Ser Met Arg Arg Thr Leu Pro Pro Ile Glu 420 425 430 Gly Thr Leu Gly Leu Ser Ala Cys Phe Leu Pro Asn Ser Val Phe Pro 435 440 445 Arg Cys Ser Glu Arg Asn Leu Gln Glu Ser Val Leu Ser Glu Gln Asp 450 455 460 Leu Met Gln Pro Glu Glu Pro Asp Tyr Leu Leu Asp Glu Met Thr Lys 465 470 475 480 Glu Ala Glu Ile Asp Asn Ser Ser Thr Val Glu Ser Leu Gly Glu Thr 485 490 495 Thr Asp Ile Leu Asn Met Thr His Ile Met Ser Leu Asn Ser Asn Glu 500 505 510 Lys Ser Leu Lys Leu Ser Pro Val Gln Lys Gln Lys Lys Gln Gln Thr 515 520 525 Ile Gly Glu Leu Thr Gln Asp Thr Ala Leu Thr Glu Asn Asp Asp Ser 530 535 540 Asp Glu Tyr Glu Glu Met Ser Glu Met Lys Glu Gly Lys Ala Cys Lys 545 550 555 560 Gln His Val Ser Gln Gly Ile Phe Met Thr Gln Pro Ala Thr Thr Ile 565 570 575 Glu Ala Phe Ser Asp Glu Glu Val Glu Ile Pro Glu Glu Lys Glu Gly 580 585 590 Ala Glu Asp Ser Lys Gly Asn Gly Ile Glu Glu Gln Glu Val Glu Ala 595 600 605 Asn Glu Glu Asn Val Lys Val His Gly Gly Arg Lys Glu Lys Thr Glu 610 615 620 Ile Leu Ser Asp Asp Leu Thr Asp Lys Ala Glu Asp His Glu Phe Ser 625 630 635 640 Lys Thr Glu Glu Leu Lys Leu Glu Asp Val Asp Glu Glu Ile Asn Ala 645 650 655 Glu Asn Val Glu Ser Lys Lys Lys Thr Val Gly Asp Asp Glu Ser Val 660 665 670 Pro Thr Gly Tyr His Ser Lys Thr Glu Gly Ala Glu Arg Thr Asn Asp 675 680 685 Asp Ser Ser Ala Glu Thr Ile Glu Lys Lys Glu Lys Ala Asn Leu Glu 690 695 700 Glu Arg Ala Ile Cys Glu Tyr Asn Glu Asn Pro Lys Gly Tyr Met Leu 705 710 715 720 Asp Asp Ala Asp Ser Ser Ser Leu Glu Ile Leu Glu Asn Ser Glu Thr 725 730 735 Thr Pro Ser Lys Asp Met Lys Lys Thr Lys Lys Ile Phe Leu Phe Lys 740 745 750 Arg Val Pro Ser Ile Asn Gln Lys Ile Val Lys Asn Asn Asn Glu Pro 755 760 765 Leu Pro Glu Ile Lys Ser Ile Gly Asp Gln Ile Ile Leu Lys Ser Asp 770 775 780 Asn Lys Asp Ala Asp Gln Asn His Met Ser Gln Asn His Gln Asn Ile 785 790 795 800 Pro Pro Thr Asn Thr Glu Arg Arg Ser Lys Ser Cys Thr Ile Leu 805 810 815 <210> 29 <211> 646 <212> PRT <213> Homo sapiens <400> 29 Met Arg Glu Pro Glu Glu Leu Met Pro Asp Ser Gly Ala Val Phe Thr 1 5 10 15 Phe Gly Lys Ser Lys Phe Ala Glu Asn Asn Pro Gly Lys Phe Trp Phe 20 25 30 Lys Asn Asp Val Pro Val His Leu Ser Cys Gly Asp Glu His Ser Ala 35 40 45 Val Val Thr Gly Asn Asn Lys Leu Tyr Met Phe Gly Ser Asn Asn Trp 50 55 60 Gly Gln Leu Gly Leu Gly Ser Lys Ser Ala Ile Ser Lys Pro Thr Cys 65 70 75 80 Val Lys Ala Leu Lys Pro Glu Lys Val Lys Leu Ala Ala Cys Gly Arg 85 90 95 Asn His Thr Leu Val Ser Thr Glu Gly Gly Asn Val Tyr Ala Thr Gly 100 105 110 Gly Asn Asn Glu Gly Gln Leu Gly Leu Gly Asp Thr Glu Glu Arg Asn 115 120 125 Thr Phe His Val Ile Ser Phe Phe Thr Ser Glu His Lys Ile Lys Gln 130 135 140 Leu Ser Ala Gly Ser Asn Thr Ser Ala Ala Leu Thr Glu Asp Gly Arg 145 150 155 160 Leu Phe Met Trp Gly Asp Asn Ser Glu Gly Gln Ile Gly Leu Lys Asn 165 170 175 Val Ser Asn Val Cys Val Pro Gln Gln Val Thr Ile Gly Lys Pro Val 180 185 190 Ser Trp Ile Ser Cys Gly Tyr Tyr His Ser Ala Phe Val Thr Thr Asp 195 200 205 Gly Glu Leu Tyr Val Phe Gly Glu Pro Glu Asn Gly Lys Leu Gly Leu 210 215 220 Pro Asn Gln Leu Leu Gly Asn His Arg Thr Pro Gln Leu Val Ser Glu 225 230 235 240 Ile Pro Glu Lys Val Ile Gln Val Ala Cys Gly Gly Glu His Thr Val 245 250 255 Val Leu Thr Glu Asn Ala Val Tyr Thr Phe Gly Leu Gly Gln Phe Gly 260 265 270 Gln Leu Gly Leu Gly Thr Phe Leu Phe Glu Thr Ser Glu Pro Lys Val 275 280 285 Ile Glu Asn Ile Arg Asp Gln Thr Ile Ser Tyr Ile Ser Cys Gly Glu 290 295 300 Asn His Thr Ala Leu Ile Thr Asp Ile Gly Leu Met Tyr Thr Phe Gly 305 310 315 320 Asp Gly Arg His Gly Lys Leu Gly Leu Gly Leu Glu Asn Phe Thr Asn 325 330 335 His Phe Ile Pro Thr Leu Cys Ser Asn Phe Leu Arg Phe Ile Val Lys 340 345 350 Leu Val Ala Cys Gly Gly Cys His Met Val Val Phe Ala Ala Pro His 355 360 365 Arg Gly Val Ala Lys Glu Ile Glu Phe Asp Glu Ile Asn Asp Thr Cys 370 375 380 Leu Ser Val Ala Thr Phe Leu Pro Tyr Ser Ser Leu Thr Ser Gly Asn 385 390 395 400 Val Leu Gln Arg Thr Leu Ser Ala Arg Met Arg Arg Arg Glu Arg Glu 405 410 415 Arg Ser Pro Asp Ser Phe Ser Met Arg Arg Thr Leu Pro Pro Ile Glu 420 425 430 Gly Thr Leu Gly Leu Ser Ala Cys Phe Leu Pro Asn Ser Val Phe Pro 435 440 445 Arg Cys Ser Glu Arg Asn Leu Gln Glu Ser Val Leu Ser Glu Gln Asp 450 455 460 Leu Met Gln Pro Glu Glu Pro Asp Tyr Leu Leu Asp Glu Met Thr Lys 465 470 475 480 Glu Ala Glu Ile Asp Asn Ser Ser Thr Val Glu Ser Leu Gly Glu Thr 485 490 495 Thr Asp Ile Leu Asn Met Thr His Ile Met Ser Leu Asn Ser Asn Glu 500 505 510 Lys Ser Leu Lys Leu Ser Pro Val Gln Lys Gln Lys Lys Gln Gln Thr 515 520 525 Ile Gly Glu Leu Thr Gln Asp Thr Ala Leu Thr Glu Asn Asp Asp Ser 530 535 540 Asp Glu Tyr Glu Glu Met Ser Glu Met Lys Glu Gly Lys Ala Cys Lys 545 550 555 560 Gln His Val Ser Gln Gly Ile Phe Met Thr Gln Pro Ala Thr Thr Ile 565 570 575 Glu Ala Phe Ser Asp Glu Glu Val Glu Ile Pro Glu Glu Lys Glu Gly 580 585 590 Ala Glu Asp Ser Lys Gly Asn Gly Ile Glu Glu Gln Glu Val Glu Ala 595 600 605 Asn Glu Glu Asn Val Lys Val His Gly Gly Arg Lys Glu Lys Thr Glu 610 615 620 Ile Leu Ser Asp Asp Leu Thr Asp Lys Ala Glu Tyr Ser Ala Ser His 625 630 635 640 Ser Gln Ile Val Ser Val 645 <210> 30 <211> 1152 <212> PRT <213> Homo sapiens <400> 30 Met Arg Glu Pro Glu Glu Leu Met Pro Asp Ser Gly Ala Val Phe Thr 1 5 10 15 Phe Gly Lys Ser Lys Phe Ala Glu Asn Asn Pro Gly Lys Phe Trp Phe 20 25 30 Lys Asn Asp Val Pro Val His Leu Ser Cys Gly Asp Glu His Ser Ala 35 40 45 Val Val Thr Gly Asn Asn Lys Leu Tyr Met Phe Gly Ser Asn Asn Trp 50 55 60 Gly Gln Leu Gly Leu Gly Ser Lys Ser Ala Ile Ser Lys Pro Thr Cys 65 70 75 80 Val Lys Ala Leu Lys Pro Glu Lys Val Lys Leu Ala Ala Cys Gly Arg 85 90 95 Asn His Thr Leu Val Ser Thr Glu Gly Gly Asn Val Tyr Ala Thr Gly 100 105 110 Gly Asn Asn Glu Gly Gln Leu Gly Leu Gly Asp Thr Glu Glu Arg Asn 115 120 125 Thr Phe His Val Ile Ser Phe Phe Thr Ser Glu His Lys Ile Lys Gln 130 135 140 Leu Ser Ala Gly Ser Asn Thr Ser Ala Ala Leu Thr Glu Asp Gly Arg 145 150 155 160 Leu Phe Met Trp Gly Asp Asn Ser Glu Gly Gln Ile Gly Leu Lys Asn 165 170 175 Val Ser Asn Val Cys Val Pro Gln Gln Val Thr Ile Gly Lys Pro Val 180 185 190 Ser Trp Ile Ser Cys Gly Tyr Tyr His Ser Ala Phe Val Thr Thr Asp 195 200 205 Gly Glu Leu Tyr Val Phe Gly Glu Pro Glu Asn Gly Lys Leu Gly Leu 210 215 220 Pro Asn Gln Leu Leu Gly Asn His Arg Thr Pro Gln Leu Val Ser Glu 225 230 235 240 Ile Pro Glu Lys Val Ile Gln Val Ala Cys Gly Gly Glu His Thr Val 245 250 255 Val Leu Thr Glu Asn Ala Val Tyr Thr Phe Gly Leu Gly Gln Phe Gly 260 265 270 Gln Leu Gly Leu Gly Thr Phe Leu Phe Glu Thr Ser Glu Pro Lys Val 275 280 285 Ile Glu Asn Ile Arg Asp Gln Thr Ile Ser Tyr Ile Ser Cys Gly Glu 290 295 300 Asn His Thr Ala Leu Ile Thr Asp Ile Gly Leu Met Tyr Thr Phe Gly 305 310 315 320 Asp Gly Arg His Gly Lys Leu Gly Leu Gly Leu Glu Asn Phe Thr Asn 325 330 335 His Phe Ile Pro Thr Leu Cys Ser Asn Phe Leu Arg Phe Ile Val Lys 340 345 350 Leu Val Ala Cys Gly Gly Cys His Met Val Val Phe Ala Ala Pro His 355 360 365 Arg Gly Val Ala Lys Glu Ile Glu Phe Asp Glu Ile Asn Asp Thr Cys 370 375 380 Leu Ser Val Ala Thr Phe Leu Pro Tyr Ser Ser Leu Thr Ser Gly Asn 385 390 395 400 Val Leu Gln Arg Thr Leu Ser Ala Arg Met Arg Arg Arg Glu Arg Glu 405 410 415 Arg Ser Pro Asp Ser Phe Ser Met Arg Arg Thr Leu Pro Pro Ile Glu 420 425 430 Gly Thr Leu Gly Leu Ser Ala Cys Phe Leu Pro Asn Ser Val Phe Pro 435 440 445 Arg Cys Ser Glu Arg Asn Leu Gln Glu Ser Val Leu Ser Glu Gln Asp 450 455 460 Leu Met Gln Pro Glu Glu Pro Asp Tyr Leu Leu Asp Glu Met Thr Lys 465 470 475 480 Glu Ala Glu Ile Asp Asn Ser Ser Thr Val Glu Ser Leu Gly Glu Thr 485 490 495 Thr Asp Ile Leu Asn Met Thr His Ile Met Ser Leu Asn Ser Asn Glu 500 505 510 Lys Ser Leu Lys Leu Ser Pro Val Gln Lys Gln Lys Lys Gln Gln Thr 515 520 525 Ile Gly Glu Leu Thr Gln Asp Thr Ala Leu Thr Glu Asn Asp Asp Ser 530 535 540 Asp Glu Tyr Glu Glu Met Ser Glu Met Lys Glu Gly Lys Ala Cys Lys 545 550 555 560 Gln His Val Ser Gln Gly Ile Phe Met Thr Gln Pro Ala Thr Thr Ile 565 570 575 Glu Ala Phe Ser Asp Glu Glu Val Glu Ile Pro Glu Glu Lys Glu Gly 580 585 590 Ala Glu Asp Ser Lys Gly Asn Gly Ile Glu Glu Gln Glu Val Glu Ala 595 600 605 Asn Glu Glu Asn Val Lys Val His Gly Gly Arg Lys Glu Lys Thr Glu 610 615 620 Ile Leu Ser Asp Asp Leu Thr Asp Lys Ala Glu Val Ser Glu Gly Lys 625 630 635 640 Ala Lys Ser Val Gly Glu Ala Glu Asp Gly Pro Glu Gly Arg Gly Asp 645 650 655 Gly Thr Cys Glu Glu Gly Ser Ser Gly Ala Glu His Trp Gln Asp Glu 660 665 670 Glu Arg Glu Lys Gly Glu Lys Asp Lys Gly Arg Gly Glu Met Glu Arg 675 680 685 Pro Gly Glu Gly Glu Lys Glu Leu Ala Glu Lys Glu Glu Trp Lys Lys 690 695 700 Arg Asp Gly Glu Glu Gln Glu Gln Lys Glu Arg Glu Gln Gly His Gln 705 710 715 720 Lys Glu Arg Asn Gln Glu Met Glu Glu Gly Gly Glu Glu Glu His Gly 725 730 735 Glu Gly Glu Glu Glu Glu Gly Asp Arg Glu Glu Glu Glu Glu Lys Glu 740 745 750 Gly Glu Gly Lys Glu Glu Gly Glu Gly Glu Glu Val Glu Gly Glu Arg 755 760 765 Glu Lys Glu Glu Gly Glu Arg Lys Lys Glu Glu Arg Ala Gly Lys Glu 770 775 780 Glu Lys Gly Glu Glu Glu Gly Asp Gln Gly Glu Gly Glu Glu Glu Glu 785 790 795 800 Thr Glu Gly Arg Gly Glu Glu Lys Glu Glu Gly Gly Glu Val Glu Gly 805 810 815 Gly Glu Val Glu Glu Gly Lys Gly Glu Arg Glu Glu Glu Glu Glu Glu 820 825 830 Gly Glu Gly Glu Glu Glu Glu Gly Glu Gly Glu Glu Glu Glu Gly Glu 835 840 845 Gly Glu Glu Glu Glu Gly Glu Gly Lys Gly Glu Glu Glu Gly Glu Glu 850 855 860 Gly Glu Gly Glu Glu Glu Gly Glu Glu Gly Glu Gly Glu Gly Glu Glu 865 870 875 880 Glu Glu Gly Glu Gly Glu Gly Glu Glu Glu Gly Glu Gly Glu Gly Glu 885 890 895 Glu Glu Glu Gly Glu Gly Glu Gly Glu Glu Glu Gly Glu Gly Glu Gly 900 905 910 Glu Glu Glu Glu Gly Glu Gly Lys Gly Glu Glu Glu Gly Glu Glu Gly 915 920 925 Glu Gly Glu Gly Glu Glu Glu Glu Gly Glu Gly Glu Gly Glu Asp Gly 930 935 940 Glu Gly Glu Gly Glu Glu Glu Glu Gly Glu Trp Glu Gly Glu Glu Glu 945 950 955 960 Glu Gly Glu Gly Glu Gly Glu Glu Glu Gly Glu Gly Glu Gly Glu Glu 965 970 975 Gly Glu Gly Glu Gly Glu Glu Glu Glu Gly Glu Gly Glu Gly Glu Glu 980 985 990 Glu Glu Gly Glu Glu Glu Gly Glu Glu Glu Gly Glu Gly Glu Glu Glu 995 1000 1005 Gly Glu Gly Glu Gly Glu Glu Glu Glu Glu Gly Glu Val Glu Gly 1010 1015 1020 Glu Val Glu Gly Glu Glu Gly Glu Gly Glu Gly Glu Glu Glu Glu 1025 1030 1035 Gly Glu Glu Glu Gly Glu Glu Arg Glu Lys Glu Gly Glu Gly Glu 1040 1045 1050 Glu Asn Arg Arg Asn Arg Glu Glu Glu Glu Glu Glu Glu Gly Lys 1055 1060 1065 Tyr Gln Glu Thr Gly Glu Glu Glu Asn Glu Arg Gln Asp Gly Glu 1070 1075 1080 Glu Tyr Lys Lys Val Ser Lys Ile Lys Gly Ser Val Lys Tyr Gly 1085 1090 1095 Lys His Lys Thr Tyr Gln Lys Lys Ser Val Thr Asn Thr Gln Gly 1100 1105 1110 Asn Gly Lys Glu Gln Arg Ser Lys Met Pro Val Gln Ser Lys Arg 1115 1120 1125 Leu Leu Lys Asn Gly Pro Ser Gly Ser Lys Lys Phe Trp Asn Asn 1130 1135 1140 Val Leu Pro His Tyr Leu Glu Leu Lys 1145 1150 <210> 31 <211> 1020 <212> PRT <213> Homo sapiens <400> 31 Met Arg Glu Pro Glu Glu Leu Met Pro Asp Ser Gly Ala Val Phe Thr 1 5 10 15 Phe Gly Lys Ser Lys Phe Ala Glu Asn Asn Pro Gly Lys Phe Trp Phe 20 25 30 Lys Asn Asp Val Pro Val His Leu Ser Cys Gly Asp Glu His Ser Ala 35 40 45 Val Val Thr Gly Asn Asn Lys Leu Tyr Met Phe Gly Ser Asn Asn Trp 50 55 60 Gly Gln Leu Gly Leu Gly Ser Lys Ser Ala Ile Ser Lys Pro Thr Cys 65 70 75 80 Val Lys Ala Leu Lys Pro Glu Lys Val Lys Leu Ala Ala Cys Gly Arg 85 90 95 Asn His Thr Leu Val Ser Thr Glu Gly Gly Asn Val Tyr Ala Thr Gly 100 105 110 Gly Asn Asn Glu Gly Gln Leu Gly Leu Gly Asp Thr Glu Glu Arg Asn 115 120 125 Thr Phe His Val Ile Ser Phe Phe Thr Ser Glu His Lys Ile Lys Gln 130 135 140 Leu Ser Ala Gly Ser Asn Thr Ser Ala Ala Leu Thr Glu Asp Gly Arg 145 150 155 160 Leu Phe Met Trp Gly Asp Asn Ser Glu Gly Gln Ile Gly Leu Lys Asn 165 170 175 Val Ser Asn Val Cys Val Pro Gln Gln Val Thr Ile Gly Lys Pro Val 180 185 190 Ser Trp Ile Ser Cys Gly Tyr Tyr His Ser Ala Phe Val Thr Thr Asp 195 200 205 Gly Glu Leu Tyr Val Phe Gly Glu Pro Glu Asn Gly Lys Leu Gly Leu 210 215 220 Pro Asn Gln Leu Leu Gly Asn His Arg Thr Pro Gln Leu Val Ser Glu 225 230 235 240 Ile Pro Glu Lys Val Ile Gln Val Ala Cys Gly Gly Glu His Thr Val 245 250 255 Val Leu Thr Glu Asn Ala Val Tyr Thr Phe Gly Leu Gly Gln Phe Gly 260 265 270 Gln Leu Gly Leu Gly Thr Phe Leu Phe Glu Thr Ser Glu Pro Lys Val 275 280 285 Ile Glu Asn Ile Arg Asp Gln Thr Ile Ser Tyr Ile Ser Cys Gly Glu 290 295 300 Asn His Thr Ala Leu Ile Thr Asp Ile Gly Leu Met Tyr Thr Phe Gly 305 310 315 320 Asp Gly Arg His Gly Lys Leu Gly Leu Gly Leu Glu Asn Phe Thr Asn 325 330 335 His Phe Ile Pro Thr Leu Cys Ser Asn Phe Leu Arg Phe Ile Val Lys 340 345 350 Leu Val Ala Cys Gly Gly Cys His Met Val Val Phe Ala Ala Pro His 355 360 365 Arg Gly Val Ala Lys Glu Ile Glu Phe Asp Glu Ile Asn Asp Thr Cys 370 375 380 Leu Ser Val Ala Thr Phe Leu Pro Tyr Ser Ser Leu Thr Ser Gly Asn 385 390 395 400 Val Leu Gln Arg Thr Leu Ser Ala Arg Met Arg Arg Arg Glu Arg Glu 405 410 415 Arg Ser Pro Asp Ser Phe Ser Met Arg Arg Thr Leu Pro Pro Ile Glu 420 425 430 Gly Thr Leu Gly Leu Ser Ala Cys Phe Leu Pro Asn Ser Val Phe Pro 435 440 445 Arg Cys Ser Glu Arg Asn Leu Gln Glu Ser Val Leu Ser Glu Gln Asp 450 455 460 Leu Met Gln Pro Glu Glu Pro Asp Tyr Leu Leu Asp Glu Met Thr Lys 465 470 475 480 Glu Ala Glu Ile Asp Asn Ser Ser Thr Val Glu Ser Leu Gly Glu Thr 485 490 495 Thr Asp Ile Leu Asn Met Thr His Ile Met Ser Leu Asn Ser Asn Glu 500 505 510 Lys Ser Leu Lys Leu Ser Pro Val Gln Lys Gln Lys Lys Gln Gln Thr 515 520 525 Ile Gly Glu Leu Thr Gln Asp Thr Ala Leu Thr Glu Asn Asp Asp Ser 530 535 540 Asp Glu Tyr Glu Glu Met Ser Glu Met Lys Glu Gly Lys Ala Cys Lys 545 550 555 560 Gln His Val Ser Gln Gly Ile Phe Met Thr Gln Pro Ala Thr Thr Ile 565 570 575 Glu Ala Phe Ser Asp Glu Glu Val Gly Asn Asp Thr Gly Gln Val Gly 580 585 590 Pro Gln Ala Asp Thr Asp Gly Glu Gly Leu Gln Lys Glu Val Tyr Arg 595 600 605 His Glu Asn Asn Asn Gly Val Asp Gln Leu Asp Ala Lys Glu Ile Glu 610 615 620 Lys Glu Ser Asp Gly Gly His Ser Gln Lys Glu Ser Glu Ala Glu Glu 625 630 635 640 Ile Asp Ser Glu Lys Glu Thr Lys Leu Ala Glu Ile Ala Gly Met Lys 645 650 655 Asp Leu Arg Glu Arg Glu Lys Ser Thr Lys Lys Met Ser Pro Phe Phe 660 665 670 Gly Asn Leu Pro Asp Arg Gly Met Asn Thr Glu Ser Glu Glu Asn Lys 675 680 685 Asp Phe Val Lys Lys Arg Glu Ser Cys Lys Gln Asp Val Ile Phe Asp 690 695 700 Ser Glu Arg Glu Ser Val Glu Lys Pro Asp Ser Tyr Met Glu Gly Ala 705 710 715 720 Ser Glu Ser Gln Gln Gly Ile Ala Asp Gly Phe Gln Gln Pro Glu Ala 725 730 735 Ile Glu Phe Ser Ser Gly Glu Lys Glu Asp Asp Glu Val Glu Thr Asp 740 745 750 Gln Asn Ile Arg Tyr Gly Arg Lys Leu Ile Glu Gln Gly Asn Glu Lys 755 760 765 Glu Thr Lys Pro Ile Ile Ser Lys Ser Met Ala Lys Tyr Asp Phe Lys 770 775 780 Cys Asp Arg Leu Ser Glu Ile Pro Glu Glu Lys Glu Gly Ala Glu Asp 785 790 795 800 Ser Lys Gly Asn Gly Ile Glu Glu Gln Glu Val Glu Ala Asn Glu Glu 805 810 815 Asn Val Lys Val His Gly Gly Arg Lys Glu Lys Thr Glu Ile Leu Ser 820 825 830 Asp Asp Leu Thr Asp Lys Ala Glu Asp His Glu Phe Ser Lys Thr Glu 835 840 845 Glu Leu Lys Leu Glu Asp Val Asp Glu Glu Ile Asn Ala Glu Asn Val 850 855 860 Glu Ser Lys Lys Lys Thr Val Gly Asp Asp Glu Ser Val Pro Thr Gly 865 870 875 880 Tyr His Ser Lys Thr Glu Gly Ala Glu Arg Thr Asn Asp Asp Ser Ser 885 890 895 Ala Glu Thr Ile Glu Lys Lys Glu Lys Ala Asn Leu Glu Glu Arg Ala 900 905 910 Ile Cys Glu Tyr Asn Glu Asn Pro Lys Gly Tyr Met Leu Asp Asp Ala 915 920 925 Asp Ser Ser Ser Leu Glu Ile Leu Glu Asn Ser Glu Thr Thr Pro Ser 930 935 940 Lys Asp Met Lys Lys Thr Lys Lys Ile Phe Leu Phe Lys Arg Val Pro 945 950 955 960 Ser Ile Asn Gln Lys Ile Val Lys Asn Asn Asn Glu Pro Leu Pro Glu 965 970 975 Ile Lys Ser Ile Gly Asp Gln Ile Ile Leu Lys Ser Asp Asn Lys Asp 980 985 990 Ala Asp Gln Asn His Met Ser Gln Asn His Gln Asn Ile Pro Pro Thr 995 1000 1005 Asn Thr Glu Arg Arg Ser Lys Ser Cys Thr Ile Leu 1010 1015 1020 <210> 32 <211> 1368 <212> PRT <213> Streptococcus pyogenes <400> 32 Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val 1 5 10 15 Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe 20 25 30 Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile 35 40 45 Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 50 55 60 Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys 65 70 75 80 Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser 85 90 95 Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys 100 105 110 His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr 115 120 125 His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp 130 135 140 Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His 145 150 155 160 Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 165 170 175 Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr 180 185 190 Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala 195 200 205 Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn 210 215 220 Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn 225 230 235 240 Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe 245 250 255 Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp 260 265 270 Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 275 280 285 Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 290 295 300 Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser 305 310 315 320 Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys 325 330 335 Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe 340 345 350 Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser 355 360 365 Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp 370 375 380 Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg 385 390 395 400 Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415 Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 420 425 430 Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440 445 Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp 450 455 460 Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu 465 470 475 480 Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr 485 490 495 Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser 500 505 510 Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525 Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 530 535 540 Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr 545 550 555 560 Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 565 570 575 Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly 580 585 590 Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp 595 600 605 Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr 610 615 620 Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala 625 630 635 640 His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 645 650 655 Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 660 665 670 Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 675 680 685 Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 690 695 700 Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu 705 710 715 720 His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly 725 730 735 Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly 740 745 750 Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln 755 760 765 Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile 770 775 780 Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro 785 790 795 800 Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu 805 810 815 Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg 820 825 830 Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys 835 840 845 Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg 850 855 860 Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys 865 870 875 880 Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys 885 890 895 Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp 900 905 910 Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 915 920 925 Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp 930 935 940 Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser 945 950 955 960 Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg 965 970 975 Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val 980 985 990 Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe 995 1000 1005 Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala 1010 1015 1020 Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe 1025 1030 1035 Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala 1040 1045 1050 Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu 1055 1060 1065 Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val 1070 1075 1080 Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr 1085 1090 1095 Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys 1100 1105 1110 Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro 1115 1120 1125 Light Light Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val 1130 1135 1140 Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys 1145 1150 1155 Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser 1160 1165 1170 Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys 1175 1180 1185 Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu 1190 1195 1200 Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly 1205 1210 1215 Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val 1220 1225 1230 Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser 1235 1240 1245 Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys 1250 1255 1260 His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys 1265 1270 1275 Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala 1280 1285 1290 Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn 1295 1300 1305 Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala 1310 1315 1320 Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser 1325 1330 1335 Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr 1340 1345 1350 Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp 1355 1360 1365 <210> 33 <211> 1053 <212> PRT <213> Staphylococcus aureus <400> 33 Met Lys Arg Asn Tyr Ile Leu Gly Leu Asp Ile Gly Ile Thr Ser Val 1 5 10 15 [[ID=3)]]Gly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly 20 25 30 Val Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg 35 40 45 Ser Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile 50 55 60 Gln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His 65 70 75 80 Ser Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu 85 90 95 Ser Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu 100 105 110 Ala Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr 115 120 125 Gly Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala 130 135 140 Leu Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys 145 150 155 160 Asp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr 165 170 175 Val Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln 180 185 190 Leu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg 195 200 205 Arg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys 210 215 220 Asp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe 225 230 235 240 Pro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr 245 250 255 Asn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn 260 265 270 Glu Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe 275 280 285 Lys Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu 290 295 300 Val Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys 305 310 315 320 Pro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr 325 330 335 Ala Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala 340 345 350 Lys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu 355 360 365 Thr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser 370 375 380 Asn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile 385 390 395 400 Asn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala 405 410 415 Ile Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln 420 425 430 Gln Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro 435 440 445 Val Val Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile 450 455 460 Ile Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg 465 470 475 480 Glu Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys 485 490 495 Arg Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr 500 505 510 Gly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp 515 520 525 Met Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu 530 535 540 Asp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro 545 550 555 560 Arg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys 565 570 575 Gln Glu Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu 580 585 590 Ser Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile 595 600 605 Leu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu 610 615 620 Tyr Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp 625 630 635 640 Phe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu 645 650 655 Met Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys 660 665 670 Val Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp 675 680 685 Lys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp 690 695 700 Ala Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys 705 710 715 720 Leu Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys 725 730 735 Gln Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu 740 745 750 Ile Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp 755 760 765 Tyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile 770 775 780 Asn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu 785 790 795 800 Ile Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu 805 810 815 Lys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His 820 825 830 Asp Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly 835 840 845 Asp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr 850 855 860 Leu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 865 870 875 880 Lys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp 885 890 895 Tyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 900 905 910 Arg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val 915 920 925 Lys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser 930 935 940 Lys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 945 950 955 960 Glu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly 965 970 975 Glu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 980 985 990 Glu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met 995 1000 1005 Asn Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser Lys 1010 1015 1020 Thr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu 1025 1030 1035 Tyr Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050 <210> 34 <211> 1300 <212> PRT <213> Francisella tularensis <400> 34 Met Ser Ile Tyr Gln Glu Phe Val Asn Lys Tyr Ser Leu Ser Lys Thr 1 5 10 15 Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Leu Glu Asn Ile Lys 20 25 30 Ala Arg Gly Leu Ile Leu Asp Asp Glu Lys Arg Ala Lys Asp Tyr Lys 35 40 45 Lys Ala Lys Gln Ile Ile Asp Lys Tyr His Gln Phe Phe Ile Glu Glu 50 55 60 Ile Leu Ser Ser Val Cys Ile Ser Glu Asp Leu Leu Gln Asn Tyr Ser 65 70 75 80 Asp Val Tyr Phe Lys Leu Lys Lys Ser Asp Asp Asp Asn Leu Gln Lys 85 90 95 Asp Phe Lys Ser Ala Lys Asp Thr Ile Lys Lys Gln Ile Ser Glu Tyr 100 105 110 Ile Lys Asp Ser Glu Lys Phe Lys Asn Leu Phe Asn Gln Asn Leu Ile 115 120 125 Asp Ala Lys Lys Gly Gln Glu Ser Asp Leu Ile Leu Trp Leu Lys Gln 130 135 140 Ser Lys Asp Asn Gly Ile Glu Leu Phe Lys Ala Asn Ser Asp Ile Thr 145 150 155 160 Asp Ile Asp Glu Ala Leu Glu Ile Ile Lys Ser Phe Lys Gly Trp Thr 165 170 175 Thr Tyr Phe Lys Gly Phe His Glu Asn Arg Lys Asn Val Tyr Ser Ser 180 185 190 Asn Asp Ile Pro Thr Ser Ile Ile Tyr Arg Ile Val Asp Asp Asn Leu 195 200 205 Pro Lys Phe Leu Glu Asn Lys Ala Lys Tyr Glu Ser Leu Lys Asp Lys 210 215 220 Ala Pro Glu Ala Ile Asn Tyr Glu Gln Ile Lys Lys Asp Leu Ala Glu 225 230 235 240 Glu Leu Thr Phe Asp Ile Asp Tyr Lys Thr Ser Glu Val Asn Gln Arg 245 250 255 Val Phe Ser Leu Asp Glu Val Phe Glu Ile Ala Asn Phe Asn Asn Tyr 260 265 270 Leu Asn Gln Ser Gly Ile Thr Lys Phe Asn Thr Ile Ile Gly Gly Lys 275 280 285 Phe Val Asn Gly Glu Asn Thr Lys Arg Lys Gly Ile Asn Glu Tyr Ile 290 295 300 Asn Leu Tyr Ser Gln Gln Ile Asn Asp Lys Thr Leu Lys Lys Tyr Lys 305 310 315 320 Met Ser Val Leu Phe Lys Gln Ile Leu Ser Asp Thr Glu Ser Lys Ser 325 330 335 Phe Val Ile Asp Lys Leu Glu Asp Asp Ser Asp Val Val Thr Thr Met 340 345 350 Gln Ser Phe Tyr Glu Gln Ile Ala Ala Phe Lys Thr Val Glu Glu Lys 355 360 365 Ser Ile Lys Glu Thr Leu Ser Leu Leu Phe Asp Asp Leu Lys Ala Gln 370 375 380 Lys Leu Asp Leu Ser Lys Ile Tyr Phe Lys Asn Asp Lys Ser Leu Thr 385 390 395 400 Asp Leu Ser Gln Gln Val Phe Asp Asp Tyr Ser Val Ile Gly Thr Ala 405 410 415 Val Leu Glu Tyr Ile Thr Gln Gln Ile Ala Pro Lys Asn Leu Asp Asn 420 425 430 Pro Ser Lys Lys Glu Gln Glu Leu Ile Ala Lys Lys Thr Glu Lys Ala 435 440 445 Lys Tyr Leu Ser Leu Glu Thr Ile Lys Leu Ala Leu Glu Glu Phe Asn 450 455 460 Lys His Arg Asp Ile Asp Lys Gln Cys Arg Phe Glu Glu Ile Leu Ala 465 470 475 480 Asn Phe Ala Ala Ile Pro Met Ile Phe Asp Glu Ile Ala Gln Asn Lys 485 490 495 Asp Asn Leu Ala Gln Ile Ser Ile Lys Tyr Gln Asn Gln Gly Lys Lys 500 505 510 Asp Leu Leu Gln Ala Ser Ala Glu Asp Asp Val Lys Ala Ile Lys Asp 515 520 525 Leu Leu Asp Gln Thr Asn Asn Leu Leu His Lys Leu Lys Ile Phe His 530 535 540 Ile Ser Gln Ser Glu Asp Lys Ala Asn Ile Leu Asp Lys Asp Glu His 545 550 555 560 Phe Tyr Leu Val Phe Glu Glu Cys Tyr Phe Glu Leu Ala Asn Ile Val 565,570,575 Pro Leu Tyr Asn With Arg Asn Tyr With Thr Gln Lys Pro Tyr Ser 580,585,590 Asp Glu Lys Phe Lys Leu Asn Phe Glu Asn Ser Thr Leu Ala Asn Gly 595,600,605 Trp Asp Lys Asn Lys Glu Pro Asp Asn Thr Ala Ile Leu Phe Ile Lys 610 615 620 Asp Asp Lys Tyr Leu Gly Val Met Lys Lys Asn Asn Lys Ile 625 630 635 640 Phe Asp Asp Lys Ala Ile Lys Glu Asn Gly Glu Gly Tyr Lys Lys 645,650,655 Ile Val Tyr Lys Leu Leu Pro Gly Ala Asn Lys Met Leu Pro Lys Val 660,665,670 Phe Phe Ser Ala Lys Ser Ile Lys Phe Tyr Asn Pro Ser Glu Asp Ile 675,680,685 Leu Arg Ile Arg Asn His Ser Thr His Thr Lys Asn Gly Ser Pro Gln 690,695,700 Lys Gly Tyr Glu Lys Phe Glu Phe Asn Ile Glu Asp Cys Arg Lys Phe 705 710 715 720 Asp Phe Tyr Lys Gln Ser Ile Ser Lys His Pro Glu Trp Lys Asp 725 730 735 Phe Gly Phe Arg Phe Ser Asp Thr Gln Arg Tyr Asn Ser Ile Asp Glu 740,745,750 Phe Tyr Arg Glu Val Glu Asn Gln Gly Tyr Lys Leu Thr Phe Glu Asn 755,760,765 Ser Glu Ser Tyr and Asp Ser Val Val Asn Gln Gly Lys Tyr 770,775,780 Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ser Ala Tyr Ser Lys Gly Arg 785,790,795,800 Pro Asn Leu His Thr Leu Tyr Trp Lys Ala Leu Phe Asp Glu Arg Asn 805 810 815 Gln Asp Val Val Tyr Lys Gln Gl Glu Ala Glu Phe Tyr 820 825 830 Arg Lys Gln Ser Ile Pro Lys Lys Ile Thr His Pro Ala Lys Glu Ala 835 840 845 Ile Ala Asn Lys Asn Lys Asp Asn Pro Lys Lys Glu Ser Val Phe Glu 850 855 860 Tyr Asp Leu Ile Lys Asp Lys Arg Phe Thr Glu Asp Lys Phe Phe Phe 865 870 875 880 His Cys Pro Ile Thr Ile Asn Phe Lys Ser Ser Gly Ala Asn Lys Phe 885 890 895 Asn Asp Glu Ile Asn Leu Leu Leu Lys Glu Lys Ala Asn Asp Val His 900 905 910 Ile Leu Ser Ile Asp Arg Gly Glu Arg His Leu Ala Tyr Tyr Thr Leu 915 920 925 Val Asp Gly Lys Gly Asn Ile Ile Lys Gln Asp Thr Phe Asn Ile Ile 930 935 940 Gly Asn Asp Arg Met Lys Thr Asn Tyr His Asp Lys Leu Ala Ala Ile 945 950 955 960 Glu Lys Asp Arg Asp Ser Ala Arg Lys Asp Trp Lys Lys Ile Asn Asn 965 970 975 Ile Lys Glu Met Lys Glu Gly Tyr Leu Ser Gln Val Val His Glu Ile 980 985 990 Ala Lys Leu Val Ile Glu Tyr Asn Ala Ile Val Val Phe Glu Asp Leu 995 1000 1005 Asn Phe Gly Phe Lys Arg Gly Arg Phe Lys Val Glu Lys Gln Val 1010 1015 1020 Tyr Gln Lys Leu Glu Lys Met Leu Ile Glu Lys Leu Asn Tyr Leu 1025 1030 1035 Val Phe Lys Asp Asn Glu Phe Asp Lys Thr Gly Gly Val Leu Arg 1040 1045 1050 Ala Tyr Gln Leu Thr Ala Pro Phe Glu Thr Phe Lys Lys Met Gly 1055 1060 1065 Lys Gln Thr Gly Ile Ile Tyr Tyr Val Pro Ala Gly Phe Thr Ser 1070 1075 1080 Lys Ile Cys Pro Val Thr Gly Phe Val Asn Gln Leu Tyr Pro Lys 1085 1090 1095 Tyr Glu Ser Val Ser Lys Ser Gln Glu Phe Phe Ser Lys Phe Asp 1100 1105 1110 Lys Ile Cys Tyr Asn Leu Asp Lys Gly Tyr Phe Glu Phe Ser Phe 1115 1120 1125 Asp Tyr Lys Asn Phe Gly Asp Lys Ala Ala Lys Gly Lys Trp Thr 1130 1135 1140 Ile Ala Ser Phe Gly Ser Arg Leu Ile Asn Phe Arg Asn Ser Asp 1145 1150 1155 Lys Asn His Asn Trp Asp Thr Arg Glu Val Tyr Pro Thr Lys Glu 1160 1165 1170 Leu Glu Lys Leu Leu Lys Asp Tyr Ser Ile Glu Tyr Gly His Gly 1175 1180 1185 Glu Cys Ile Lys Ala Ala Ile Cys Gly Glu Ser Asp Lys Lys Phe 1190 1195 1200 Phe Ala Lys Leu Thr Ser Val Leu Asn Thr Ile Leu Gln Met Arg 1205 1210 1215 Asn Ser Lys Thr Gly Thr Glu Leu Asp Tyr Leu Ile Ser Pro Val 1220 1225 1230 Ala Asp Val Asn Gly Asn Phe Phe Asp Ser Arg Gln Ala Pro Lys 1235 1240 1245 Asn Met Pro Gln Asp Ala Asp Ala Asn Gly Ala Tyr His Ile Gly 1250 1255 1260 Leu Lys Gly Leu Met Leu Leu Gly Arg Ile Lys Asn Asn Gln Glu 1265 1270 1275 Gly Lys Lys Leu Asn Leu Val Ile Lys Asn Glu Glu Tyr Phe Glu 1280 1285 1290 Phe Val Gln Asn Arg Asn Asn 1295 1300 <210> 35 <211> 297 <212> PRT <213> Adeno-associated virus-1 <400> 35 Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala 1 5 10 15 His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr 20 25 30 Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn 35 40 45 Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln 50 55 60 Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser 65 70 75 80 Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala 85 90 95 Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr 100 105 110 Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser 115 120 125 Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala 130 135 140 Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Lys Asp 165 170 175 Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly Lys 180 185 190 Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile Thr \\(195\\) 200 205 Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg Phe 210 215 220 Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala Thr 225 230 235 240 Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln Asp 245 250 255 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr 260 265 270 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys 275 280 285 Asn Pro Pro Pro Gln Ile Leu Ile Lys 290 295 <210> 36 <211> 240 <212> PRT <213> Adeno - associated virus - 6 <400> 36 Note: In the translation of the sequence part, it is assumed that the numbers are in a sequence - related context. If there are specific requirements for the format of these numbers, they may need to be adjusted accordingly. Also, for the specific tags like <210>, <211>, <212>, <213>, <400>, , etc., they are left unchanged as per the instruction. The name "Adeno - associated virus - 6" is a common English name for the virus in this context. If there are specific naming conventions required for this virus in a particular field, it may need to be further verified and adjusted.Thr Phe Ser Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala 1 5 10 15 His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr 20 25 30 Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn 35 40 45 Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln 50 55 60 Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser 65 70 75 80 Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala 85 90 95 Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr 100 105 110 Ala Met Ala Ser His Lys Asp Asp Lys Asp Lys Phe Phe Pro Met Ser 115 120 125 Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala 130 135 140 Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Leu Gln Ser 165 170 175 Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Val Met Gly Ala Leu 180 185 190 Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile 195 200 205 Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu 210 215 220 Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys 225 230 235 240 <210> 37 <211> 240 <212> PRT <213> Adeno-associated virus-3 <400> 37 Phe Ser Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His 1 5 10 15 Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu 20 25 30 Tyr Tyr Leu Asn Arg Thr Gln Gly Thr Thr Ser Gly Thr Thr Asn Gln 35 40 45 Ser Arg Leu Leu Phe Ser Gln Ala Gly Pro Gln Ser Met Ser Leu Gln 50 55 60 Ala Arg Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Leu Ser 65 70 75 80 Lys Thr Ala Asn Asp Asn Asn Asn Ser Asn Phe Pro Trp Thr Ala Ala 85 90 95 Ser Lys Tyr His Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Pro 100 105 110 Ala Met Ala Ser His Lys Asp Asp Glu Glu Lys Phe Phe Pro Met His 115 120 125 Gly Asn Leu Ile Phe Gly Lys Glu Gly Thr Thr Ala Ser Asn Ala Glu 130 135 140 Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Arg Thr Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Gln Tyr Gly Thr Val Ala Asn Asn Leu Gln Ser 165 170 175 Ser Asn Thr Ala Pro Thr Thr Gly Thr Val Asn His Gln Gly Ala Leu 180 185 190 Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile 195 200 205 Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu 210 215 220 Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Met Ile Lys 225 230 235 240 <210> 38 <211> 240 <212> PRT <213> Adeno-associated virus-2 <400> 38 Phe Ser Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His 1 5 10 15 Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu 20 25 30 Tyr Tyr Leu Ser Arg Thr Asn Thr Pro Ser Gly Thr Thr Thr Gln Ser 35 40 45 Arg Leu Gln Phe Ser Gln Ala Gly Ala Ser Asp Ile Arg Asp Gln Ser 50 55 60 Arg Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys 65 70 75 80 Thr Ser Ala Asp Asn Asn Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr 85 90 95 Lys Tyr His Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala 100 105 110 Met Ala Ser His Lys Asp Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly 115 120 125 Val Leu Ile Phe Gly Lys Gln Gly Ser Glu Lys Thr Asn Val Asp Ile 130 135 140 Glu Lys Val Met Ile Thr Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro 145 150 155 160 Val Ala Thr Glu Gln Tyr Gly Ser Val Ser Thr Asn Leu Gln Arg Gly 165 170 175 Asn Arg Gln Ala Ala Thr Ala Asp Val Asn Thr Gln Gly Val Leu Pro 180 185 190 Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp 195 200 205 Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu Met 210 215 220 Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn 225 230 235 240 <210> 39 <211> 243 <212> PRT <213> Adeno-associated virus-8 <400> 39 Asn Phe Gln Phe Thr Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser 1 5 10 15 Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp 20 25 30 Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala 35 40 45 Asn Thr Gln Thr Leu Gly Phe Ser Gln Gly Gly Pro Asn Thr Met Ala 50 55 60 Asn Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg 65 70 75 80 Val Ser Thr Thr Thr Gly Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr 85 90 95 Ala Gly Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Ala Asn Pro 100 105 110 Gly Ile Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg Phe Phe Pro 115 120 125 Ser Asn Gly Ile Leu Ile Phe Gly Lys Gln Asn Ala Ala Arg Asp Asn 130 135 140 Ala Asp Tyr Ser Asp Val Met Leu Thr Ser Glu Glu Glu Ile Lys Thr 145 150 155 160 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Ile Val Ala Asp Asn Leu 165 170 175 Gln Gln Gln Asn Thr Ala Pro Gln Ile Gly Thr Val Asn Ser Gln Gly 180 185 190 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 195 200 205 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 210 215 220 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 225 230 235 240 Ile Lys Asn <210> 40 <211> 243 <212> PRT <213> Adeno-associated virus-8.1 <400> 40 Asn Phe Gln Phe Thr Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser 1 5 10 15 Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp 20 25 30 Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala 35 40 45 Asn Thr Gln Thr Leu Gly Phe Ser Gln Gly Gly Pro Asn Thr Met Ala 50 55 60 Asn Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg 65 70 75 80 Val Ser Thr Thr Thr Gly Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr 85 90 95 Ala Gly Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Ala Asn Pro 100 105 110 Gly Ile Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg Phe Phe Pro 115 120 125 Ser Asn Gly Ile Leu Ile Phe Gly Lys Gln Asn Ala Ala Arg Asp Asn 130 135 140 Ala Asp Tyr Ser Asp Val Met Leu Thr Ser Glu Glu Glu Ile Lys Thr 145 150 155 160 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Ile Val Ala Asp Asn Leu 165 170 175 Gln Gly Gln Arg Gln Ala Ala Gln Ile Gly Thr Val Asn Ser Gln Gly 180 185 190 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 195 200 205 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 210 215 220 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 225 230 235 240 Ile Lys Asn <210> 41 <211> 241 <212> PRT <213> Adeno - associated virus - 8 Rh8 <400> 41 Phe Gln Phe Ser Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr 1 5 10 15 Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln 20 25 30 Tyr Leu Tyr Tyr Leu Val Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr 35 40 45 Gln Thr Leu Ala Phe Ser Gln Ala Gly Pro Ser Ser Met Ala Asn Gln 50 55 60 Ala Arg Asn Trp Val Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser 65 70 75 80 Thr Thr Thr Asn Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala 85 90 95 Ala Lys Phe Lys Leu Asn Gly Arg Asp Ser Leu Met Asn Pro Gly Val 100 105 110 Ala Met Ala Ser His Lys Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser 115 120 125 Gly Val Leu Ile Phe Gly Lys Gln Gly Ala Gly Asn Asp Gly Val Asp 130 135 140 Tyr Ser Gln Val Leu Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Glu Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala 165 170 175 Ala Asn Thr Gln Ala Gln Thr Gly Leu Val His Asn Gln Gly Val Ile 180 185 190 Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile 195 200 205 Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu 210 215 220 Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys 225 230 235 240 Asn <210> 42 <211> 243 <212> PRT <213> Adeno-associated virus-10 <400> 42 Asn Phe Glu Phe Ser Tyr Thr Phe Glu Asp Val Pro Phe His Ser Ser ​​​​​​Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser Thr Gly Gly Thr Gln 35 40 45 Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly Pro Ala Asn Met Ser 50 55 60 Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg 65 70 75 80 Val Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr 85 90 95 Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp Ser Leu Val Asn Pro 100 105 110 Gly Val Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg Phe Phe Pro 115 120 125 Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly Ala Gly Arg Asp Asn 130 135 140 Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu Glu Glu Ile Lys Thr 145 150 155 160 Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ala Asp Asn Leu 165 170 175 Gln Gln Ala Asn Thr Gly Pro Ile Val Gly Asn Val Asn Ser Gln Gly 180 185 190 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 195 200 205 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 210 215 220 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 225 230 235 240 Ile Lys Asn <210> 43 <211> 242 <212> PRT <213> Adeno-associated virus-7 <400> 43 Phe Glu Phe Ser Tyr Ser Phe Glu Asp Val Pro Phe His Ser Ser Tyr 1 5 10 15 Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln 2​​​​​​​​​​​​​​ 85 90 95 Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Val Asn Pro 100 105 110 Gly Val Ala Met Ala Thr His Lys Asp Asp Glu Asp Arg Phe Phe Pro 115 120 125 Ser Ser Gly Val Leu Ile Phe Gly Lys Thr Gly Ala Thr Asn Lys Thr 130 135 140 Thr Leu Glu Asn Val Leu Met Thr Asn Glu Glu Glu Ile Arg Pro Thr 145 150 155 160 Asn Pro Val Ala Thr Glu Glu Tyr Gly Ile Val Ser Ser Asn Leu Gln 165 170 175 Ala Ala Asn Thr Ala Ala Gln Thr Gln Val Val Asn Asn Gln Gly Ala 180 185 190 Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro 195 200 205 Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro 210 215 220 Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile 225 230 235 240 Lys Asn <210> 44 <211> 240 <212> PRT <213> Adeno-associated virus-9 <400> 44 Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr 1 5 10 15 Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln 20 25 30 Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln 35 40 45 Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln 50 55 60 Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser 65 70 75 80 Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala 85 90 95 Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro 100 105 110 Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser 115 120 125​​​​​Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser 165 170 175 Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu 180 185 190 Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile 195 200 205 Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu 210 215 220 Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys 225 230 235 240 <210> 45 <211> 240 <212> PRT <213> Adeno-associated virus-9.1 <400> 45 Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr 1 5 10 15 Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln 20 25 30 Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln 35 40 45 Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln 50 55 60 Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser 65 70 75 80 Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala 85 90 95 Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro 100 105 110 Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser 115 120 125 Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp 130 135 140 Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn 145 150 155 160 Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser 165 170 175 Gly Gln Ala Gln Ala Ala Thr Gly Trp Val Gln Asn Gln Gly Ile Leu 180 185 190 Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile 195 200 205 Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu 210 215 220 Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys 225 230 235 240 <210> 46 <211> 240 <212> PRT <213> Adeno - associated virus - 5 <400> 46 Asn Phe Glu Phe Thr Tyr Asn Phe Glu Glu Val Pro Phe His Ser Ser 1 5 10 15 Phe Ala Pro Ser Gln Asn Leu Phe Lys Leu Ala Asn Pro Leu Val Asp 20 25 30 Gln Tyr Leu Tyr Arg Phe Val Ser Thr Asn Asn Thr Gly Gly Val Gln 35 40 45 Phe Asn Lys Asn Leu Ala Gly Arg Tyr Ala Asn Thr Tyr Lys Asn Trp 50 55 60 Phe Pro Gly Pro Met Gly Arg Thr Gln Gly Trp Asn Leu Gly Ser Gly 65 70 75 80 Val Asn Arg Ala Ser Val Ser Ala Phe Ala Thr Thr Asn Arg Met Glu 85 90 95 Leu Glu Gly Ala Ser Tyr Gln Val Pro Pro Gln Pro Asn Gly Met Thr 100 105 110 Asn Asn Leu Gln Gly Ser Asn Thr Tyr Ala Leu Glu Asn Thr Met Ile 115 120 125 Phe Asn Ser Gln Pro Ala Asn Pro Gly Thr Thr Ala Thr Tyr Leu Glu 130 135 140 Gly Asn Met Leu Ile Thr Ser Glu Ser Glu Thr Gln Pro Val Asn Arg 145 150 155 160 Val Ala Tyr Asn Val Gly Gly Gln Met Ala Thr Asn Asn Gln Ser Ser 165 170 175 Thr Thr Ala Pro Ala Thr Gly Thr Tyr Asn Leu Gln Glu Ile Val Pro 180 185 190 Gly Ser Val Trp Met Glu Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp 195 200 205 Ala Lys Ile Pro Glu Thr Gly Ala His Phe His Pro Ser Pro Ala Met 210 215 220 Gly Gly Phe Gly Leu Lys His Pro Pro Pro Met Met Leu Ile Lys Asn 225 230 235 240 <210> 47 <211> 9 <212> PRT <213> Artificial Sequence <220><00千3840><223> Synthetic Peptide <400> 四十七 Leu Ala Lys Asp Ala Thr Lys Asn Ala 1 5 <210> 48 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 48 Pro Ala His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 49 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 49 Leu Ala His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 50 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 50 Leu Ala Thr Thr Ser Gln Asn Lys Pro Ala 1 5 10 <210> 51 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 51 Leu Ala Ile Ser Asp Gln Thr Lys His Ala 1 5 10 <210> 52 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 52 Ile Ala Arg Gly Val Ala Pro Ser Ser Ala 1 5 10 <210> 53 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 53 Leu Ala Pro Asp Ser Thr Thr Arg Ser Ala 1 5 10 <210> 54 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 54 Leu Ala Lys Gly Thr Glu Leu Lys Pro Ala 1 5 10 <210> 55 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 55 Leu Ala Ile Ile Asp Ala Thr Lys Asn Ala 1 5 10 <210> 56 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 56 Leu Ala Val Asp Gly Ala Gln Arg Ser Ala 1 5 10 <210> 57 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 57 Pro Ala Pro Gln Asp Thr Thr Lys Lys Ala 1 5 10 <210> 58 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 58 Leu Pro His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 59 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 59 Leu Ala Lys Asp Ala Thr Lys Thr Ile Ala 1 5 10 <210> 60 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 60 Leu Ala Lys Gln Gln Ser Ala Ser Thr Ala 1 5 10 <210> 61 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 61 Leu Ala Lys Ser Asp Gln Ser Lys Pro Ala 1 5 10 <210> 62 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 62 Leu Ser His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 63 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 63 Leu Ala Ala Asn Gln Pro Ser Lys Pro Ala 1 5 10 <210> 64 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 64 Leu Ala Val Ser Asp Ser Thr Lys Ala Ala 1 5 10 <210> 65 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 65 Leu Ala Ala Gln Gly Thr Ala Lys Pro Ala 1 5 10 <210> 66 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 66 Leu Ala Pro Asp Gln Thr Thr Arg Asn Ala 1 5 10 <210> 67 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 67 Leu Ala Ala Ser Asp Ser Thr Lys Ala Ala 1 5 10 <210> 68 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 68 Leu Ala Pro Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 69 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 69 Leu Ala Lys Ala Asp Glu Thr Arg Pro Ala 1 5 10 <210> 70 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 70 Leu Ala His Gln Asp Thr Ala Lys Asn Ala 1 5 10 <210> 71 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 71 Leu Ala His Gln Asp Thr Lys Lys Asn Ala 1 5 10 <210> 72 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 72 Leu Ala His Gln Asp Thr Thr Lys His Ala 1 5 10 <210> 73 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 73 Leu Ala His Gln Asp Thr Thr Lys Lys Ala 1 5 10 <210> 74 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 74 Leu Ala His Gln Asp Thr Thr Arg Asn Ala 1 5 10 <210> 75 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 75 Leu Ala His Gln Asp Thr Thr Thr Asn Ala 1 5 10 <210> 76 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 76 Leu Ala His Gln Gly Thr Thr Lys Asn Ala 1 5 10 <210> 77 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 77 Leu Ala His Gln Val Thr Thr Lys Asn Ala 1 5 10 <210> 78 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 78 Leu Ala Ile Ser Asp Gln Ser Lys Pro Ala 1 5 10 <210> 79 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 79 Leu Ala Lys Asp Ala Thr Lys Thr Ala 1 5 <210> 80 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 80 Leu Ala Lys Asp Thr Thr Lys Asn Ala 1 5 <210> 81 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 81 Leu Ala Lys Ser Asp Gln Ser Arg Pro Ala 1 5 10 <210> 82 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 82 Leu Ala Pro Gln Asp Thr Lys Lys Asn Ala 1 5 10 <210> 83 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 83 Leu Ala Thr Ser Asp Ser Thr Lys Ala Ala 1 5 10 <210> 84 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 84 Leu Ala Val Asp Gly Ser Gln Arg Ser Ala 1 5 10 <210> 85 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 85 Leu Pro Ile Ser Asp Gln Thr Lys His Ala 1 5 10 <210> 86 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 86 Leu Pro Lys Asp Ala Thr Lys Thr Ile Ala 1 5 10 <210> 87 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 87 Leu Pro Pro Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 88 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 88 Pro Ala Pro Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 89 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 89 Gln Ala His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 90 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 90 Leu Ala His Glu Thr Ser Pro Arg Pro Ala 1 5 10 <210> 91 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 91 Leu Ala Lys Ser Thr Ser Thr Ala Pro Ala 1 5 10 <210> 92 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 92 Leu Ala Asp Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 93 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 93 Leu Ala Glu Ser Asp Gln Ser Lys Pro Ala 1 5 10 <210> 94 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 94 Leu Ala His Lys Asp Thr Thr Lys Asn Ala 1 5 10 <210> 95 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 95 Leu Ala His Lys Thr Gln Gln Lys Met 1 5 <210> 96 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 96 Leu Ala His Gln Asp Thr Thr Glu Asn Ala 1 5 10 <210> 97 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 97 Leu Ala His Gln Asp Thr Thr Ile Asn Ala 1 5 10 <210> 98 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 98 Leu Ala His Gln Asp Thr Thr Lys Lys Thr 1 5 10 <210> 99 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 99 Leu Ala His Gln Asp Thr Thr Lys Asn Asp 1 5 10 <210> 100 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 100 Leu Ala His Gln Asp Thr Thr Lys Asn Thr 1 5 10 <210> 101 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 101 Leu Ala His Gln Asp Thr Thr Lys Asn Val 1 5 10 <210> 102 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 102 Leu Ala His Gln Asp Thr Thr Lys Thr Met 1 5 10 <210> 103 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 103 Leu Ala His Gln Asn Thr Thr Lys Asn Ala 1 5 10 <210> 104 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 104 Leu Ala His Arg Asp Thr Thr Lys Asn Ala 1 5 10 <210> 105 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 105 Leu Ala Ile Ser Asp Gln Thr Asn His Ala 1 5 10 <210> 106 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 106 Leu Ala Lys Gln Lys Ser Ala Ser Thr Ala 1 5 10 <210> 107 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 107 Leu Ala Lys Ser Asp Gln Cys Lys Pro Ala 1 5 10 <210> 108 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 108 Leu Ala Lys Ser Asp Gln Ser Lys Pro Asp 1 5 10 <210> 109 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 109 Leu Ala Lys Ser Asp Gln Ser Asn Pro Ala 1 5 10 <210> 110 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 110 Leu Ala Lys Ser Tyr Gln Ser Lys Pro Ala 1 5 10 <210> 111 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 111 Leu Ala Asn Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 112 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 112 Leu Ala Pro Gln Asn Thr Thr Lys Asn Ala 1 5 10 <210> 113 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 113 Leu Ala Pro Ser Ser Ile Gln Lys Pro Ala 1 5 10 <210> 114 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 114 Leu Ala Gln Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 115 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 115 Leu Ala Tyr Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 116 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 116 Leu Asp His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 117 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 117 Leu Asp His Gln Asp Thr Thr Lys Ser Ala 1 5 10 <210> 118 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 118 Leu Gly His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 119 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 119 Leu Pro His Gln Asp Thr Thr Lys Asn Asp 1 5 10 <210> 120 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 120 Leu Pro His Gln Asp Thr Thr Lys Asn Thr 1 5 10 <210> 121 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 121 Leu Pro His Gln Asp Thr Thr Asn Asn Ala 1 5 10 <210> 122 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 122 Leu Thr His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 123 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 123 Leu Thr Lys Asp Ala Thr Lys Thr Ile Ala 1 5 10 <210> 124 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 124 Leu Thr Pro Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 125 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 125 Leu Val His Gln Asp Thr Thr Lys Asn Ala 1 5 10 <210> 126 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 126 Leu Ala Lys Ala Asn Gln Asn Thr Pro Ala 1 5 10 <210> 127 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 127 Leu Ala Thr Thr Pro Ile Thr Lys Pro Ala 1 5 10 <210> 128 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 128 Leu Ala Thr Thr Pro Ile Ala Lys Pro Ala 1 5 10 <210> 129 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 129 Leu Ala Ile Glu Asp His Thr Lys Ser Ala 1 5 10 <210> 130 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 130 Leu Ala Gln Ser Glu His Gln Arg Pro Ala 1 5 10 <210> 131 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 131 Leu Ala Lys Ser Pro Asn Lys Asp Asn Ala 1 5 10 <210> 132 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 132 Leu Ala Asn Gln Asp Tyr Thr Lys Thr Ala 1 5 10 <210> 133 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 133 Leu Ala Asn Ser Thr Asp Gln Thr Arg Ala 1 5 10 <210> 134 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 134 Leu Ala Leu Gly Glu Thr Thr Arg Pro Ala 1 5 10 <210> 135 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 135 Leu Ala Asn Ser Thr Glu Gln Thr Arg Ala 1 5 10 <210> 136 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 136 Leu Ala Gln Ala Asp Thr Thr Lys Asn Ala 1 5 10 <210> 137 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 137 Leu Ala Ser Lys Asp Ile Thr Lys Thr Ala 1 5 10 <210> 138 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 138 Leu Ala Ser Pro Arg His Asn Lys Lys Cys 1 5 10 <210> 139 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 139 Leu Ala His Gln Asp Thr Thr Lys Thr Ile Ala 1 5 10 <210> 140 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 140 Leu Ala Ala Gln Gly Thr Ala Asn Leu 1 5 <210> 141 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 141 Val Ala Ile Glu Asp His Thr Lys Ser Ala 1 5 10 <210> 142 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 142 Leu Ala Lys Ala Asn Gln Asn Thr Pro Lys Asn Ala 1 5 10 <210> 143 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <220> <221> Misc_feature <222> (10)..(10) <223> Xaa is any amino acid <400> 143 Leu Ala His Gln Asp Thr Thr Lys Lys Xaa 1 5 10 <210> 144 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 144 Leu Ala His Gln Asp Thr Thr Lys Lys Asp 1 5 10 <210> 145 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 145 Leu Ala His Gln Asp Thr Thr Lys Lys Val 1 5 10 <210> 146 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 146 Leu Ala His Gln Asp Thr Thr Lys Lys Met 1 5 10 <210> 147 <211> 7 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <400> 147 Leu Gly Glu Thr Thr Arg Pro 1 5 <210> 148 <211> 11 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <220> <221> Misc_feature <222> (9)..(9) <223> Xaa is Lys, Thr, Asn or His <220> <221> Misc_feature <222> (10)..(10) <223> Xaa is Ala, Thr, Val, Ile, Met or Asp <220> <221> Misc_feature <222> (11)..(11) <223> Xaa is Ala <400> 148 Leu Ala His Gln Asp Thr Thr Lys Xaa Xaa Xaa 1 5 10 <210> 149 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <220> <221> Misc_feature <222> (3) <223> Xaa is Ala, Pro, Asp or His <220> <221> Misc_feature <222> (5)..(5) <223> Xaa is Gly or Asp <220> <221> Misc_feature <222> (7)..(7) <223> Xaa is Ala, Thr or Lys <220> <221> Misc_feature <222> (8) <223> Xaa is Asn, Glu, Lys, Arg or Thr <220> <221> Misc_feature <222> (9)..(9) <223> Xaa is Leu, Asn, Lys or Thr <220> <221> Misc_feature <222> (10)..(10) <223> Xaa is Ala, Thr, Asp, Val, or Met <400> 149 Leu Ala Xaa Gln Xaa Thr Xaa Xaa Xaa Xaa 1 5 10 <210> 150 <211> 10 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <220> <221> Misc_feature <222> (1)..(1) <223> Xaa is Val or Leu <220> <221> Misc_feature <222> (3) <223> Xaa is Ile, Val, His or Asp <220> <221> Misc_feature <222> (4)..(4) <223> Xaa is Glu, Ser, Lys or Gln <220> <221> Misc_feature <222> (6) <223> Xaa is His, Ser or Thr <220> <221> Misc_feature <222> (9)..(9) <223> Xaa is Ser, Ala, Asn, His or Lys <400> 150 Xaa Ala Xaa Xaa Asp Xaa Thr Lys Xaa Ala 1 5 10 <210> 151 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic peptides <220> <221> Misc_feature <222> (1)..(1) <223> Xaa is Leu <220> <221> Misc_feature <222> (2)..(2) <223> Xaa is Ala <220> <221> Misc_feature <222> (3) <223> Xaa is Lys, Leu or Pro <220> <221> Misc_feature <222> (5)..(5) <223> Xaa is Asn, His, Pro or Tyr <220> <221> Misc_feature <222> (7)..(7) <223> Xaa is Asn, Gly, Val or Asp <220> <221> Misc_feature <222> (9)..(9) <223> Xaa is Pro or Thr <400> 151 Xaa Xaa Xaa Ala Xaa Gln Xaa Thr Xaa Lys Asn Ala 1 5 10 <210> 152 <211> 27 <212> RNA <213> Artificial sequence <220> <223> synthetic sequence <400> 152 cgcaaucagu gaaugcuuau acauccg 27

Claims

1. A recombinant adeno-associated virus (rAAV) virion, comprising: a) a variant AAV capsid protein, wherein relative to the corresponding parent AAV capsid protein, the variant AAV capsid protein comprises an insertion of a heterologous peptide in the capsid protein GH loop, wherein the heterologous peptide consists of the amino acid sequence LAPDSTTRSA shown in SEQ ID NO: 53, wherein the variant capsid protein confers increased infectivity to retinal cells compared to the infectivity to retinal cells of a control AAV virion comprising the corresponding parental AAV capsid protein; and b) a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous gene product.

2. The rAAV virion of claim 1, wherein the rAAV virion exhibits at least a 5-fold increase in infectivity to retinal cells compared to the infectivity of a control AAV virion comprising the corresponding parental AAV capsid protein to retinal cells, and / or wherein the rAAV virion exhibits at least a 5-fold increase in localization to one or more of the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, and retinal pigment epithelial cells compared to the extent to which an AAV virion comprising the corresponding parental AAV capsid protein localizes to the inner nuclear layer, outer nuclear layer, photoreceptor layer, ganglion cell layer, or retinal pigment epithelial cells.

3. The rAAV virion of claim 1 or 2, wherein the insertion site is between amino acids corresponding to amino acids 570 and 611 of VP1 of AAV2, or a corresponding position in the capsid protein VP1 of another AAV serotype.

4. The rAAV virion of claim 3, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VP1 of AAV2, or a corresponding position in the capsid protein VP1 of another AAV serotype.

5. The rAAV virion of any one of claims 1, 2 or 4, wherein the gene product is: a) interfering RNA or aptamer; b) a polypeptide; or c) RNA-guided endonucleases and guide RNAs.

6. The rAAV virion of claim 5, wherein the polypeptide is a neuroprotective polypeptide, an anti-angiogenic polypeptide, an anti-apoptotic polypeptide, or a polypeptide that enhances the function of retinal cells, or an RNA-guided endonuclease.

7. The rAAV virion of any one of claims 1, 2 or 4, wherein the heterologous gene product is glial-derived neurotrophic factor, fibroblast growth factor 2, neurotrophin, ciliary neurotrophic factor, nerve growth factor, brain-derived neurotrophic factor, epidermal growth factor, rhodopsin, X-linked inhibitor of apoptosis, retinoschisis protein, RPE65, retinitis pigmentosa GTPase interacting protein-1, peripherin, peripherin-2, RdCVF, retinitis pigmentosa GTPase regulator or sonic hedgehog.

8. The rAAV virion of claim 3, wherein the gene product is: a) interfering RNA or aptamer; b) a polypeptide; or c) RNA-guided endonucleases and guide RNAs.

9. The rAAV virion of claim 8, wherein the polypeptide is a neuroprotective polypeptide, an anti-angiogenic polypeptide, an anti-apoptotic polypeptide, or a polypeptide that enhances the function of retinal cells, or an RNA-guided endonuclease.

10. A pharmaceutical composition comprising: a) the recombinant adeno-associated virus rAAV virion of any one of claims 1 to 9; and b) pharmaceutically acceptable excipients.

11. Use of the recombinant adeno-associated virus rAAV virion of any one of claims 1 to 9 in the preparation of a pharmaceutical composition for a method of delivering a gene product to retinal cells in an individual, wherein the method comprises administering the recombinant adeno-associated virus rAAV virion of any one of claims 1 to 9 to the individual.

12. Use of the recombinant adeno-associated virus rAAV virion of any one of claims 1 to 9 in the preparation of a pharmaceutical composition for a method for treating retinal diseases, wherein the method comprises administering an effective amount of the recombinant adeno-associated virus rAAV virion of any one of claims 1 to 9 to an individual in need.

13. The use according to claim 12, wherein the administration is by intraocular injection.

14. The use according to claim 12, wherein the administration is performed by intravitreal injection.

15. The use according to any one of claims 12 to 14, wherein the retinal disease is glaucoma, retinitis pigmentosa, macular degeneration, retinoschisis, Leber's congenital amaurosis, diabetic retinopathy, achromatopsia or color blindness.

16. An isolated nucleic acid comprising a nucleotide sequence encoding a variant adeno-associated virus (AAV) capsid protein, wherein relative to the corresponding parent AAV capsid protein, the variant AAV capsid protein comprises an insertion of a heterologous peptide in the capsid protein GH loop, wherein the heterologous peptide consists of the amino acid sequence LAPDSTTRSA shown in SEQ ID NO: 53, Wherein the variant capsid protein, when present in an AAV virion, provides the AAV virion with increased infectivity to retinal cells.

17. The isolated nucleic acid of claim 16, wherein the insertion site is between amino acids 570 and 611 of VP1 of AAV2, or a corresponding position in the capsid protein VP1 of another AAV serotype.

18. The isolated nucleic acid of claim 17, wherein the insertion site is between amino acids 587 and 588 of VP1 of AAV2, between amino acids 590 and 591 of VP1 of AAV1, between amino acids 575 and 576 of VP1 of AAV5, between amino acids 590 and 591 of VP1 of AAV6, between amino acids 589 and 590 of VP1 of AAV7, between amino acids 590 and 591 of VP1 of AAV8, between amino acids 588 and 589 of VP1 of AAV9, or between amino acids 588 and 589 of VP1 of AAV10.

19. An isolated genetically modified host cell comprising the nucleic acid of any one of claims 16 to 18.

20. The isolated genetically modified host cell of claim 19, further comprising a nucleotide sequence encoding an AAV rep protein.

21. A variant adeno-associated virus AAV capsid protein, wherein relative to the corresponding parent AAV capsid protein, the variant AAV capsid protein comprises an insertion of a heterologous peptide in the GH loop, wherein the heterologous peptide consists of the amino acid sequence LAPDSTTRSA shown in SEQ ID NO:

53.

22. The variant adeno-associated virus (AAV) capsid protein according to claim 21, wherein the insertion site is between amino acids 570 and 611 of VP1 of AAV2, or a corresponding position in the capsid protein VP1 of another AAV serotype.

23. The variant adeno-associated virus AAV capsid protein according to claim 22, wherein the insertion site is between amino acids 587 and 588 of VP1 of AAV2, between amino acids 590 and 591 of VP1 of AAV1, between amino acids 575 and 576 of VP1 of AAV5, between amino acids 590 and 591 of VP1 of AAV6, between amino acids 589 and 590 of VP1 of AAV7, between amino acids 590 and 591 of VP1 of AAV8, between amino acids 588 and 589 of VP1 of AAV9, or between amino acids 588 and 589 of VP1 of AAV10.

24. A host cell that produces the rAAV virion of any one of claims 1 to 9.